NATIONAL HEALTH
EXPENDITURE DATABASE





Contents of this publication may be reproduced in whole or in part provided the intended use is for non-commercial purposes and full acknowledgement is given to the Canadian Institute for Health Information.

Canadian Institute for Health Information 377 Dalhousie Street Suite 200 Ottawa, Ontario K1N 9N8

Telephone: (613) 241-7860 Fax: (613) 241-8120

www.cihi.ca

ISBN #: 1-55392-404-5 (PDF)

© 2004 Canadian Institute for Health Information

Cette publication est disponible en français sous le titre :  $D\'{e}penses$  en  $m\'{e}dicaments$  au Canada, de~1985 à 2003 ISBN 1-55392-405-3 (PDF)

### **Table of Contents**

Executive Summary	i
Introduction	1
National Drug Expenditure Overview	3
Total Drug Expenditure	3
Total Drug Expenditure Per Capita	4
The Share of Drugs in Total Health Expenditure	5
Drug Expenditure: Prescribed and Non-Prescribed Drugs	7
Prescribed Drug Expenditure by Source of Finance	8
Drug Expenditure in the Provinces and Territories	. 13
The Share of Drugs in Total Health Expenditure	. 14
Total Drug Expenditure by Source of Finance	. 15
Total Drug Expenditure Per Capita by Source of Finance	. 16
Drug Expenditure by Type of Drug and by Source of Finance	. 17
International Comparisons	. 27
Comparability of Health Expenditure Across Countries	. 27
Share of Drugs in Total Health Expenditure	. 28
Share of Public Expenditure in Total Expenditure on Drugs	. 29
Share of Drugs in Public Expenditure on Health	. 31
Factors Affecting Drug Expenditure in Canada	. 33
Methodological Notes	. 35
Background	. 35
Major Data Limitations	. 40
Collection and Non-Response	. 42
Sources of Data	. 50
Series A—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2003	. 53
Series B—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory,	
1985 to 2003	
Series C—International Comparisons	113
Appendix—Comparison of Provincial and Territorial Drug Subsidy Programs	A-1

### **List of Figures**

Figure 1	Total Drug Expenditure, Canada, 1985 to 2003	3
Figure 2	Total Drug Expenditure Per Capita, Current and Constant Dollars, Canada, 1985 to 2003	4
Figure 3	Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2003	5
Figure 4	Annual Growth Rate for Total Drug Expenditure, Total Health Expenditure and Consumer Price Index (CPI), Canada, 1985 to 2003	6
Figure 5	Total Health Expenditure by Use of Funds, Canada, 2003	6
Figure 6	Total Drug Expenditure by Type, Canada, 1985 to 2003	7
Figure 7	Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2003	9
Figure 8	Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2003	9
Figure 9	Prescribed Drug Expenditure by Private Sector Source of Finance, Canada, 1988 to 2003	12
Figure 10	Drug Expenditure as a Percentage of Total Health Expenditure by Province/Territory and Canada, 1985 and 2001	14
Figure 11	Publicly Financed Drug Expenditure as a Percentage of Total Drug Expenditure by Province/Territory and Canada, 1985 and 2001	15
Figure 12	Total Drug Expenditure Per Capita by Source of Finance by Province/Territory and Canada, 2001	16
Figure 13	Public and Private Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure Per Capita by Province/Territory and Canada, 1985 to 2003	18
Figure 14	Annual Growth Rate for Prescribed Drug Expenditure (Rx) by Source of Finance, by Province/Territory, 1985 to 2003	21
Figure 15	Public Sector Prescribed Drug Expenditure as a Percentage of Prescribed Drug Expenditure by Province/Territory, 1985 to 2003	24
Figure 16	Drug Expenditure Per Capita, Selected Countries, 1985 to 2001	29
Figure 17	Composition of Total Health Expenditure by Source of Finance	36
Figure 18	Patented Medicine Price Index, Consumer Price Index and Industrial Product Price Index, 1985 to 2003 (1987 = 100)	42

### **List of Text Tables**

Table 1	Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2001	. 11
Table 2	Drug Expenditure Summary by Province/Territory and Canada, 2001	. 13
Table 3	Total Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2001	. 28
Table 4	Public Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2001	. 30
Table 5	Public Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Public Sector Health Expenditure, Reporting OECD Comparator Countries, 2001	. 32
Table 6	Factors That May Influence Drug Expenditure in Canada	. 33
Table 7	Provincial/Territorial Government Drug Expenditure Data	. 43
Table 8	Comparison of Provincial and Territorial Drug Subsidy Programs	A-2

#### **List of Data Tables**

Series A—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2003

- Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2003
- 2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditure, Canada, 1985 to 2003

# Series B—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2003

- 1.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2003
- 1.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2003
- 2.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2003
- 2.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2003
- 3.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2003
- 3.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2003
- 4.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2003
- 4.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2003
- 5.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985 to 2003
- 5.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Quebec, 1985 to 2003
- 6.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985 to 2003
- 6.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Ontario, 1985 to 2003

#### List of Data Tables (cont'd)

#### Series B—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2003

- 7.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985 to 2003
- 7.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Manitoba, 1985 to 2003
- 8.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2003
- 8.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2003
- 9.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Alberta, 1999 to 2003
- 9.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Alberta, 1985 to 2003
- 10.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985 to 2003
- 10.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2003
- 11.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2003
- 11.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2003
- 12.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2003
- 12.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2003
- 13.1 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nunavut, 1985 to 2003
- 13.2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nunavut, 1985 to 2003

#### List of Data Tables (cont'd)

#### Series C—International Comparisons

- The Share of Pharmaceutical Goods in Total Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2000 and 2001
- The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-Durables, in Descending Order, OECD Reporting Countries, 1985, 2000 and 2001
- The Share of Pharmaceutical Goods in Public Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2000 and 2001

# **Executive Summary**

Total expenditure on drugs<sup>1</sup> was an estimated \$16.7 billion<sup>2</sup> in 2001, and is forecast to have reached \$19.6 billion in 2003. The share of drugs in total health expenditure was 9.5% in 1985. It has increased each year thereafter to reach 15.7% in 2001, and is forecast to have grown to 16.2% in 2003. Since 1997, among major categories of health expenditure, drugs have accounted for the second largest share, after hospitals. In 2001, drug expenditure was equivalent to over 50% of the amount spent on hospitals, and exceeded the amount spent on physicians' services.

At the national level, the data indicate that:

- From 1985 to 2001, total drug expenditure grew at an average annual rate of 9.7%, well beyond what can be attributed to economy-wide inflation and growth in the population.
- Total drug expenditure per capita in Canada grew by 9.3% in 2001. It is forecast to have risen by 7.6% in 2002 and 7.2% in 2003.
- In 2001, expenditure on prescribed drugs was \$13.2 billion, and accounted for 79.3% of all drug expenditure. In 2003, prescribed drug expenditure is forecast to have reached \$16.0 billion and account for 81.6% of total drug expenditure in Canada.
- In 2001, 46.3% of expenditure on prescribed drugs was financed by the public sector. Private insurers financed 34.0% of prescribed drug expenditure while households funded the remaining 19.8%. The public sector is forecast to have financed 47.2% of prescribed drug expenditure in 2003.
- Drugs accounted for 3.7% of total public sector health expenditure in 1985 and 8.2% in 2001. In 1985, drugs represented 27.5% of total private sector health expenditure; this proportion rose to 33.3% in 2001.
- Expenditure on non-prescribed drugs, composed of over-the-counter (OTC) drugs and personal health supplies, are financed primarily by households (out-of-pocket). In 2001, expenditure on non-prescribed drugs was \$3.5 billion (\$1.8 billion on OTC drugs and \$1.7 billion on personal health supplies). In 2003, expenditure on non-prescribed drugs is forecast to have been \$3.6 billion.

\_

Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX) and are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups, and appropriate taxes. Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs (over-the-counter drugs and personal health supplies). For more information on over-the-counter drugs and personal health supplies, see General Methods section of the Methodological Notes.

<sup>&</sup>lt;sup>2</sup> All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

At the provincial level, the data indicate that:

- There is considerable variation in the level and growth of drug expenditure across the provinces. In 2001, estimated total drug expenditure per capita ranged from \$444 in British Columbia to \$584 in Prince Edward Island.
- In 2001, the share of prescribed drugs in total drug expenditure ranged from 75.8% in British Columbia to 84.6% in Quebec.
- The proportion of prescribed drugs financed by the public sector in 2001 varied across the provinces, from a low of 30.8% in Prince Edward Island to a high of 53.3% in British Columbia.

At the international level, the data indicate that in 2001, among eleven OECD comparator countries<sup>3</sup>:

- Canada had the third highest level of total drug expenditure per capita after the United States and France.
- Canada was the fourth highest, after Hungary, France, and Japan in drug expenditure as a percentage of total health expenditure.
- The public sector funded 36.1% of total drug expenditure in Canada. This was the third lowest share after the United States (18.7%) and Korea (17.4%). The share of public drug expenditure in total drug expenditure was highest in Germany at 70.6%.
- Drugs accounted for 8.2% of public sector health expenditure in Canada. This was the fourth lowest share after Korea (6.2%), Denmark (5.5%) and the United States (5.2%). The share of drug expenditure in public sector health expenditure was highest in Hungary at 25.3%.

Factors affecting Drug Expenditure:

Numerous factors, many of which are interrelated, may influence drug expenditure.
 Since drug prices, as measured by several price indices, have been relatively stable over
 the past ten years, factors affecting increased drug spending in Canada essentially
 relate to the volume of drug use and the entry of new drugs (typically introduced to the
 market at higher prices).

ii

Omparator countries are Australia, Canada, Denmark, France, Germany, Hungary, Japan, Korea, Netherlands, Switzerland, and the United States. For more information, see the International Comparisons section of this report.

# Introduction

As the Romanow Commission pointed out, prescription drugs have fundamentally changed the face of health care in Canada.<sup>4</sup> The Commission stated that in the future, two key issues must be addressed: Canadians must have access to the prescription drugs they need and the integration of new prescription drugs must be accomplished in a safe and cost-effective manner.

Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX) maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro level health expenditure statistics by province and territory beginning in 1960. Drug expenditure data in NHEX are macro level data and do not allow for decomposition of prescription costs or drug classes.

The "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups, and appropriate taxes. NHEX data does not include drug expenditure by non-Canadians (for example, Americans via Canadian Internet pharmacies). This classification system is consistent with international standards developed by the Organisation for Economic Cooperation and Development (OECD).

Drug expenditure estimates within NHEX provide insight into total drug expenditure<sup>5</sup> by public and private payers and by type of drugs (prescribed and non-prescribed) at the provincial/territorial and national levels. All drug expenditure estimates stated in this report are in current dollars (unadjusted for inflation) unless otherwise stated.

Drug Expenditure in Canada, 1985 to 2003 is CIHI's fourth annual drug expenditure trends publication and provides updated information on drug expenditure in Canada. This publication includes:

- National drug expenditure;
- Provincial and territorial drug expenditure;
- International comparisons; and
- Factors that may affect drug expenditure.

More information on drug expenditure and the methods used in the preparation of this document is available by contacting the Pharmaceuticals unit of CIHI by telephone (613) 241-7860 or by e-mail drugs@cihi.ca.

<sup>4</sup> Romanow RJ. *Building on Values: the Future of Health Care in Canada*. Saskatoon: Commission on the Future of Health Care in Canada; 2002.


Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs. Non-prescribed drugs are composed of over-the-counter drugs (e.g. cold remedies, cough remedies, and headache remedies) and personal health supplies (e.g. anti-perspirants, dental floss, and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see General Methods section of the Methodological Notes.

# National Drug Expenditure Overview

#### TOTAL DRUG EXPENDITURE

#### ■ Outlook—2002 and 2003

Total drug expenditure is forecast to have reached \$18.1 billion<sup>6</sup> in 2002 and \$19.6 billion in 2003, representing annual increases of 8.8% and 8.1%, respectively.



#### ■ Highlights

Canada's total drug expenditure has increased steadily from \$3.8 billion in 1985 to \$16.7 billion in 2001. The annual average rate of growth during this period was 9.7% (Figure 1). Over the period 1985 to 1992, expenditure grew at an average annual rate of 12.2%. Between 1992 and 1997, annual growth rates decreased to an average of 6.0%. Drug expenditure increased to an average annual growth rate of 9.9% between 1997 and 2001 to reach an estimated \$16.7 billion.


See Data Table A.1.

<sup>&</sup>lt;sup>6</sup> All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

#### TOTAL DRUG EXPENDITURE PER CAPITA

#### Outlook—2002 and 2003

Total drug expenditure per capita in Canada is expected to have reached \$578 in 2002 and \$620 in 2003, representing annual rates of increase of 7.6% and 7.2%, respectively.



#### **■** Highlights

Per capita drug expenditure trends are similar to those of total drug spending, reflecting a 1.1% average annual rate of growth in the overall population in Canada from 1985 to 2001. Total drug expenditure increased from \$147 per person in 1985 to \$537 in 2001 (Figure 2). The annual average growth rate in drug expenditure per capita during this period was 8.4%.

Typically, expenditure is deflated by a price index to measure change in quantity. There is no authoritative composite price index for all drugs sold in Canada. However, measuring drug expenditure in constant (adjusted for inflation) dollars, using the Consumer Price Index (CPI) reported by Statistics Canada, gives a sense of change in drug expenditure in the context of economy-wide inflation. Readers should cautiously interpret inflation-adjusted trends in expenditure, as drug-specific inflation may differ from that depending upon the broad basket of goods and services purchased by Canadians.

<sup>&</sup>lt;sup>7</sup> For more information on drug prices, see Major Data Limitations section of the Methodological Notes.

<sup>8</sup> A measure of the average percentage change over time in the cost of a fixed basket of goods and services purchased by Canadian consumers.


In terms of constant (1985) dollars, per capita drug expenditure increased from \$147 in 1985 to \$346 in 2001, reflecting an average annual growth rate of 5.5% during this period. Trends in per capita drug expenditure measured in constant dollars are similar to those of per capita drug expenditure measured in current dollars, though growth between 1985 and 2001 is less pronounced when it is considered relative to economy-wide inflation (Figure 2).

See Data Table A.2.

### THE SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

#### ■ Outlook—2002 and 2003


The share of drugs in total health expenditure is forecast to have reached 16.0% in 2002 and 16.2% in 2003 (Figure 3).



#### ■ Highlights


Drugs have been one of the fastest-growing components of total health expenditure in Canada. From 1985 to 2001, total health spending grew at an average annual rate of 6.3%. During this period, expenditure on drugs increased at an average annual rate of 9.7% (Figure 4). In each of those years, the annual rate of growth for drugs exceeded the rate for total health expenditure.

Drug expenditure grew at an annual rate beyond what can be attributed to economy-wide inflation (as measured by CPI) in every year between 1985 and 2001 (Figure 4). Total health expenditure grew at an annual rate above the rate of inflation in all years during this period with the exception of 1995 and 1996.



The National Health Expenditure Database (NHEX) breaks down total health expenditure into eight major spending categories. Since 1997, among major categories of health expenditure, drugs have accounted for the second largest share, after hospitals (Figure 5).

See Data Table A.1.




# DRUG EXPENDITURE: PRESCRIBED AND NON-PRESCRIBED DRUGS

#### Outlook—2002 and 2003

Expenditure on prescribed drugs<sup>9</sup> is expected to have reached \$14.5 billion in 2002 and \$16.0 billion in 2003, representing growth rates of 10.0% and 10.1%, respectively. Expenditure on non-prescribed drugs is forecast to have reached \$3.6 billion in both 2002 and 2003, representing increases of 4.4% and 0.2%, respectively.

Non-prescribed drugs, which are typically financed out-of-pocket by consumers (households), include over-the-counter drugs (e.g. cold remedies, cough remedies and headache remedies) and personal health supplies (e.g. anti-perspirants, dental floss, and disposable diabetic syringes). Since the National Health Expenditure Database (NHEX) consists of macro level health expenditure data, some personal health supplies that are covered under some drug benefit plans may be counted as prescribed drug expenditure.

Prescribed drugs are expected to account for 80.1% of total drug expenditure in Canada in 2002 and 81.6% in 2003. Conversely, the share of non-prescribed drugs in total drug expenditure is expected to decrease to 19.9% in 2002 and 18.4% in 2003.



<sup>9</sup> A prescribed drug is a substance considered to be a drug under the Food and Drugs Act, and which is sold for human use as the result of a prescription from a health professional.

<sup>&</sup>lt;sup>10</sup> For more information on over-the-counter drugs and personal health supplies, see General Methods section of the Methodological Notes.

<sup>&</sup>lt;sup>11</sup> For example, diabetic test strips, where covered under drug benefit plans, may be included in prescribed drug expenditure, subject to source of data.

#### ■ Highlights

From 1985 to 2001, expenditure on prescribed drugs grew from \$2.6 billion to \$13.2 billion, at an average annual rate of 10.8%. Spending on non-prescribed drugs increased from \$1.2 billion to \$3.5 billion, at an average of 6.6% per year. During this period, with the exception of 1987 and 1994, annual growth in drug spending was higher in prescribed drugs than in non-prescribed drug. As a result, prescribed drugs have captured a larger share of total drug spending, rising from 67.5% in 1985 to 79.3% in 2001 (Figure 6).

Non-prescribed drug expenditure represented 20.7% of total drug expenditure in 2001. Over-the-counter (OTC) drugs accounted for \$1.8 billion or 10.8% of total drug expenditure, while personal health supplies amounted \$1.7 billion or 9.9% of the total.

See Data Table A.1.


# PRESCRIBED DRUG EXPENDITURE BY SOURCE OF FINANCE


While non-prescribed drugs are typically financed out-of-pocket by consumers (households), multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial/federal drug subsidy programs and social security funds (e.g. Workers' Compensation Boards). In the private sector, they include private insurers and households. This section examines prescribed drug expenditure by public and private sector sources of finance.

#### Outlook—2002 and 2003

Public sector expenditure on prescribed drugs is forecast to have reached \$6.8 billion in 2002 and \$7.6 billion in 2003, representing annual growth rates of 11.6% and 10.7%, respectively. Private sector expenditure on prescribed drugs is forecast to have reached \$7.7 billion in 2002 and \$8.5 billion in 2003, with corresponding annual growth rates of 8.6% and 9.6%.

The share of prescribed drug expenditure financed by the public sector is forecast to have risen to 46.9% in 2002, and 47.2% in 2003 (Figure 7).





#### ■ Highlights

The intersections of the two series depicted in Figure 8 identify three distinct periods of growth in publicly and privately financed prescribed drug expenditure.

Between 1985 and 1992, expenditure on prescribed drugs in the public sector grew by an annual average rate of 14.6%, while this rate was 12.0% for prescribed drug expenditure financed by the private sector. Consequently, the share of prescribed drugs financed from public sources increased from 43.6% in 1985 to 47.7% in 1992.

From 1992 to 1997, spending on prescribed drugs by the private sector grew at an average annual rate of 9.1%, more than twice the 4.4% average annual rate of growth in publicly financed prescribed drug expenditure. Fiscal restraint introduced in several provinces led to negative growth in publicly financed prescribed drug expenditure in 1996. By 1997, the share of prescribed drugs financed from public sources had declined to 42.2%, below its share in 1985 (43.6%).

Between 1997 and 2001, expenditure on prescribed drugs by the public sector grew at an average annual rate 14.1%, compared to 9.5% in the private sector. The share of prescribed drug expenditure financed by the public sector reached 46.3% in 2001.

See Data Tables A.1 and A.2.

Spending on prescribed drugs by the public sector is financed by two levels of government—provincial/territorial and federal governments; and by Social Security funds such as Workers' Compensation Boards and the Quebec Drug Insurance Fund. Private sector expenditure on prescribed drugs is financed by two sources: private insurers and households (out-of-pocket) expenditure. Table 1 shows the distribution of prescribed drug expenditure by these sources of finance.

Table 1—Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2001

	1988		2001	
	(\$ 'millions)	(%)	(\$ 'millions)	(%)
Provincial/Territorial				
Governments	1,592.7	42.6	5,267.9	39.9
Federal Direct	89.3	2.4	392.0	3.0
Social Security Funds:				
Workers' Compensation Boards	20.8	0.6	75.8	0.6
Quebec Drug Insurance Fund*			379.9	2.9
Sub-Total Public Sources	1,702.8	45.6	6,115.6	46.3
Private Insurers**	1,131.3	30.3	4,490.0	34.0
Household (out-of-pocket)**	902.7	24.2	2,613.5	19.8
Sub-Total Private Sources	2,034.0	54.4	7,103.5	53.7
Total All Sources	3,736.8	100.0	13,219.1	100.0

<sup>\*</sup> Data not available prior to January 1, 1997 when the program was first introduced in Quebec.

Source: Canadian Institute for Health Information

Provincial/territorial government expenditure on prescribed drugs was almost \$1.6 billion in 1988, accounting for 42.6% of total expenditure on prescribed drugs. By 2001, provincial/territorial government expenditure had grown to almost \$5.3 billion, and its share of total expenditure on prescribed drugs had diminished to 39.9%.

All provinces provide some form of prescribed drug coverage to seniors and social assistance recipients (see the Appendix for an overview of provincial and territorial drug subsidy programs). In 2001, the number of Canadians covered by provincial plans was estimated to be between 10.5 and 11.5 million.<sup>12</sup>


Federal direct expenditure was \$89.3 million in 1988, equivalent to 2.4% of total expenditure on prescribed drugs. Federal direct expenditure increased to \$392.0 million in 2001, representing 3.0% of total expenditure on prescribed drugs. The Federal government provides drug benefits to Aboriginal Canadians (in 2001, an estimated 700,000 Aboriginal Canadians had drug coverage through the Non-Insured Health Benefits Program of Health Canada<sup>12</sup>), veterans, members of the military and the RCMP, and prisoners in federal correctional facilities.

<sup>\*\*</sup> Data not available separately before 1988.

<sup>&</sup>lt;sup>12</sup> Bryan Ferguson, "A Presentation to the Senate Hearings on the State of Health Care in Canada," (FCMC Partner Applied Management: Toronto, June 13, 2002) (with reference to Canadians' Access to Insurance for Prescribed Medicines, submitted to Health Canada in March 2000 by Applied Management in association with Fraser Group, and Tristat Resources).

Expenditure by social security funds was \$20.8 million in 1988, equivalent to 0.6% of total prescribed drug expenditure. In 2001, expenditure by social security funds was \$455.7 million and accounted for 3.4% of total expenditure on prescribed drugs. Social security funds figures have largely represented spending by the Quebec Drug Insurance Fund since its institution in 1997. Quebec residents not otherwise covered by the provincial program or by private health insurance are insured by the fund through the compulsory payment of premiums.

Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.



Expenditure on prescribed drugs by private insurers amounted to more than \$1.1 billion in 1988, or 30.3% of prescribed drug expenditure. Private insurers' spending has increased to almost \$4.5 billion in 2001 and its share of prescribed drug expenditure increased to 34.0%. Private insurers include group and individual insurance. Many employers offer group benefit plans covering prescribed drugs for employees and their family. In some cases, individuals will continue to be covered by a group plan even after they retire. In 2001, the number of people covered by private plans was estimated to be between 17.5 and 18.5 million.<sup>13</sup>

Out-of-pocket spending by households was an estimated \$0.9 billion in 1988, representing 24.2% of total expenditure on prescribed drugs. By 2001, out-of-pocket prescribed drug expenditure had risen to more than \$2.6 billion and its share of prescribed drug expenditure had decreased to 19.8%.

See Data Table A.2.

<sup>&</sup>lt;sup>13</sup> Bryan Ferguson, "A Presentation to the Senate Hearings on the State of Health Care in Canada," (FCMC Partner Applied Management: Toronto, June 13, 2002) (with reference to Canadians' Access to Insurance for Prescribed Medicines, submitted to Health Canada in March 2000 by Applied Management in association with Fraser Group, and Tristat Resources).

# Drug Expenditure in the Provinces and Territories

There is considerable variation in the level and growth of drug expenditure across the provinces and territories. These variations are influenced by several factors, including differences in provincial drug subsidy programs (see Appendix for an overview of provincial and territorial drug subsidy programs), variations in the age and sex distribution of provincial/territorial populations, the health needs of targeted populations, and the manner in which health care is delivered (including the balance between institutional and ambulatory care). Other possible sources of variation in drug expenditure are tabled in the section "Factors Affecting Drug Expenditure in Canada".

Table 2 gives an overview of Provincial/Territorial drug expenditure in 2001.

Table 2—Drug Expenditure Summary by Province/Territory and Canada, 2001

	Total Drug Exp.	Total Drug Exp. as a % of Total Health Exp.	Total Drug Exp. Per Capita	Prescribed Drug Exp. Per Capita	Prescribed Drug Exp. as a % of Total Drug Exp.	Public Prescribed Drug Exp. as a % of Prescribed Drug Exp.
	(\$ 'millions)	(%)	(\$)	(\$)	(%)	(%)
N.L.	262.1	14.5	502.06	417.37	83.1	40.7
P.E.I.	79.9	17.6	584.28	454.89	77.9	30.8
N.S.	510.9	17.1	547.96	429.45	78.4	38.2
N.B.	412.9	16.9	550.64	437.23	79.4	33.2
Que.	4,117.0	17.9	556.57	470.71	84.6	49.6
Ont.	6,945.8	16.7	583.79	453.74	77.7	44.1
Man.	534.0	12.5	463.85	364.17	78.5	49.4
Sask.	487.1	14.2	487.06	382.02	78.4	43.4
Alta.	1,471.7	13.6	481.45	368.91	76.6	45.2
B.C.	1,810.7	12.4	443.97	336.66	75.8	53.3
Y.T.	14.2	9.9	472.75	349.86	74.0	66.3
N.W.T.	18.0	6.8	440.14	359.87	81.8	75.1
Nun.	5.5	3.1	194.17	114.71	59.1	52.7
Canada	16,669.7	15.7	537.36	426.13	79.3	46.3

Sources: Canadian Institute for Health Information, Statistics Canada

\_

<sup>&</sup>lt;sup>14</sup> S. Morgan (2004), Sources of Variation in Provincial Drug Spending, Canadian Medical Association Journal, 170(3): 329-330.

In 2001, expenditure on drugs accounted for 15.7% of total health expenditure in Canada. Among the provinces and territories, the share of drugs in total health expenditure ranged from 3.1% in Nunavut to 17.9% in Quebec.

Total drug expenditure per capita in Canada was \$537 in 2001. Per capita spending on drugs in the provinces and territories ranged from \$194 in Nunavut to \$584 in Prince Edward Island.


Prescribed drugs accounted for 79.3% of total expenditure on drugs in Canada in 2001. Among the provinces and territories, the share of prescribed drugs in total drug expenditure ranged from 59.1% in Nunavut to 84.6% in Quebec.

In 2001, the proportion of prescribed drugs in Canada financed by the public sector was 46.3%. The Northwest Territories had the highest proportion at 75.1% and Prince Edward Island had the lowest at 30.8%.

# THE SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

The share of drugs in total health expenditure was higher in 2001 than in 1985 in all provinces and territories except for Newfoundland and Labrador, Prince Edward Island, and the Northwest Territories and Nunavut (Figure 10).

It should be noted that the share of drugs in total health expenditure was higher in 2001 than in 1986 in all provinces and territories.




In 1985, expenditure on drugs accounted for 9.5% of total health expenditure in Canada. Newfoundland and Labrador, Prince Edward Island, Nova Scotia, New Brunswick, and Ontario exceeded the national average. Prince Edward Island had the highest share at 18.0%, followed closely by Newfoundland and Labrador at 16.3%, while among the other provinces and territories, shares ranged from 7.1% in the Northwest Territories and Nunavut to 12.0% in Nova Scotia and New Brunswick.

In 2001, Prince Edward Island, Nova Scotia, New Brunswick, Quebec and Ontario had drug expenditure as a percentage of total health expenditure above the Canadian average (15.7%), with Quebec having the highest share at 17.9%. Newfoundland and Labrador and the western provinces (Manitoba, Saskatchewan, Alberta and British Columbia) were below the Canadian average, with British Columbia having the lowest share at 12.4%. The Yukon Territory and the Northwest Territories and Nunavut had lower shares than the provinces at 9.9% and 5.3%, respectively.

See Data Tables B.1.1 to B.13.1.

# TOTAL DRUG EXPENDITURE BY SOURCE OF FINANCE

The share of publicly financed drug expenditure in total drug expenditure increased between 1985 and 2001 in every province/territory with the exception of Nova Scotia, New Brunswick, and Saskatchewan (Figure 11).



In 1985, the public share of total drug expenditure ranged from 7.6% in Prince Edward Island to 54.4% in Saskatchewan. Nova Scotia, Quebec, Saskatchewan, British Columbia, the Northwest Territories and Nunavut had public shares greater than the Canadian average (29.4%).

In 2001, Quebec, Manitoba, British Columbia, the Yukon Territory, the Northwest Territories and Nunavut had public shares of total drug expenditure that exceeded the national average (36.7%). The share of total drug expenditure funded by the public sector ranged from 24.0% in Prince Edward Island to 54.4% in the Northwest Territories and Nunavut.

#### TOTAL DRUG EXPENDITURE PER CAPITA BY SOURCE OF FINANCE

In 2001, total drug expenditure per capita in Canada was estimated at \$537. Per capita drug spending financed by the public and private sectors amounted to \$197 and \$340, respectively (Figure 12).



Figure 12—Total Drug Expenditure Per Capita by Source of Finance by Province/Territory and Canada, 2001

Sources: Canadian Institute for Health Information, Statistics Canada

In 2001, per capita spending on drugs by the public sector ranged from \$60 in Nunavut to \$270 in the Northwest Territories. In the same year, Quebec (\$234), Ontario (\$200), the Yukon Territory (\$232) and the Northwest Territories (\$270) had publicly financed drug expenditure per capita above the Canadian average.

Drug expenditure per capita financed by the private sector ranged from \$134 in Nunavut to \$444 in Prince Edward Island. Prince Edward Island (\$444), Nova Scotia (\$384), New Brunswick (\$405) and Ontario (\$384) had privately financed drug expenditure per capita higher than the Canadian average.


See Data Tables B.1.2 to B.13.2.

#### DRUG EXPENDITURE BY TYPE OF DRUG AND BY SOURCE OF FINANCE

#### Public and Private Sector Prescribed and Non-Prescribed Drug Expenditure


Figure 13 illustrates provincial/territorial trends in public and private prescribed drug expenditure as well as private non-prescribed drug expenditure per capita from 1985 to 2001 and forecasts to 2003 (figures are not adjusted for inflation).

Figure 13—Public and Private Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure Per Capita by Province/Territory and Canada, 1985 to 2003



Sources: Canadian Institute for Health Information, Statistics Canada

Figure 13 (cont'd)—Public and Private Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure Per Capita by Province/Territory and Canada, 1985 to 2003



<sup>\*</sup>On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Sources: Canadian Institute for Health Information, Statistics Canada


Between 1985 and 2001, in all provinces and territories, the average annual rate of growth was higher in prescribed drug expenditure per capita (average annual growth rate ranged from 5.5% in Newfoundland and Labrador to 10.9% in Quebec), than in non-prescribed drug expenditure per capita (average annual growth rate ranged from 0.4% in the Northwest Territories and Nunavut to 7.2% in Saskatchewan).


During the same period, three provinces/territories, Nova Scotia, Quebec and the Yukon Territory experienced higher average annual growth rates for prescribed drug expenditure per person than the Canadian average of 9.5%. Four provinces (Quebec, Ontario, Saskatchewan and Alberta) experienced higher average annual growth rates in non-prescribed drug spending per person than the Canadian average of 5.4%. Most provinces experienced relatively stable growth in non-prescribed drugs through most of the series.


#### **Public and Private Sector Prescribed Drug Expenditure**


Figure 14 illustrates provincial/territorial annual growth trends in public and private prescribed drug expenditure from 1985 to 2001 and forecasts to 2003.


Figure 14—Annual Growth Rate for Prescribed Drug Expenditure (Rx) by Source of Finance, by Province/Territory, 1985 to 2003


















Source: Canadian Institute for Health Information


Figure 14 (cont'd)—Annual Growth Rate for Prescribed Drug Expenditure (Rx) by Source of Finance, by Province/Territory, 1985 to 2003

















<sup>\*</sup>On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Source: Canadian Institute for Health Information

In the early to mid-1990s, all provinces/territories in Canada initiated health system reforms and public expenditure restraints that affected nearly all categories of health spending.<sup>15</sup> Between 1992 and 1997, each province/territory, except for Alberta, experienced at least one year of decline in publicly financed prescribed drug expenditure.

The analysis of annual growth rates should be interpreted cautiously. Annual growth rates should be considered in the context of the level/magnitude of prescribed drug expenditure by source of finance (presented in the following section), as the understanding of the relationship between the two is necessary before interpreting the information. For instance, the level of drug expenditure in the last year of a reference period is impacted by the initial level of drug expenditure and its annual growth rates over time.

Between 1985 and 2001, publicly financed prescribed drug expenditure grew at a higher average annual rate than privately financed prescribed drug expenditure in all provinces and territories, except for Nova Scotia, New Brunwsick and Saskatchetwan. During this period, average annual growth in public sector prescribed drug spending ranged from 5.2% in Saskatchewan to 17.6% in the Yukon Territory. Prescribed drug expenditure financed by the private sector grew at average annual rates ranging from 2.8% in Newfoundland and Labrador to 13.9% in Saskatchewan.

In 2001, public prescribed drug expenditure grew in every province and territory; growth rates ranged from 9.8% in the Yukon Territory to 23.1% in Nunavut.

#### **Public Sector Prescribed Drug Expenditure**


Figure 15 illustrates provincial/territorial trends in the share of publicly financed prescribed drug expenditure as a percentage of prescribed drug expenditure, from 1985 to 2001 and forecasts to 2003.


-


<sup>&</sup>lt;sup>15</sup> Canadian Institute for Health Information, National Health Expenditure Trends 1975 to 2003, December 2003. Ottawa


### **Public Sector Prescribed Drug Expenditure**


Figure 15—Public Sector Prescribed Drug Expenditure as a Percentage of Prescribed Drug Expenditure by Province/Territory, 1985 to 2003















Source: Canadian Institute for Health Information

Figure 15 (cont'd)—Public Sector Prescribed Drug Expenditure as a Percentage of Prescribed Drug Expenditure by Province/Territory, 1985 to 2003



<sup>\*</sup>On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Source: Canadian Institute for Health Information

Between 1985 and 2001, the share of prescribed drug expenditure financed by the public sector decreased in Nova Scotia, New Brunswick and Saskatchewan. During the same period, the share increased in the remaining provinces and territories, with increases ranging from less than one percentage point in British Columbia to more than thirty percentage points in the Yukon Territory.

In 2001, the share of prescribed drug expenditure financed by the public sector in Canada was 46.3%. This was exceeded by the Northwest Territories (75.1%), the Yukon Territory (66.3%), British Columbia (53.3%), Nunavut (52.7%), Quebec (49.6%) and Manitoba (49.4%).

# **International Comparisons**

## COMPARABILITY OF HEALTH EXPENDITURE ACROSS COUNTRIES

In general, international comparisons should be interpreted with caution, as variation exists between countries with regard to reporting, inclusion, and classification of health expenditure.

For the last two annual updates of the health database maintained by the Organisation for Economic Cooperation and Development (OECD), member-countries were asked to report health expenditure according to concepts presented in the OECD manual *A System of Health Accounts* (SHA) released in May 2000. Countries are at varying stages of reporting total health expenditure according to the boundary of health care proposed in the SHA manual. This means that data presented in OECD Health Data 2003 are at varying levels of comparability.

This section shows health expenditure information for the twelve countries that most closely follow the health care boundary proposed in the OECD manual. The OECD states that the data for those countries are believed to be fairly comparable, although some deviations from SHA definitions may still exist among the sub-aggregate variables of total health expenditure. The twelve countries are Australia, Canada, Denmark, France, Germany, Hungary, Japan, Korea, the Netherlands, Switzerland, the United Kingdom<sup>16</sup> and the United States.

Level of income and institutional characteristics also cause differences in drug expenditure across countries. Drugs consumed in low or middle-income countries often originate from more developed countries with high living standards and high labour costs. Consequently, the share of drugs in total health expenditure tends to be higher in low or middle-income countries because of the high price of drugs relative to other health goods and services.<sup>17</sup> Differences in service delivery across countries will also cause differences in the share of drugs in total health expenditure.

<sup>&</sup>lt;sup>16</sup> United Kingdom has not provided health expenditure data by use of funds since 1997.

<sup>&</sup>lt;sup>17</sup> S. Jacobzone, Organisation for Economic Cooperation and Development, *Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals*, Labour Market and Social Policy; Occasional Papers, No. 40, April 2000, Paris.

#### SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

The OECD maintains a comparative database on health related statistics, including health expenditure. This database captures information on expenditure for pharmaceuticals and other medical non-durables outside an institutional setting (equivalent to drugs purchased in retail establishments in Canada). Pharmaceutical and other medical non-durables comprise prescribed drugs, over-the-counter drugs and a wide range of medical non-durables such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In 1985, drug expenditure in Canada represented 9.6%<sup>18</sup> of total health expenditure. Korea had the largest share of drug expenditure in total health expenditure at 28.7% in 1985 and Denmark had the lowest at 6.6%. Canada ranked six among the eleven comparator countries for which data were available.<sup>19, 20</sup>

By 2001, drug expenditure in Canada had increased its share in total health expenditure by more than six percentage points to 16.2%. Among the comparator countries for which data were available, Canada ranked third in drug expenditure per capita, after the United States and France. Canada ranked fourth in the share of drugs in total health expenditure. Denmark had the lowest share of drug expenditure in total health expenditure at 8.9%, and Hungary had the highest at 30.7% (Table 3).

Table 3—Total Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2001<sup>21</sup>

Country*	GDP Per Capita		Total Drug Expenditure Per Capita		Total Health Expenditure Per Capita		Total Drug Expenditure as a % of Total Health Expenditure	
	(Can\$, PPP)	Rank	(Can\$, PPP)	Rank	(Can\$, PPP)	Rank	%	Rank
United States	42,218	1	726	1	5,864	1	12.4	8
Switzerland	35,851	2	422	6	3,986	2	10.6	9
Netherlands	35,269	3	319	9	3,151	5	10.1	10
Denmark	35,059	4	268	10	3,004	8	8.9	11
Canada	34,573	5	541	3	3,350	4	16.2	4
Australia	32,890	6	415	7	3,016	7	13.8	7
France	32,255	7	644	2	3,073	6	21.0	2
Japan	31,982	8	479	5	2,557	9	18.7	3
Germany	31,439	9	482	4	3,370	3	14.3	6
Korea (a)	18,375	10	172	11	1,081	11	15.9	5
Hungary	16,117	11	336	8	1,093	10	30.7	1

<sup>\*</sup>Countries appear in descending order of GDP per capita.

(a) 2000 data

Source: OECD Health Data 2003, 3rd edition. Organisation for Economic Cooperation and Development and CREDES, Paris.

OECD data are standardized for international comparability; consequently, figures calculated from these data may differ from those calculated from the national health accounts of member countries. Specific to Canada, expenditure on health research and the training of health care workers is included in the national health accounts, but excluded from OECD health expenditure data.

<sup>&</sup>lt;sup>19</sup> The OECD data were not available for France or Hungary in 1985.

<sup>&</sup>lt;sup>20</sup> With the exception of Denmark, the comparator countries did not begin conforming to SHA guidelines until after 1985.

<sup>&</sup>lt;sup>21</sup> Canadian data reported by the OECD are as of August 2003. In December 2003, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into OECD database until the summer of 2004.




Figure 16 illustrates the trends of drug expenditure per capita  $(Can\$, PPP)^{22}$  in five selected OECD comparator countries.<sup>23</sup>

Between 1985 and 2001, per capita drug expenditure grew at a faster average annual rate in Canada (8.9%) than in Denmark, the Netherlands, Switzerland or the United States. During this period, Switzerland experienced the lowest average annual growth rate in per capita drug expenditure (5.6%). Drug expenditure in the United States grew at an average annual rate of 8.7% during the same period.

## SHARE OF PUBLIC EXPENDITURE IN TOTAL EXPENDITURE ON DRUGS

The OECD database on health contains statistics on total expenditure on pharmaceutical goods and public expenditure on pharmaceutical goods. In both 1985 and 2001, at least half of the OECD comparator countries, for which data are available, reported that public drug expenditure represented more than 50% of expenditure on pharmaceutical goods. In Canada, drug expenditure by the public sector rose from 29.4% of total expenditure on pharmaceutical goods in 1985 to 36.1% in 2001.

In OECD countries, with the exception of those in North America, the entire population usually has coverage for prescribed drugs through public insurance. Most countries have formularies restricting the number of drugs covered under public insurance and impose cost sharing (deductibles, co-insurance or co-payments) with waivers for certain groups of beneficiaries.

<sup>&</sup>lt;sup>22</sup> Although using Purchasing Power Parity adjusted dollars (PPP\$) accounts for the relative change in inflation between countries, average annual growth rates should still be considered in the context of economy-wide inflation.

<sup>&</sup>lt;sup>23</sup> The five countries that had the highest GDP per capita in 2001.

Table 4 shows that among the eleven OECD comparator countries for which data were available in 2001, Canada ranked seventh in public sector drug expenditure per capita and ninth in share of public expenditure in total drug spending. The United States ranked ninth and tenth, respectively, in these two categories.

France had the highest level of public drug spending per capita (\$425) and Germany had the highest public share of total drug spending (70.6%).

Table 4—Public Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods,
Reporting OECD Comparator Countries, 2001<sup>21</sup>

Country*	Public Drug E Per Ca	•	Total Drug Ex Per Ca	-	Public Drug Expenditure as a % of Total Drug Expenditure		
	(Can\$, PPP)	Rank	(Can\$, PPP)	Rank	%	Rank	
United States	136	9	726	1	18.7	10	
Switzerland	265	4	422	6	62.6	4	
Netherlands	193	8	319	9	60.6	6	
Denmark	136	10	268	10	50.5	8	
Canada	196	7	541	3	36.1	9	
Australia	223	5	415	7	53.7	7	
France	425	1	644	2	65.9	3	
Japan	323	3	479	5	67.5	2	
Germany	341	2	482	4	70.6	1	
Korea (a)	30	11	172	11	17.4	11	
Hungary	208	6	336	8	61.8	5	

<sup>\*</sup>Countries appear in descending order of GDP per capita.

(a) 2000 data

Source: OECD Health Data 2003, 3rd edition. Organisation for Economic Cooperation and Development and CREDES, Paris.

The high share of total drug expenditure financed by the public sector in some European countries (e.g. Germany, France, Netherlands) reflects the inclusion of drug benefits provided through employment related social security funds in publicly financed drug expenditure (see Data Table C.2.). These funds are social insurance programs covering the community as a whole or large sections of the community and are imposed or controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms on which benefits are paid to recipients. In some European countries, expenditure by social security funds represents the major share of public expenditure on drugs (e.g. 98.7% in Germany in 2001).

By contrast, in Canada, until 1996, drug benefits under social security funds included only spending by workers' compensation boards and they represented less than 2% of public expenditure on drugs in retail establishments. Starting in 1997, they also included expenditure by the Quebec Drug Insurance Fund (Fonds de l'assurance-médicaments). The share of social security funds in public expenditure on drugs in Canada increased from 6.0% in 1997 to 7.5% in 2001. The Quebec Drug Insurance Fund, financed by the mandatory payment of premiums, covers residents not otherwise insured by the provincial program (for seniors, social assistance recipients, etc.) or by private health insurance generally offered through employment.

Group insurance plans offered by employers, unions and professional associations that resemble the European model do exist in Canada. However, since group health insurance in Canada is not imposed by a government authority, and policy-holders may voluntarily opt-out, it is considered to be privately financed. Private group health insurance accounted for 26.9% of total drug expenditure in retail establishments in Canada in 2001.

# SHARE OF DRUGS IN PUBLIC EXPENDITURE ON HEALTH

In Canada, drugs accounted for only 3.8% of health expenditure by the public sector in 1985. This proportion increased to 8.2% in 2001 reflecting substantially higher growth in drug expenditure than in other types of public sector health expenditure between 1985 and 2001. Among the comparator countries for which data were available<sup>24</sup> in 1985, the share of drugs in public sector health expenditure ranged from 1.9% in the United States to 15.4% in Japan. In 2001, the share of drugs in public sector health expenditure ranged from 5.2% in the United States to 25.3% in Hungary.

In 2001, the share of drug spending in public sector health expenditure was lower than the share of drug spending in total health expenditure in each of the comparator countries except for Switzerland, reflecting generally higher cost sharing for drugs than for other health expenditure. In the case of Canada, the low share of drugs in total public expenditure on health (8.2% in 2001) when compared with the share of drugs in total health expenditure (16.2% in 2001) also reflects the absence of universal coverage of prescribed drugs by public insurance, while there exists universal and full coverage of medically necessary hospital and physician services.

-

<sup>&</sup>lt;sup>24</sup> The OECD data were not available for France, Hungary, Korea or Switzerland in 1985.

Table 5—Public Expenditure on Pharmaceutical Goods Per Capita and as a Percentage of Public Sector Health Expenditure, Reporting OECD Comparator Countries, 2001<sup>21</sup>

Country*	Public Drug E Per Ca	-	Public Health E Per Ca	•	Public Drug Expenditure as a % of Public Health Expenditure		
	(Can\$, PPP)	Rank	(Can\$, PPP)	Rank	%	Rank	
United States	136	9	2,602	1	5.2	11	
Switzerland	265	4	2,278	6	11.6	5	
Netherlands	193	8	1,996	8	9.7	7	
Denmark	136	10	2,476	3	5.5	10	
Canada	196	7	2,374	4	8.2	8	
Australia	223	5	2,046	7	10.9	6	
France	425	1	2,336	5	18.2	2	
Japan	323	3	1,992	9	16.2	3	
Germany	341	2	2,525	2	13.5	4	
Korea (a)	30	11	479	11	6.2	9	
Hungary	208	6	821	10	25.3	1	

<sup>\*</sup>Countries appear in descending order of GDP per capita.

Source: OECD Health Data 2003, 3rd edition. Organisation for Economic Cooperation and Development and CREDES, Paris.

<sup>(</sup>a) 2000 data

# Factors Affecting Drug Expenditure in Canada

Numerous factors, many of which are interrelated, may influence drug expenditure. Since drug prices, as measured by several price indices, have been relatively stable over the past ten years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

These factors present important challenges for the development of indicators to monitor trends and results that affect not only the performance of the health care system, but also the health of the population.

Although some literature exists on the effects of various factors on drug expenditure, more research is required to quantify the effect of each factor and to inform the relationship between drug expenditure and other health care spending. The following table outlines some of the factors that may influence drug expenditure.

#### Table 6—Factors That May Influence Drug Expenditure in Canada

#### **Prices**

Changes in the unit prices of drugs (both patented and non-patented)
Changes in retail and wholesale mark-ups and professional fees
Availability of generics
International prices
Inflation

#### **Entry of New Drug Chemicals**

#### Table 6—Factors That May Influence Drug Expenditure in Canada (cont'd)

#### Volume of Drug Use

• Population-related

Changes in population size

Changes in population structure/distribution

Age, gender and ethnicity

Changes in health status of a population

Emergence of new diseases

**Epidemics** 

Prevalence and severity of disease

• System-related

Changes and transition associated with health system reform

Availability and access to third party insurance coverage

Changes in policies and programs

The extent of formulary listings

Eligibility and co-payments

Research and Technology-Related

New treatment approaches

Drugs replacing surgery

Drug therapy for previously untreatable or under-treated diseases

Availability of more and/or improved diagnostic technology

Outcomes research, evidence-based preventive or curative approaches in diagnosis or treatment

Use of programs and technology in monitoring patients

Pharmaceutical Industry

Development of new drug products (e.g. new strengths, new drug forms and presentations)

Promotion of drugs to physicians

Drug sampling

Direct to consumer advertising

• Practice and People-Related (Health Care Providers and Consumers)

Changes in prescribing and dispensing practices

Number and mix of prescribers (specialists, general practitioners, nurse practitioners and others)

Multiple doctoring

Consumers' expectations and behaviours

Adherence to treatment

## Methodological Notes

#### BACKGROUND

Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX) maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro level health expenditure statistics by province and territory beginning in 1960. Drug expenditure data in NHEX are macro level data and do not allow for decomposition of prescription costs or drug classes.

The "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, which include dispensing fees, mark-ups and appropriate taxes. NHEX data does not account for drug expenditure by non-Canadians (for example, Americans via Canadian Internet pharmacies). This classification system is consistent with international standards developed by the Organisation for Economic Cooperation and Development (OECD).

#### National Health Expenditure (NHEX) Database

The mandate of the National Health Expenditure (NHEX) database is twofold:

- 1. To support the development and evaluation of health programs in Canada by all levels of government, and within the private sector.
- 2. To compile information on health expenditure that will accurately portray the importance of health care as a component of national expenditure.

**Health Expenditure**—includes any type of expenditure for which the primary objective is to improve or prevent the deterioration of health status.

This definition allows economic activities to be measured according to primary purpose and secondary effects. Activities that are undertaken with the direct purpose of improving or maintaining health are included. Other activities are not included, even though they may impact health. For example, housing and income support policies have social welfare goals as their primary purpose and are not considered to be health expenditure, yet they are recognized as powerful factors in determining population health.

#### Source of Finance

National health expenditure is reported based on the principle of *responsibility for payment* rather than on the source of the funds. It is for this reason, for example, that federal health transfers to the provinces are included in the provincial government sector since it is the responsibility of provincial governments to expend federal transfers on health services. The exception to this principle is that provincial government health transfers to municipal governments are included in the provincial government sector. The following figure depicts the decomposition of total health expenditure by source of finance.




Figure 17 — Composition of Total Health Expenditure by Source of Finance

**Public Sector**—includes health care spending by governments and government agencies. It is sub-divided into *Provincial Government Sector* and *Other Public Sector*, as described below:

- 1. The *Provincial Government Sector* includes health spending from provincial/territorial government funds, federal health transfers to the provinces/territories, and provincial government health transfers to municipal governments.
- 2. The *Federal Direct Sector* refers to direct health care spending by the federal government in relation to health care services for special groups such as Aboriginals, the Armed Forces and veterans. Federal Direct health expenditure does not include federal health transfers to the provinces.
- 3. The Municipal Government Sector expenditure includes health care spending by municipal governments for institutional services; public health; capital construction and equipment; and, dental services provided by municipalities in the provinces of Nova Scotia, Manitoba and British Columbia. Designated funds transferred by provincial governments for health purposes are not included in the municipal sector, but are included with provincial government expenditure. Currently, no estimates of drug spending are included in this sector.

- 4. Social Security Funds are social insurance programs that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms on which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by workers' compensation boards and the drug insurance fund component of the Quebec Ministry of Health and Social Services drug subsidy program.
  - Health spending by Workers' Compensation Boards (WCB) includes what the
    provincial boards commonly refer to as medical aid. Non-health related items often
    reported by the Workers' Compensation Boards as medical aid expenditure such as
    funeral expenses, travel, clothing etc. are removed.
  - On January 1, 1997 the government of Quebec introduced a drug program that
    covered residents of the province, who were not otherwise covered by the
    provincial program or by private health insurance, generally offered through
    employment. Drug claims for these participants of the new plan are paid from the
    Drug Insurance Fund. This component of the Quebec drug program is self-funded
    through income-based premiums, deductibles and co-payments paid by the insured.

**Private Sector**—includes health care spending by individuals and private sources as described below:

- 1. Non-consumption includes non-patient revenues received by health care institutions such as donations and investment income, private spending on health-related capital construction and equipment and health research funded by private sources. Currently, no estimates of drug spending are included in this portion of private sector.
- 2. Out-of-pocket health expenditure made by individuals for health care goods and services.
- 3. Private health insurance includes health expenditure paid by commercial and not-for-profit insurance firms, as well as the cost of administering those claims.

#### **Hierarchy of Classification**

National health expenditure in Canada is based on a system of classification that is consistent with international standards developed by the Organisation for Economic Cooperation and Development (OECD) for reporting of health expenditure.<sup>25</sup>

National health expenditure are grouped within the broad categories of "Personal Health Care" or "Other Expenditure":

**Personal health care** consists of expenditure for health goods and services used by individuals.

Other health expenses consist of expenditure on behalf of society, such as public health; expenditure made as investments for purposes of future consumption, such as capital expenditure; the administrative expenses of planning and managing the health care system; and research.

Personal health expenditure is classified within categories that describe the type of health care used. Certain categories overlap. The hierarchy of classification that is used to allocate overlapping categories of expenditure is:

Institutional setting—health care services consumed in hospitals or other institutions are allocated to the institutional category if the institution purchases the services on behalf of its patients. For example, drugs paid through hospital budgets are classified as hospital expenditure. This allocates expenditure to the supplier actually paid by patients or their agents in the form of government or insurance companies. It also reflects data availability.

**Self employed provider of service**—for example, all expenses of physicians' practices are considered to be expenditure for physicians services, even though some of these expenses would be for employment of other health professionals, drugs or personal health supplies.

**Type of good or service**—drugs and personal health supplies are examples.

One of the categories of health expenditure within NHEX is "Drugs". Other categories include: hospitals, other institutions, physicians', other professionals, capital, public health and administration and other health spending. In NHEX, these categories are also named Use of Funds.

Below is a description of the drug category within NHEX, it is not a definition supplied by the OECD.

<sup>25</sup> Statistics Canada (Public Institutions Division) publishes estimates of government health expenditure as part of its comprehensive reporting system of all government expenditure, the Financial Management System (FMS). The FMS public sector health spending estimates are lower than those reported by CIHI because different classification methods are applied and a narrower definition of health expenditure is used in the FMS.

**Drugs**—at the aggregate level, include expenditure on prescribed drugs and non-prescribed products purchased in retail stores. Estimates represent the final costs to consumers including dispensing fees, mark-ups and appropriate taxes. This category has been disaggregated at the Canada level in the Data Tables to provide information on the following sub-categories:

Prescribed Drugs—substances considered to be drugs under the Food and Drugs Act, and which are sold for human use as the result of a prescription from a health professional.

*Non-Prescribed Drugs*<sup>26</sup>—include two sub-components: Over-the-counter drugs; and, Personal Health Supplies.

Over-the-Counter Drugs<sup>26</sup>—therapeutic drug products not requiring a prescription.

*Personal Health Supplies*<sup>26</sup>—include items used primarily to promote or maintain health, e.g. oral hygiene products, diagnostic items such as diabetic test strips and medical items such as incontinence products.

The drug category in NHEX does not include drugs dispensed in hospitals and generally in other institutions. These are included with the category of hospitals or other institutions.

#### Other Terms

**Gross Domestic Product (GDP)**<sup>27</sup>—GDP Implicit Price Index (in 1997 dollars) is used to compare annual percentage change of drug expenditure with inflation in the Canadian economy. GDP is the unduplicated value of production originating within the boundaries of Canada, regardless of the ownership of the factors of production.

**Purchasing Power Parity (PPP)**<sup>28</sup>—Purchasing Power Parities (PPPs) are the rates of currency conversion that equalize the purchasing power of different currencies. This means that a given sum of money, when converted into different currencies at the PPPs rates, will buy the same basket of goods and services in all countries. Thus PPPs are the rates of currency conversion, which eliminate differences in price levels between countries.

<sup>&</sup>lt;sup>26</sup> For more information on over-the-counter drugs and personal health supplies, see General Methods section of the Methodological Notes.

<sup>27</sup> Statistics Canada, Guide to the Income and Expenditure Accounts, catalogue 13-603E, 1996, pp. 137 and 139.

<sup>&</sup>lt;sup>28</sup> OECD Health Data 2003, Organisation for Economic Cooperation and Development, Paris, 2003.

#### MAJOR DATA LIMITATIONS

Data contained in the national health expenditure database are estimates. The data are collected from diverse sources and include varying classes of financial information. The data are collected and classified according to methods established by a Review Committee. CIHI analysts and external experts continue to improve the comprehensiveness, accuracy and currency of the data, in order to provide the most complete and objective estimates possible. Notwithstanding, national health expenditure data are estimates and should be used accordingly.

Most private sector expenditure is estimated from survey data. Prior to 1997, the Family Expenditure Survey by Statistics Canada<sup>29</sup>, an important source of private sector data, was not carried out annually; therefore, trend data have been imputed for years between surveys. Private sector data were revised following a methodology review in the early 1990s. The revised private sector data incorporated information estimated directly from new sources for 1988 and subsequent years. Prior years were estimated using trend data. As a result, readers should use caution when using the private sector expenditure data for small provinces and for years prior to 1988.

#### **Drugs in Hospitals**

The National Health Expenditure Database (NHEX) at CIHI uses a classification system that is consistent with international standards developed by the Organisation for Economic Cooperation and Development (OECD) for the reporting of health expenditure. Similar to the functional category "Pharmaceutical and Other Medical Non-Durables" in the OECD system of health accounts, the "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third party payers on their behalf, generally from retail outlets. Drugs in hospitals are considered as inputs (intermediate consumption) to the production of health care in hospitals. Consequently, drugs paid through hospital budgets are not identified separately in NHEX but classified as hospital expenditure. Similarly, drugs purchased by residential care facilities for their residents are classified as institutional expenditure. All expenses of physicians' and dentists' practices, including drugs, are considered to be expenditure for physicians' and dentists' services. Some drug expenditure is also included in the NHEX category of public health (e.g. vaccines).

While the above hierarchy of classification is essential in allocating overlapping categories of expenditure, it also reflects data availability. For example, data on expenditure by provincial/territorial governments are usually extracted from provincial/territorial government Public Accounts. In the Accounts, it is generally not possible to isolate drug spending from other categories of expenditure within program areas (e.g. hospitals, public health, etc.). While there exist other possible data sources, the use of a single data source, such as the provincial/territorial Public Accounts, for the different categories of provincial government health expenditure has the major advantage of minimizing the risk of double counting.

40

<sup>&</sup>lt;sup>29</sup> Family Expenditure in Canada, Statistics Canada Catalogue Number 65-555. Statistics Canada, Periodical, Ottawa.

Data on drug expenditure in hospitals can be obtained from the Annual Hospital Survey, conducted by Statistics Canada, until 1994 and by CIHI thereafter through the Canadian MIS Database (CMDB).30,31

#### **Measuring Drug Prices**


There is no authoritative composite price index for all drugs sold in Canada. The difficulty lies in the fact that traditional statistical measurement considers the price of tablets or capsules rather than measuring the nature of the product itself (i.e. its therapeutic properties). In pure economic terms, the price of a drug is the price per unit of health gain attained. From a practical perspective, however, people buy tablets, capsules or other forms of medication, some of which may contain multiple active ingredients.

There are several commonly accepted price indices that can potentially be used to measure shifts in drug prices at the retail level. These include the Consumer Price Index (CPI), the pharmaceutical component of the Industrial Product Price Index (IPPI [pharma]) and the Patented Medicine Price Index (PMPI). Each index is built upon a unique set of assumptions pertaining to inclusion criteria, definitions, updating, and weighting methodologies. As a result, these indices produce differing results (Figure 18).

It is important to determine whether two different products, with similar therapeutic elements used to treat similar health conditions, are essentially different. Several price indices assume they are different products. The consequence is that when new products enter the market, price indices do not compare their prices to existing products; they are simply added to the basket of goods.

<sup>&</sup>lt;sup>30</sup> The Canadian MIS Database (CMDB) contains financial and statistical information from hospitals, and limited data from health regions, across Canada. The data are collected according to a standardized framework for collecting and reporting financial and statistical data on the day-to-day operations of health service organizations. The framework is known as the Guidelines for Management Information Systems in Canadian Health Service Organizations (MIS Guidelines).

<sup>&</sup>lt;sup>31</sup> Drug expenditure in hospitals includes only the cost of the drug supplied. They do not include associated costs of hospital pharmacy pertaining to the requisitioning, storage, control, compounding, standardizing, distribution, and monitoring of drugs, and for acting as an information source on all pharmaceutical matters. The full cost of hospital pharmacy may be identified in the Canadian MIS Database.



#### COLLECTION AND NON-RESPONSE

The definitions and methods used in the preparation of this document are for the most part based on those adopted in 1994 by the National Health Expenditure Methodology Review Committee. This committee included representation from Health Canada, Statistics Canada, ministère de la Santé et des services sociaux du Québec, the Canadian Medical Association and the Canadian Healthcare Association. Some of the recommendations for change made during that process are still under development.

#### **General Methods**

The following is intended as a general overview of the methods applied to calculate estimates of drug expenditure in Canada. More detailed information can be obtained by contacting the National Health Expenditure section by phone (613) 241-7860, by fax (613) 241-8120, or by e-mail nhex@cihi.ca.

#### Provincial/Territorial Government

Provincial/territorial government expenditure principally includes drugs that are dispensed through provincial/territorial drug subsidy programs (see Appendix). This drug expenditure data is extracted predominantly from audited and consolidated provincial/territorial documents detailing provincial government expenditure (Table 7).

Provincial/territorial government drug spending figures include spending by the provincial/territorial ministry responsible for health as well as by other departments who may provide drug coverage. CIHI's estimates of provincial/territorial government drug expenditure were submitted to provincial/territorial departments of health for review.

Provincial/territorial government figures identified as forecasts are based on the growth rates of major programs reported in provincial/territorial government "Main Estimates and Budgets."

Table 7—Provincial/Territorial Government Drug Expenditure Data

Province/ Territory		Description
Newfoundland and Labrador	Drug Expenditure Data Source	Drug expenditure data are collected from the Provincial Public Accounts Volume III, Consolidated Revenue Fund Supplementary Statements and Schedules for three drug programs: Indigents, Seniors and the Special Drug Programs.
Prince Edward Island	Drug Expenditure Data Source	The Drug Cost Assistance Program is reported under Provincial Pharmacy program in the Queens Region Health and Community Services operating statement, which is reported in Prince Edward Island Provincial Public Accounts Volume II.
Nova Scotia	Drug Expenditure Data Source	Drugs data is extracted from three sources, the Nova Scotia. Supplementary Estimates Details, special tabulations from the Nova Scotia Seniors' Pharmacare Program, and the Nova Scotia Department of Community Services, Income Assistance and Employment Support Services.
New Brunswick	Drug Expenditure Data Source	Drugs data are provided through special reports from the Department of Health and Community Services and the Department of Human Resources. A small component of drug expenditure by the provincial government is from the New Brunswick. Public Accounts Volume 2 under Payments to Vendors and Grants and Contribution Payments.
Quebec	Drug Expenditure Data Source	Provincial government expenditure is extracted from volume 2 of the Quebec provincial public accounts. Spending on drugs by the provincial government is represented by total transfers of Program 5, Régie de l'assurance-maladie du Québec (RAMQ), for médicaments et services pharmaceutiques. See also the section, below, on Social Security Funds and the Quebec Drug Insurance Fund.
Ontario	Drug Expenditure Data Source	Data is collected from volume 1 of the Ontario Provincial Public Accounts. Information is collected for the drug programs provided by the Ministry of Health (Ontario Drug Benefit Program, Trillium Drug Program, Special Drug Program) and by the Ministry of Community and Social Services, under Social Assistance and Employment under the Adult and Children's Service Program.
Manitoba	Drug Expenditure Data Source	Data is from the Manitoba Health's Pharmacare program under the Health Services Insurance Fund, Pharmacare Program. Data is also collected from the annual report of the Manitoba Department of Family Services under Income Assistance of the Employment and Income Assistance Program.

Table 7—Provincial/Territorial Government Drug Expenditure Data (cont'd)

Drovings/		
Province/ Territory		Description
Saskatchewan	Drug Expenditure Data Source	Data sources include the Saskatchewan Public Accounts volume 2 and the Saskatchewan Health Annual Statistical Report for the Drug Plan and Extended Benefits Branch. Data are collected for the Saskatchewan Prescription Drug Plan from their Annual Report. A total for the Supplementary Health Program (SHP) is also extracted from the annual report. The distribution of detailed expenditure of the Supplementary Health Programs provided in the Statistical Report for the Drug Plan and Extended Benefits is applied to the total for the SHP extracted from the public accounts. One of the components of the SHP that is also collected is "non-formulary drugs." Drug expenditure amounts are collected under the Ministry of Social Services in the Supplier Payments section of the public accounts.
Alberta	Drug Expenditure Data Source	Drug Expenditure data from Alberta Health and Wellness are extracted from the annual report of Alberta Health and Wellness. Detailed claims summary data is provided from Alberta Blue Cross Non-Group Benefits. The largest single expenditure component of Alberta Blue Cross Non-group Benefits are drug benefits. The detailed claims distribution is applied to the total for Blue Cross Non-Group Benefits under Practitioner Services extracted from the annual report of the Ministry of Health and Wellness.  Drug expenditure information is also collected from Children's Services, Department of Community Development, and the Department of Human Resources and Employment. Drug expenditure amounts are compiled from various Income Assistance programs, including Income Support to
		Individuals and Families, Social Support to Individuals and Families, and Services to Persons with Disabilities.
British Columbia	Drug Expenditure Data Source	Data is received in the Financial Management Reports (FMRs) from the Ministry of Health Services. Control totals for major programs are from the Public Accounts. With few exceptions, expenditure items from the FMRs sum to the control totals. The Ministry of Health Services administers drug subsidization for all targeted groups (seniors, income assistance recipients, and families) under the Medical Services Program.
Yukon Territory	Drug Expenditure Data Source	Control totals on major programs are extracted from the Yukon Public Accounts. Additional details are in a special tabulation provided by the territorial Ministry of Health and Social Services on spending for Pharmacare, Prescription drugs under the Chronic Disease Program and Extended Health Benefits for Seniors.
Northwest Territories	Drug Expenditure Data Source	Drug expenditure data is provided from the Finance Division of the Department of Health and Social Services under the Extended Health Benefits of the Supplementary Health Programs.
Nunavut	Drug Expenditure Data Source	The government of Nunavut is unable to provide drug expenditure amounts to CIHI. The method used to estimate expenditure in Nunavut was to allocate the same proportion that drugs were in the Northwest Territories of the aggregate of individual programs in the Northwest Territories that make up Supplementary Health Benefits Program in Nunavut.

#### Federal Direct

Prescribed drugs data is derived from information provided by federal government organizations supplemented with information from the National Public Accounts. Federal government health care spending is generally provided according to the province in which the expenditure was made. Some data, however, is provided only at the national level, in these cases it is distributed by the appropriate provincial/ territorial population.

#### Social Security Funds

Social Security Funds are financially autonomous social insurance schemes that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms by which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by workers' compensation boards and the drug insurance fund component of the Quebec Ministry of Health and Social Services drug subsidy program.

Workers' Compensation Boards—Prescribed drug expenditure for the Workers' Compensation Boards (WCB) and la Commission de la santé et de la sécurite du travail du Québec are collected through special tabulations from contacts in each provincial/territorial WCB.

Quebec Drug Insurance Fund—On January 1, 1997 the Quebec Ministry of Health and Social Services, through the RAMQ introduced a universal drug program that covered residents of the province who were not otherwise covered by the provincial program or by private health insurance generally offered through employment. Drug claims for these participants are paid from the Drug Insurance Fund. This fund is self-financed through the compulsory payment of premiums generally by the self-employed and employees of organizations that do not offer private drug insurance as a benefit of employment.

Data for this component of the provincial drug program are compiled by subtracting the amount for Médicaments et services pharmaceutiques paid on behalf of the Régie de l'assurance maladie du Québec (RAMQ) by the provincial government and reported in the Quebec Public Accounts from the total amount of the program reported in the RAMQ annual report. Essentially, subtracting the amount of the Quebec drug subsidy program funded by the province from the overall claims of the RAMQ, leaving the portion of the program that is self-financed.

#### Private Sector

Private sector drug data were revised in 1995 following a methodology review that began in the early 1990s. Private sector data under the revised methodology incorporated information estimated directly from new sources for 1988 and subsequent years. Expenditure amounts prior to 1988 were estimated using trend data. Therefore, readers should exercise caution when using the private sector expenditure data for small provinces and for years prior to 1988.

The recommendations pertaining to prescribed and non-prescribed drugs that were ultimately implemented included the following:

- Data on drug benefits paid by private insurers were to be estimated based on information provided by the Canadian Life and Health Insurance Association (CLHIA) and from surveys of non-profit insurers.
- Out-of-pocket expenditure on drugs were to be estimated from Statistics Canada Family Expenditure in Canada survey (FAMEX) re-named in 1997, the Survey of Household Spending (SHS).
- Non-prescribed drug estimates would include two components, over-the-counter drugs and personal health supplies. Estimates would be based on information from the market research firm A.C. Nielsen.

As part of the original agreement with the not-for-profit insurance firms that provide data to NHEX, the administrators of the NHEX database agreed not to report the components of the private sector—insurance and out-of-pocket expenditure—at the provincial level. The purpose was to protect the proprietary nature of the information of the not-for-profit insurance firms. Consequently, CIHI only reports the private sector sum of components by province, and the out-of-pocket and insurance components of the private sector, at the national level.

The data sources and methodologies related to these recommendations are described below.

Health insurance drug claims paid are collected from nine not-for-profit insurance companies and the Canadian Life and Health Insurance Association. The Canadian Life and Health Insurance Association data is based on their survey of member companies. Currently, drug spending that may occur by insurance companies providing casualty insurance is not included in the estimates.

**Out-of-pocket** prescribed drug expenditure is based on purchased data from the Survey of Household Spending (SHS), formerly the Family Expenditure Survey, fielded by Statistics Canada. Specifically, average household costs associated with question 14, in section "P" of the SHS, relating to medicines, drugs and pharmaceutical products *prescribed by a doctor* are the basis of the estimates. The average household expenditure of prescribed drugs is multiplied by the number of estimated households reported in the survey.

The SHS is an annual survey, which began in 1997. Prior to 1997, full surveys that included both urban and rural areas were carried out in 1986 and 1992. In 1990 a survey was conducted that included only metropolitan areas. In years when complete surveys are carried out, data are available for the ten provinces and for 17 urban centres. The urban centres include Yellowknife and Whitehorse, which are used to derive estimates of expenditure in the territories. Metropolitan expenditure per household tend to be somewhat higher than provincial estimates. All relevant categories were updated in complete survey years. In years when only urban surveys were carried out, the percentage changes in urban expenditure within each province or territory were used to update category estimates from complete survey years. Between 1992 and 1997 when no surveys were conducted, provincial growth rates of the Statistics Canada variables of drug and drug sundries was used to impute missing years.

The non-prescribed drug estimate is based on data from the market research firm, A.C. Nielsen, which tracks consumer sales of non-prescribed drugs sold in Canada at retail. Each year, A.C. Nielsen reports retail sales data for two consistent years for 48 plus non-prescribed drug categories. Data are reported by sales channel,<sup>32</sup> total dollar sales volume and by regional sales distribution for five regions that includes nine provinces. Newfoundland and Labrador and the territories are not included. The data is processed by classifying the non-prescribed drug categories as either over-the-counter drugs or personal health supplies. Regional sales amounts are separated into nine provinces and estimates for Newfoundland and Labrador and the territories are calculated, using provincial distributions of Direct Costs for Health Care from the SHS. Lastly, appropriate provincial and federal sales taxes are incorporated into the estimates.

\_

<sup>&</sup>lt;sup>32</sup> As a general rule Statistics Canada definitions govern the classification of stores by class of trade. Sales channels include Drug Stores; Food Stores with Pharmacies; Grocery Banners; Mass Merchandiser and Warehouse Clubs, which are estimated from A.C. Nielsen's household panel data.

The following list provides the various drug classes that are supplied to CIHI by A.C. Nielsen. The choice of classes to be included in the non-prescribed drug expenditure estimate and the classification according to which drugs are included as over-the-counter or personal health supplies was made by the NHEX Drug Expenditure Review Committee during the NHEX methodology review and adopted in 1995.

#### Over-the-Counter Drugs Personal Health Supplies

Analgesic rubs Adhesive bandages and dressing strips

Anti-fungals (external) Anti-perspirants

Athletes' foot products (included in Artificial sweeteners

anti-fungals in later years)

Athletic supports/braces

Cold remedies Condoms

Cough remedies Contact lens preparations

Diarrhoea remedies Cotton swabs

Dietary aids Cover and tape products

Headache remedies Dental floss
Headache remedies—child's acetaminophen Dentrifice

Hemorrhoidal remedies Denture adhesives
Infant feeding products Denture cleansers

Laxatives Diabetic test strips

Medical nutritional supplements Disposable diabetic syringes

Milk intolerant products Elastic bandages

Nasal preparations Eye drops and lotions

Oral backache remedies Feminine hygiene products

Pediculicides Fever thermometers
Personal lubricants Incontinent products
Pre-menstrual products Medical supports/braces

Sleeping aids Oral antiseptics

Throat remedies Pregnancy test kits

Topical wound care Sanitary pads

Upset stomach remedies Selected hot/cold compress

Vitamins—children Selected insoles

Vitamins—adult Tampons

Wart removers Toothbrushes (incl. denture brushes)

#### **Calculation Methods**

#### Calculation of Average Annual Rate of Growth

The Average Annual Rate of Growth is the constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. The formula used to calculate the average annual rate of growth is:

= (e 
$$\frac{(\ln(\text{value at end of period}) - \ln(\text{value at beginning of period}))}{(T-1)}$$
)-1

Where the constant e equals 2.718, which is the base of the natural logarithm, and T equals the number of years in the period.

#### Calculation of Calendar Year

Some information sources provide data in fiscal years. Calendar year data were derived by adding ¾ of one fiscal year to ¼ of the previous fiscal year.

#### Calculation of Per Capita Dollars

Per capita expenditure were calculated using the most recent revised population estimates and forecasts from the Demography Division of Statistics Canada. These take into account the results of the census adjustment for net census under-count, non-permanent residents and returning Canadians.

#### Calculation of TOTAL Health Expenditure

Total health expenditure refers to the sum of the public and the private sectors. Canada refers to the sum of the 10 provinces and 3 territories. Canada Average is the sum of provincial/territorial expenditure divided by the sum of provincial/territorial data of another variable, such as population.

#### Calculation of Deflated Drug Expenditure Per Capita by Using CPI

Where drug expenditure per capita is presented in constant 1985 dollars, constant dollar drug expenditure per capita was calculated using Consumer Price Index (CPI), provided by Statistics Canada. A more complete explanation of the methodology for calculating Consumer Price Index is available from Statistics Canada.<sup>33</sup>

<sup>33</sup> Your Guide to the Consumer Price Index, Statistics Canada catalogue number 62-557-XPB, Statistics Canada, Ottawa

#### **Forecasting Methods**

Provincial government sector drug spending forecasts are based on the growth rates of drug subsidy programs of provincial health departments reported in provincial Main Estimates and Budgets. In the case of territorial government forecasts of the Northwest Territories and Nunavut, estimates were based on amounts reported in their Main Estimates. In other sectors, the figures for these two territories were calculated by developing a forecast for the Northwest Territories including Nunavut. The share of Nunavut spending in the last year of actual data of the combined total of the Northwest Territories and Nunavut was used as a proxy to break out the forecasts for the Northwest Territories and Nunavut.

Forecasts for the Federal Direct, Workers' Compensation Boards, and the Private sector were entirely based on econometric analysis of time series trends. For each series, up to 40 different univariate forecasting specifications were evaluated, and the best one (based on the root mean square error of prediction) was selected. The functional forms studied included the exponential smoothing family (simple, double, Holt, Brown, Winters, damped trend, etc.); time trends; ARIMA specifications; etc. Logarithmic transformations were used when the data warranted its use.

Forecasts of health expenditure are identified in the figures by special symbols and in the Data Tables by the letter "f".

#### SOURCES OF DATA

Drug Expenditure estimates, from the National Health Expenditure database, are compiled based on information from the following sources.

#### **Provincial Government Sector**

- Provincial Public Accounts and Main Estimates
- Provincial Departments of Health Annual Reports and Statistical Supplements, where available
- Annual Reports of various foundations, agencies and commissions
- Special tabulations and specific information from various provincial departments reporting health expenditure

#### **Federal Direct Sector**

- Public Accounts of Canada
- Special tabulations/information from:
  - Health Canada
  - Department of Veterans Affairs
  - Department of National Defense
  - Solicitor General of Canada
  - Statistics Canada
  - Citizenship and Immigration Canada
  - Several organizations that are responsible for administering research funds from federal government such as Canada Foundation for Innovation, Canadian Health Services Research Foundation and the Canadian Institute for Advanced Research

#### **Social Security Funds Sector**

- Special tabulations on medical aid spending provided by the provincial/territorial Workers' Compensation Boards
- Annual Reports of provincial/territorial Workers' Compensation Boards
- Annual Report of the Régie de l'assurance-maladie du Québec

#### **Private Sector**

- Private Insurance Component
  - The not-for-profit portion is captured from special tabulations provided by the not-for-profit insurance companies
  - The commercial portion is captured by a special tabulation provided by the Canadian Life and Health Insurance Association (CLHIA)
- Out-of-Pocket Component
  - Survey of Household Spending, Statistics Canada (formerly the Family Expenditure Survey [FAMEX]); and,
  - Over-the-counter Drugs and Personal Health Supplies—Market Review of Selected Drug Categories at Retail, a special tabulation purchased from A.C. Nielsen Canada

#### **Economic and Demographic Data**

- Gross Domestic Product
  - 1975 to 2002: purchased from National Accounts and Environment Division, Statistics Canada
  - 2003: purchased from the Conference Board of Canada (GDP growth rates)
- Population: purchased from the Demography Division, Statistics Canada
- Price Indices:
  - Patented Medicine Price Index (PMPI) from Patented Medicine Prices Review Board
  - Consumer Price Index (CPI), and Industrial Product Price Index (IPPI) purchased from the Prices Division, Statistics Canada

## Series A

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2003

Table A.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Canada, 1985–2003

			Public		Prescribe	d Drugs	Private				Prescribed D	_
	Provincial/ Territorial	Federal _	Social Secur W.C.B.	ity Funds  Drug Insurance Funds	Sub-Total Public	Insurers	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year						(\$ mi	llions)					
1985	1,048.1	58.0	12.6		1,118.7			1,447.7	2,566.5			1,235.9
1986	1,240.6	63.3	15.2		1,319.2			1,698.8	3,018.0			1,399.0
1987	1,406.7	68.2	17.8		1,492.7			1,800.4	3,293.1			1,621.7
1988	1,592.7	89.3	20.8		1,702.8	1,131.3	902.7	2,034.0	3,736.8			1,784.9
1989	1,838.0	110.0	22.9		1,970.9	1,261.6	1,030.4	2,292.0	4,262.9			1,975.6
1990	2,120.2	130.3	27.5		2,278.0	1,467.9	1,126.0	2,593.9	4,871.8			2,058.7
1991	2,428.0	145.6	33.2		2,606.7	1,672.5	1,189.4	2,861.9	5,468.7			2,236.6
1992	2,710.7	159.7	38.1		2,908.5	1,948.4	1,243.8	3,192.3	6,100.7	1,290.0	1,128.1	2,418.1
1993	2,817.0	187.6	40.2		3,044.9	2,089.3	1,469.4	3,558.7	6,603.5	1,373.0	1,203.1	2,576.0
1994	2,845.0	207.1	35.5		3,087.6	2,105.2	1,568.2	3,673.3	6,760.9	1,387.7	1,288.9	2,676.6
1995	3,099.7	227.8	37.8		3,365.3	2,350.1	1,683.6	4,033.8	7,399.0	1,389.4	1,314.2	2,703.6
1996	3,053.4	234.0	41.4		3,328.8	2,476.6	1,796.7	4,273.3	7,602.1	1,417.2	1,338.8	2,756.0
1997	3,140.3	252.5	42.7	172.0	3,607.6	2,785.2	2,148.0	4,933.2	8,540.8	1,469.9	1,407.6	2,877.5
1998	3,475.9	283.7	47.9	218.2	4,025.7	3,220.8	2,223.0	5,443.8	9,469.5	1,557.3	1,509.7	3,067.0
1999	3,939.6	320.9	53.7	264.0	4,578.2	3,387.5	2,302.0	5,689.5	10,267.7	1,675.6	1,576.7	3,252.3
2000	4,594.8	343.3	64.8	332.3	5,335.3	3,866.8	2,562.5	6,429.3	11,764.6	1,724.2	1,604.4	3,328.6
2001	5,267.9	392.0	75.8	379.9	6,115.6	4,490.0	2,613.5	7,103.5	13,219.1	1,797.8	1,652.8	3,450.6
2002 f	5,848.8	438.8	84.1	450.4	6,822.1	5,005.5	2,710.8	7,716.3	14,538.4	1,893.5	1,708.8	3,602.4
2003 f	6,425.4	493.0	94.3	538.1	7,550.8	5,576.4	2,880.8	8,457.3	16,008.0	1,877.6	1,733.4	3,611.1
						(annual perce	ntage change	e)				
1985												
1986	18.4	9.2	20.9		17.9			17.3	17.6			13.2
1987	13.4	7.7	16.9		13.2			6.0	9.1			15.9
1988	13.2	30.9	16.6		14.1			13.0	13.5			10.1
1989	15.4	23.2	10.0		15.7	11.5	14.1	12.7	14.1			10.7
1990	15.4	18.4	20.0		15.6	16.3	9.3	13.2	14.3			4.2
1991	14.5	11.7	20.8		14.4	13.9	5.6	10.3	12.3			8.6
1992 1993	11.6 3.9	9.7 17.5	14.8 5.7		11.6 4.7	16.5 7.2	4.6 18.1	11.5 11.5	11.6 8.2	6.4	6.6	8.1 6.5
1994	1.0	10.4	-11.9		1.4	0.8	6.7	3.2	2.4	1.1	7.1	3.9
1995	9.0	10.0	6.5		9.0	11.6	7.4	9.8	9.4	0.1	2.0	1.0
1996	-1.5	2.7	9.6		-1.1	5.4	6.7	5.9	2.7	2.0	1.9	1.9
1997	2.8	7.9	3.3		8.4	12.5	19.6	15.4	12.3	3.7	5.1	4.4
1998	10.7	12.4	12.0	26.8	11.6	15.6	3.5	10.4	10.9	5.9	7.3	6.6
1999	13.3	13.1	12.1	21.0	13.7	5.2	3.6	4.5	8.4	7.6	4.4	6.0
2000	16.6	7.0	20.8	25.9	16.5	14.2	11.3	13.0	14.6	2.9	1.8	2.3
2001	14.6	14.2	17.0	14.3	14.6	16.1	2.0	10.5	12.4	4.3	3.0	3.7
2002 f	11.0	11.9	11.0	18.6	11.6	11.5	3.7	8.6	10.0	5.3	3.4	4.4
2003 f	9.9	12.3	12.1	19.5	10.7	11.4	6.3	9.6	10.1	-0.8	1.4	0.2
					(percen	tage share of	total drug exp	penditure)				
1985	27.6	1.5	0.3		29.4			38.1	67.5			32.5
1986	28.1	1.5	0.3		29.4			38.5	68.3			31.7
1987	28.6	1.4	0.4		30.4			36.6	67.0			33.0
1988	28.8	1.6	0.4		30.4	20.5	16.3	36.8	67.7			32.3
1989	29.5	1.8	0.4		31.6	20.2	16.5	36.7	68.3			31.7
1990	30.6	1.9	0.4		32.9	21.2	16.2	37.4	70.3			29.7
1991	31.5	1.9	0.4		33.8	21.7	15.4	37.1	71.0	15.1	10.0	29.0
1992	31.8	1.9	0.4		34.1	22.9	14.6	37.5	71.6	15.1	13.2	28.4
1993	30.7	2.0	0.4		33.2	22.8	16.0	38.8	71.9	15.0	13.1	28.1
1994	30.1	2.2	0.4		32.7	22.3	16.6	38.9	71.6	14.7	13.7	28.4
1995	30.7	2.3	0.4		33.3	23.3	16.7	39.9	73.2	13.8	13.0	26.8
1996	29.5	2.3	0.4		32.1	23.9	17.3	41.3	73.4	13.7	12.9	26.6
1997	27.5	2.2	0.4	1.5	31.6	24.4	18.8	43.2	74.8	12.9	12.3	25.2
1998	27.7	2.3	0.4	1.7	32.1	25.7	17.7	43.4	75.5	12.4	12.0	24.5
1999	29.1	2.4	0.4	2.0	33.9	25.1	17.0	42.1	75.9	12.4	11.7	24.1
2000	30.4	2.3	0.4	2.2	35.3	25.6	17.0	42.6	77.9	11.4	10.6	22.1
2001	31.6	2.4	0.5	2.3	36.7	26.9	15.7	42.6	79.3	10.8	9.9	20.7
2002 f	32.2	2.4	0.5	2.5	37.6	27.6	14.9	42.5	80.1	10.4	9.4	19.9
2003 f	32.8	2.5	0.5	2.7	38.5	28.4	14.7	43.1	81.6	9.6	8.8	18.4
f - Forecast												CIHI 2004

Table A.1—Part 2 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Canada, 1985-2003 (continued) Share of Drugs in Public, Private and All Drugs Health Expenditure Total Health Expenditures Public Total Public Total Public Total Private Private Private (\$ millions) (percentage share) 1985 1,118.7 2,683.6 3,802.3 30,094.9 9,746.9 39,841.7 3.7 27.5 9.5 1986 1,319.2 3,097.9 4,417.1 32,528.6 10,808.7 43,337.3 4.1 28.7 10.2 1987 1,492.7 3,422.2 4,914.9 35,054.7 11,733.5 46,788.2 4.3 29.2 10.5 29.8 1988 1,702.8 3,818.9 5,521.7 38,162.8 12,795.4 50,958.2 4.5 10.8 1989 1,970.9 4,267.7 6,238.5 41,911.1 14,184.3 56,095.5 4.7 30.1 11.1 1990 2,278.0 4,652.5 6,930.5 45,445.5 15,577.1 61,022.6 5.0 29.9 11.4 1991 2,606.7 5,098.5 7,705.3 49,382.2 16,906.9 66,289.1 5.3 30.2 11.6 2,908.5 51,693.8 69,805.7 1992 5,610.4 8,518.8 18,112.0 31.0 5.6 12.2 3,044.9 6.134.7 9,179.6 51,979.7 19,577.5 71,557.2 31.3 1993 5.9 12.8 1994 3.087.6 6.349.9 9,437.5 52,598.7 20,483.5 73,082.1 5.9 31.0 12.9 1995 3,365.3 6,737.3 10.102.6 52.790.6 21.275.2 74.065.8 6.4 31.7 13.6 3,328.8 10.358.1 74.685.1 1996 7.029.3 52,877.1 21.808.1 6.3 32.2 13.9 1997 3,607.6 7,810.7 11,418,3 55,024.3 23,427.9 78,452,2 6.6 33.3 14.6 1998 4.025.7 8.510.8 12,536.5 59,058,4 24,706.0 83,764.4 6.8 34 4 15.0 1999 4,578.2 8.941.8 13,520.0 63,479.7 26.586.9 90,066.6 7.2 33.6 15.0 5 335 3 9 758 0 15 093 2 68 803 1 28 893 5 97 696 7 7.8 33.8 2000 15 4 2001 6,115.6 10,554.1 16,669.7 74,274.7 31,678.9 105,953.6 8.2 33.3 15.7 2002 f 6,822.1 11,318.7 18,140.8 79,238.4 34,157.6 113,396.0 8.6 33.1 16.0 2003 f 7,550.8 12,068.4 19,619.1 84,822.0 36,608.8 121,430.8 8.9 33.0 16.2 (annual percentage change) 1985 ---1986 17.9 15 4 16.2 8 1 10.9 8 8 1987 13.2 10.5 11.3 7.8 8.6 8.0 1988 14.1 11.6 12.3 8.9 9.1 8.9 1989 11.8 9.8 10.1 15.7 13.0 10.9 1990 15.6 9.0 11.1 8.4 9.8 8.8 1991 14.4 9.6 11.2 8.7 8.5 8.6 1992 11.6 10.0 4.7 7.1 5.3 10.6 1993 4.7 9.3 7.8 0.6 8.1 2.5 1994 1.4 3.5 2.8 4.6 2.1 1.2 1995 9.0 6 1 7.0 0.4 1.3 3.9 1996 -1.1 4.3 2.5 0.2 2.5 0.8 1997 8.4 11.1 10.2 4.1 7.4 5.0 1998 11.6 9.0 9.8 7.3 5.5 6.8 1999 13.7 5.1 7.8 7.5 7.6 7.5 2000 16.5 9.1 11.6 8.4 8.7 8.5 2001 14.6 8.2 10.4 8.0 9.6 8.5 2002 f 11.6 7.2 8.8 6.7 7.8 7.0 2003 f 10.7 6.6 8.1 7.0 7.2 7.1 (percentage share of total drug expenditure) 1985 29.4 70.6 100.0 1986 29.9 70.1 100.0 1987 30.4 69.6 100.0 1988 30.8 69.2 100.0 31.6 1989 68.4 100.0 1990 32.9 67.1 100.0 1991 33.8 66.2 100.0 1992 34.1 65.9 100.0 1993 33.2 66.8 100.0 1994 32.7 67.3 100.0 1995 66.7 100.0 33.3 1996 32.1 67.9 100.0 1997 31.6 68.4 100.0 1998 32.1 67.9 100.0 1999 33.9 66.1 100.0 100.0 2000 35.3 64.7 2001 36.7 63.3 100.0 2002 f 37.6 62.4 100.0

CIHI 2004

2003 f

f - Forecast

38.5

61.5

100.0

Table A.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Canada, 1985–2003

			Public		Prescribed	d Drugs	Private				Prescribed D	
	Provincial/ Territorial	Federal	Social Secu W.C.B.	Drug	Sub-Total Public	Insurers	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over the	Personal Health	Total Non-Presc.
				Insurance Funds					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ per	capita)					
1985	40.56	2.24	0.49		43.29			56.02	99.31			47.82
1986	47.53	2.43	0.58		50.54			65.09	115.63			53.60
1987	53.18	2.58	0.67		56.44	40.00		68.07	124.51			61.32
1988 1989	59.44 67.37	3.33 4.03	0.78 0.84		63.55 72.24	42.22 46.24	33.69 37.77	75.91 84.01	139.46 156.25			66.61 72.42
1990	76.55	4.70	0.99		82.24	53.00	40.65	93.65	175.89			74.33
1991	86.62	5.19	1.18		92.99	59.67	42.43	102.10	195.09	45.40		79.79
1992 1993	95.56 98.22	5.63 6.54	1.34 1.40		102.53 106.16	68.69 72.84	43.85 51.23	112.54 124.07	215.07 230.24	45.48 47.87	39.77 41.95	85.24 89.81
1994	98.11	7.14	1.22		106.47	72.59	54.08	124.67	233.14	47.85	44.45	92.30
1995	105.78	7.78	1.29		114.85	80.20	57.46	137.66	252.51	47.42	44.85	92.26
1996 1997	103.12	7.90	1.40	 6 76	112.42	83.64	60.68	144.32	256.74	47.86	45.21 47.07	93.07 96.21
1997	105.00 115.26	8.44 9.41	1.43 1.59	5.75 7.24	120.63 133.49	93.13 106.80	71.82 73.71	164.95 180.52	285.58 314.01	49.15 51.64	50.06	
1999	129.58	10.56	1.77	8.68	150.58	111.42	75.71	187.13	337.71	55.11	51.86	
2000	149.72	11.19	2.11	10.83	173.85	126.00	83.50	209.50	383.35	56.18	52.28	
2001 2002 f	169.82 186.49	12.64 13.99	2.44 2.68	12.25 14.36	197.14 217.53	144.74 159.61	84.25 86.44	228.99 246.04	426.13 463.57	57.95 60.38	53.28 54.49	111.23 114.87
2002 f	203.14	15.59	2.98	17.01	238.72	176.30	91.08	267.38	506.11	59.36	54.80	
2000 .	200.11	10.00	2.00	.,,,,,	200.72	(annual perce			000.11	00.00	01.00	
1985												
1986	17.2	8.1	19.7		16.8			16.2	16.4			12.1
1987	11.9	6.3	15.4		11.7			4.6	7.7			14.4
1988	11.8	29.2	15.1		12.6			11.5	12.0			8.6
1989	13.3	21.0	8.1		13.7	9.5	12.1	10.7	12.0			8.7
1990	13.6	16.7	18.2		13.8	14.6	7.6	11.5	12.6			2.6
1991	13.2	10.4	19.4		13.1	12.6	4.4	9.0	10.9			7.3
1992	10.3	8.4	13.4		10.3	15.1	3.3	10.2	10.2			6.8
1993	2.8	16.2	4.5		3.5	6.1	16.8	10.3	7.1	5.3	5.5	5.4
1994	-0.1	9.2	-12.8		0.3	-0.3	5.6	2.1	1.3	0.0	6.0	2.8
1995	7.8	8.9	5.4		7.9	10.5	6.3	8.7	8.3	-0.9	0.9	0.0
1996	-2.5	1.6	8.5		-2.1	4.3	5.6	4.8	1.7	0.9	0.8	0.9
1997	1.8	6.8	2.2		7.3	11.3	18.4	14.3	11.2	2.7	4.1	3.4
1998 1999	9.8 12.4	11.4 12.2	11.1 11.2	25.8 20.0	10.7 12.8	14.7 4.3	2.6 2.7	9.4 3.7	10.0 7.5	5.1 6.7	6.4 3.6	5.7 5.2
2000	15.5	6.0	19.6	24.7	15.5	13.1	10.3	12.0	13.5	1.9	0.8	
2001	13.4	13.0	15.7	13.1	13.4	14.9	0.9	9.3	11.2	3.2	1.9	2.6
2002 f 2003 f	9.8	10.7	9.8	17.3	10.3 9.7	10.3 10.5	2.6 5.4	7.4	8.8	4.2	2.3	
2003 1	8.9	11.4	11.1	18.5 (annual)	ercentage cha			8.7 n the Canadia	9.2 an economy)	-1.7	0.6	-0.6
1985												
1986	14.4	5.3	16.9		14.0			13.4	13.6			9.3
1987	7.1	1.6	10.6		6.9			-0.2	2.9			9.7
1988	7.2	24.7	10.6		8.1			7.0	7.5			4.1
1989	8.8	16.4	3.5		9.1			6.1	7.5			4.1
1990	10.6	13.6	15.2		10.8			8.4	9.5			-0.4
1991	10.4	7.6	16.6		10.3			6.3	8.2			4.6
1992	9.1	7.1	12.2		9.0			9.0	9.0			5.6
1993	1.3	14.7	3.1		2.1			8.8	5.6	3.8	4.0	3.9
1994	-1.2	8.1	-13.9		-0.8			1.0	0.2	-1.1	4.9	1.7
1995	5.5	6.5	3.0		5.5			6.3	6.0	-3.2	-1.4	-2.4
1996	-4.2	0.0	6.8		-3.8			3.2	0.0	-0.7	-0.9	-0.8
1997	0.8	5.8	1.2	26.2	6.3			13.3	10.2	1.7	3.1	2.4
1998 1999	10.2 10.6	11.9 10.4	11.5 9.4	26.2 18.2	11.1 11.0			9.9 1.9	10.4 5.7	5.5 4.9	6.8 1.8	6.1 3.4
2000	11.6	2.0		20.7				8.0				
2000	12.2	11.7	15.7 14.5	11.8	11.5 12.1			8.0	9.5 9.9	-2.0 1.9	-3.2 0.6	
2001 2002 f	8.8	9.7	8.8	16.3	9.3			6.4	7.8	3.2	1.3	
2003 f	5.6	8.1	7.8	15.2	6.4			5.4	5.9	-5.0	-2.7	
f - Forecast												CIHI 2004

Table A.2—Part 2 Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Canada, 1985-2003 (continued) GDP Implicit All Drugs Health Expenditure Price Index-Canada Public Private Total Public Private Total (1997 = 100)Year (\$ per capita) 1985 43.29 103.84 147.13 1,164.54 377.16 1,541,70 73.6 1986 50.54 118 69 169 23 1 246 25 414 11 1 660 36 75.6 1987 56.44 129.39 185.82 1,325,38 443.63 1,769.01 79.2 1988 63.55 142.52 206.07 1,424.23 477.52 1.901.75 82.8 1989 72.24 156.43 228.67 1,536.23 519.92 2,056.15 86.6 1990 82.24 167.98 250.22 1,640,78 562.40 2,203,18 89.2 1991 92.99 181.89 274.88 1,761.68 603.14 2,364.82 91.6 1992 102.53 197.78 300.31 1,822.34 638.49 2,460.83 92.8 1993 106.16 213.89 320.05 1,812.30 682.58 2,494.88 94.1 1994 106.47 218.97 325.44 1,813.81 706.35 2,520.16 95.2 1995 114.85 229.93 344.77 1,801.60 726.06 2,527.66 97.4 112.42 237.39 349.81 2,522.23 1996 1,785.74 736.49 99.0 1997 120.63 261.16 381.79 1,839.83 783.36 2,623.19 100.0 1998 133.49 282.22 415.71 819.24 2,777.60 1,958.36 99.6 150.58 2.087.88 2.962.34 101.4 1999 294.10 444.68 874.46 2000 173.85 317.96 491.81 2,241.95 941.49 3,183.44 105.4 537.36 2.394.32 1.021.20 3.415.52 2001 197.14 340.22 106.7 2002 f 217.53 360.91 578.44 2,526,60 1,089,15 3,615,76 107.8 381.55 620.28 1 157 42 3 839 14 111.4 2003 f 238.72 2,681,72 (annual percentage change) 1985 1986 16.8 14.3 15.0 7.0 9.8 7.7 2.8 1987 11.7 9.0 9.8 6.3 7.1 6.5 4.7 10.2 10.9 7.5 4.5 12.6 7.5 8.1 1989 13.7 9.8 11.0 7.9 8.9 4.6 1990 13.8 7.4 9.4 6.8 8.2 7.2 3.0 13.1 8.3 2.8 1991 9.9 7.2 7.3 1992 10.3 8.7 3.4 5.9 4.1 9.3 1.3 1993 8.1 -0.6 6.9 1.4 3.5 6.6 1.4 1994 0.3 2.4 1.7 0.1 3.5 1.0 1.1 1995 7.9 5.0 5.9 -0.7 2.8 0.3 2.3 -2.1 1996 3.2 1.5 -0.9 1.4 -0.2 1.7 1997 7.3 10.0 9.1 3.0 6.4 4.0 1.0 10.7 1998 8.1 8.9 6.4 4.6 5.9 -0.4 1999 12.8 4.2 7.0 6.6 6.7 6.7 1.8 2000 15.5 8.1 10.6 7.4 7.7 7.5 4.0 2001 13.4 7.0 9.3 6.8 8.5 7.3 1.3 2002 f 10.3 6.1 7.6 5.5 5.9 6.7 1.0 2003 f 5.7 6.1 6.2 9.7 7.2 6.3 3.3 (annual percentage change in excess of inflation in the Canadian economy) 1985 1986 14.0 11.5 12.2 4.2 7.0 4.9 1987 6.9 4.3 1.6 1.8 5.1 2.4 1988 8.1 5.6 6.4 2.9 3.1 3.0 5.2 6.4 3.3 3.6 1989 9.1 4.3 1990 10.8 4.4 6.4 3.8 5.1 4.1 1991 10.3 5.5 7.1 4.6 4.5 4.6 1992 9.0 7.5 8.0 22 4.6 2.8 1993 2.1 6.7 5.1 -2.0 5.5 -0.1 1994 -0.8 1.3 0.6 -1.0 -0.1 1995 5.5 2.7 3.6 -3.0 0.5 -2.0 1996 -3.8 1.6 -0.2 -2.6 -0.2-1.9 1997 6.3 9.0 8 2 2.0 5 4 3.0 1998 11.1 8.5 9.3 6.9 5.0 6.3 1999 11.0 2.4 5.2 4.8 4.9 4.8 2000 11.5 4.1 6.6 3.4 3.7 3.5 2001 12.1 5.7 8.0 5.5 7.2 6.0 2002 f 9.3 5.1 6.6 4.5 5.6 4.9 2003 f 6.4 2.4 3.9 2.8 3.0 2.9

CIHI 2004

f - Forecast

## **Series B**

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2003

Table B.1.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985–2003

			D. LU-		Prescribe	d Drugs	Dulcosto				Prescribed D te (Out-of-Po	
	Provincial	Federal	Public Social Secu	urity Eunde	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over	Personal	Total
	FIOVIIICIAI	reuerai _	W.C.B.	Drug Insurance	Public	ilisuleis	Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
Year				Funds		(\$ milli	ione)			Drugs		
		2.2	0.4		20.4			22.2	100.0			
1985 1986	18.0 21.4	2.3 2.7	0.1 0.2		20.4 24.4			82.8 51.6	103.2 76.0			24.9 28.2
1987	24.7	3.1	0.2		28.1			55.1	83.2			32.7
1988	28.2	1.6	0.4		30.2			58.7	88.9			32.3
1989	31.2	1.3	0.4		32.9			62.5	95.4			32.0
1990	35.3	1.6	0.6		37.5			64.7	102.2			34.3
1991	40.3	1.7	0.8		42.8			65.8	108.5			37.8
1992	43.9	1.7	1.1		46.6			72.9	119.5	20.6	17.9	38.6
1993	47.8	2.2	1.2		51.1			76.1	127.2	21.7	18.2	39.9
1994	52.1	2.5	1.2		55.8			77.9	133.7	21.5	18.3	39.8
1995	54.5	2.8	1.5		58.8			85.6	144.4	21.2	19.9	41.0
1996	54.5	2.7	1.8		59.0			90.0	149.0	23.2	21.9	45.2
1997	53.6	3.3	1.9		58.8			87.9	146.7	19.8	18.9	38.7
1998	56.1	3.7	2.4		62.1			93.7	155.8	21.8	21.0	
1999	60.0	4.1	2.8		66.9			103.3	170.2	24.0	22.5	46.5
2000	68.0	5.8	3.8		77.6			119.9	197.5	24.0	21.7	45.7
2001	77.9	6.6	4.2		88.7			129.2	217.9	22.8	21.4	44.2
2002 f	87.9	7.5	5.0		100.5			143.2	243.7	22.5	21.1	43.6
2003 f	96.7	8.6	5.6		110.9			151.6	262.5	22.1	20.3	42.4
					(;	annual percent	tage change	9)				
1985												
1986	19.2	20.4	35.5		19.4			-37.6	-26.3			13.2
1987	15.4	13.5	34.3		15.3			6.7	9.4			16.0
1988 1989	13.9 10.6	-48.0 -20.2	50.0 14.5		7.4 9.0			6.6 6.6	6.8 7.4			-1.0 -1.0
1990	13.4	21.5	38.7		14.0			3.4	7.1			7.1
1991	14.1	9.6	25.5		14.1			1.7	6.2			10.3
1992	8.8	-3.5	40.5		8.9			10.8	10.1			2.0
1993	8.9	31.4	9.2		9.7			4.5	6.5	5.4	1.1	3.4
1994	9.1	12.4	7.4		9.2			2.3	5.1	-1.0	0.8	-0.2
1995	4.6	12.3	22.5		5.4			9.9	8.0	-1.6	8.6	3.1
1996	0.0	-2.7	18.8		0.4			5.1	3.2	9.7	10.3	10.0
1997	-1.6	23.0	3.4		-0.4			-2.3	-1.5	-14.7	-14.0	
1998	4.6	10.5	28.6		5.6			6.5	6.2	10.1	11.5	10.8
1999	7.0	12.0	16.0		7.7			10.3	9.3	10.1	7.0	8.6
2000	13.4	40.7	37.7		16.1			16.0	16.0	0.0	-3.7	-1.8
2001	14.5	15.5	8.8		14.3			7.8	10.3	-5.0	-1.4	
2002 f	12.9	13.5	20.2		13.3			10.9	11.9	-1.4	-1.4	
2003 f			12.6		10.3			5.9	7.7	-1.7	-3.9	-2.8
					(percenta	ge share of to	tal drug exp	enditure)				
1985	14.0	1.8	0.1		15.9			64.6	80.6			19.4
1986	20.6	2.6	0.2		23.4			49.6	73.0			27.0
1987	21.3	2.7	0.2		24.3			47.5	71.8			28.2
1988 1989	23.2 24.4	1.3 1.0	0.3		24.9 25.8			48.4 49.1	73.3 74.9			26.7 25.1
1990	25.9	1.2	0.4		27.5			47.4	74.9			25.1
1990	27.5	1.2	0.4		27.5			44.9	74.9			25.1
1992	27.8	1.1	0.7		29.5			46.1	75.6	13.0	11.4	
1993	28.6	1.3	0.7		30.6			45.6	76.1	13.0	10.9	
1994	30.0	1.4	0.7		32.2			44.9	77.1	12.4	10.5	22.9
1995	29.4	1.5	0.8		31.7			46.2	77.9	11.4	10.7	22.1
1996	28.1	1.4	0.9		30.4			46.4	76.7	12.0	11.3	23.3
1997	28.9	1.8	1.0		31.7			47.4	79.1	10.7	10.2	
1998	28.2	1.8	1.2		31.3			47.2	78.4	11.0	10.6	
1999	27.7	1.9	1.3		30.9			47.7	78.5	11.1	10.4	21.5
2000	28.0	2.4	1.6		31.9			49.3	81.2	9.9	8.9	
2001	29.7	2.5	1.6		33.8			49.3	83.1	8.7	8.2	
2002 f	30.6	2.6	1.7		35.0			49.9	84.8	7.8	7.3	
2003 f	31.7	2.8	1.8		36.4			49.7	86.1	7.3	6.6	13.9
f - Forecast	and the control of		and the second									01111 0000
Note: Confide	entiality precludes	reporting provi	ncial level insu	rance data.								CIHI 200

Table B.1.1—Part 2 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985-2003 (continued) Share of Drugs in Public, Private and All Drugs Health Expenditure **Total Health Expenditures** Public Private Public Private Total Public Private Year (\$ millions) (percentage share) 1985 20.4 107.7 128.1 588.8 197.1 785.8 3.5 54.6 1986 24.4 79.8 104.2 642.9 169.6 812.5 3.8 47.1 12.8 1987 28.1 87.8 115.9 693.6 188.0 881.6 4.1 46.7 13.1 1988 30.2 91.0 121.2 733.8 197.1 930.9 4.1 46.2 13.0 1989 32.9 94.6 127.4 787.7 203.9 991.6 4.2 46.4 12.9 1990 875.9 1,096.4 37.5 99.0 136.5 220.6 4.3 44.9 12.4 1991 42.8 103.6 146.4 905.7 247.5 1,153.2 4.7 41.8 12.7 158.0 1992 46.6 111.4 928.3 269.1 1,197.4 41.4 13.2 5.0 116.0 924 9 1993 51 1 167 1 284 2 1,209.1 5.5 40.8 13.8 1994 55.8 117.7 173.5 948.1 299.7 1,247.9 5.9 39.3 13.9 1995 58.8 126.7 185 4 973 1 295.0 1 268 1 6.0 42 9 14 6 1996 59.0 135.2 194.1 974.4 277.5 1,251.9 6.1 48 7 15.5 1997 58.8 126.6 185 4 1,020.8 282.9 1,303.7 5.8 44 8 14.2 1998 62.1 136.5 198.6 1,107.0 326.4 1,433.4 5.6 41.8 13.9 1999 66.9 149.9 216.7 1,253.1 323.4 1,576.5 5.3 46.3 13.7 2000 77.6 165.6 243.2 1,317.3 364.5 1,681.8 5.9 45 4 14.5 2001 88.7 173.4 262.1 1,425.6 384.6 1,810.2 6.2 45.1 14.5 100.5 186.8 287.3 407.3 1,923.4 2002 f 1,516.1 6.6 45.9 14.9 2003 f 110.9 194.0 304.9 1,567.9 426.6 1,994.5 7.1 45.5 15.3 (annual percentage change) 1985 ---1986 19.4 -25.9 -18.6 9.2 -13.9 3.4 1987 15.3 9.9 11.2 7.9 10.9 8.5 1988 3.7 5.8 4.8 5.6 7.4 4.6 1989 9.0 3.9 5.1 7.4 3.4 6.5 1990 14.0 4.7 7.1 11.2 8.2 10.6 4.7 1991 14.1 7.3 3.4 12.2 5.2 1992 8.9 7.6 8.0 2.5 8.7 3.8 1993 9.7 -0.4 4.1 5.8 5.6 1.0 1994 1.5 9.2 3.8 2.5 5.5 3.2 1995 5.4 7.6 6.9 2.6 -1.6 1.6 1996 0.4 6.7 4.7 0.1 -6.0 -1.3 1997 -0.4 -6.3 -4.5 4.8 2.0 4.1 1998 5.6 7.8 7.1 8.5 15.4 10.0 1999 7.7 9.8 9.1 13.2 -0.9 10.0 2000 10.5 12.2 5.1 12.7 6.7 16.1 2001 14.3 4.7 7.8 8.2 5.5 7.6 2002 f 13.3 7.8 9.6 6.3 5.9 6.3 2003 f 10.3 3.8 6.1 4.7 3.7 (percentage share of total drug expenditure) 1985 15.9 84.1 100.0 1986 23.4 76.6 100.0 1987 24.3 75.7 100.0 1988 24.9 75.1 100.0 1989 25.8 74.2 100.0 1990 27.5 72.5 100.0 1991 29.2 70.8 100.0 1992 29.5 70.5 100.0 100.0 1993 30.6 69.4 67.8 100.0 1994 32.2 1995 31.7 68.3 100.0 69.6 1996 30.4 100.0 1997 31 7 68.3 100.0 1998 31.3 68.7 100.0 1999 30.9 69.1 100.0 100.0 2000 31 9 68 1 2001 33.8 66.2 100.0 2002 f 100.0 35.0 65.0

CIHI 2004

2003 f

f - Forecast

36.4

63.6

100.0

Table B.1.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985–2003

			Public		Prescribed	d Drugs	Private				Prescribed D	
	Provincial	Federal	Social Secu	rity Funds	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
	Trovincia	_	W.C.B.	Drug Insurance	Public	mourers	Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc.
Voor				Funds		lê nav a	anita)		-	Drugs		-
Year						(\$ per c						
1985	31.05	3.94	0.24		35.23			142.89	178.12			42.96
1986	37.19	4.77	0.32		42.28			89.58	131.86			48.89
1987 1988	43.00 49.00	5.42 2.82	0.44 0.66		48.86 52.48			95.77 102.08	144.63 154.56			56.82 56.25
1989	54.05	2.02	0.75		57.04			102.08	165.56			55.53
1990	61.11	2.72	1.03		64.87			111.92	176.79			59.30
1991	69.56	2.97	1.30		73.83			113.48	187.30			65.26
1992	75.61	2.87	1.82		80.30			125.66	205.95	35.54	30.94	66.48
1993	82.36	3.77	1.99		88.12			131.28	219.40	37.46	31.30	68.77
1994	90.69	4.28	2.15		97.12			135.64	232.75	37.45	31.86	69.31
1995	96.05	4.86	2.67		103.58			150.89	254.47	37.31	35.02	72.33
1996	97.36	4.80	3.22		105.37			160.78	266.15	41.49	39.17	80.66
1997	97.30	6.00	3.38		106.67			159.58	266.25	35.98	34.22	70.20
1998	103.81	6.76	4.43		115.01			173.46	288.47	40.43	38.93	79.36
1999	112.49	7.67	5.20		125.36			193.70	319.07	45.06	42.18	87.25
2000	128.84	10.90	7.24		146.98			226.98	373.96	45.51	41.03	86.54
2001	149.21	12.73	7.97		169.91			247.46	417.37	43.74	40.94	84.68
2002 f	169.35	14.53	9.63		193.51			275.83	469.34	43.35	40.58	83.93
2003 f	186.07	16.49	10.84		213.40			291.82	505.22	42.59	38.98	81.57
						annual percen						
1985	10.0											10.0
1986 1987	19.8 15.6	21.0 13.7	36.2 34.7		20.0 15.6			-37.3 6.9	-26.0 9.7			13.8 16.2
1988	14.0	-48.0	50.0		7.4			6.6	6.9			-1.0
1989	10.3	-20.4	14.2		8.7			6.3	7.1			-1.3
1000	10.1	01.0	20.2		10.7			0.1	0.0			
1990 1991	13.1 13.8	21.2 9.3	38.3 25.2		13.7 13.8			3.1 1.4	6.8 5.9			6.8 10.0
1992	8.7	-3.5	40.4		8.8			10.7	10.0			1.9
1993	8.9	31.4	9.3		9.7			4.5	6.5	5.4	1.2	3.4
1994	10.1	13.4	8.4		10.2			3.3	6.1	0.0	1.8	0.8
1995	5.9	13.7	24.1		6.7			11.2	9.3	-0.4	9.9	4.4
1996	1.4	-1.3	20.4		1.7			6.6	4.6	11.2	11.8	11.5
1997	-0.1	25.0	5.1		1.2			-0.7	0.0	-13.3	-12.6	-13.0
1998	6.7	12.8	31.2		7.8			8.7	8.3	12.4	13.8	13.0
1999	8.4	13.4	17.4		9.0			11.7	10.6	11.5	8.3	9.9
2000	14.5	42.2	39.1		17.2			17.2	17.2	1.0	-2.7	-0.8
2001	15.8	16.8	10.1		15.6			9.0	11.6	-3.9	-0.2	
2002 f	13.5	14.1	20.9		13.9			11.5	12.5	-0.9	-0.9	-0.9
2003 f	9.9	13.5	12.6	,	10.3			5.8	7.6	-1.8	-3.9	-2.8
				-	centage chang	ge in excess o	t intlation in	the Canadia				
1985	17.0	10.0	22.4		17.0			40.1				11.0
1986 1987	17.0 10.9	18.2 9.0	33.4 29.9		17.2 10.8			-40.1 2.2	-28.8 4.9			11.0 11.5
1988	9.4	-52.5	45.5		2.9			2.1	2.3			-5.5
1989	5.7	-25.0	9.6		4.1			1.7	2.6			-5.8
1990	10.0	18.2	35.3		10.7			0.1	3.8			3.8
1991	11.1	6.6	22.4		11.1			-1.4	3.2			7.3
1992	7.4	-4.8	39.1		7.5			9.5	8.7			0.6
1993	7.5	29.9	7.8		8.3			3.0	5.1	4.0	-0.3	2.0
1994	9.0	12.3	7.3		9.1			2.2	5.0	-1.1	0.7	-0.3
1995	3.6	11.4	21.7		4.3			8.9	7.0	-2.7	7.6	2.0
1996	-0.3	-3.0	18.7		0.1			4.9	2.9	9.6	10.2	
1997	-1.1	24.0	4.1		0.2			-1.7	-1.0	-14.3	-13.6	
1998	7.1	13.2	31.7		8.3			9.1	8.8	12.8	14.2	
1999	6.6	11.6	15.6		7.2			9.9	8.8	9.7	6.5	8.1
2000	10.6	38.2	35.1		13.3			13.2	13.2	-3.0	-6.7	
2001	14.5	15.5	8.8		14.3			7.8	10.3	-5.2	-1.5	
2002 f	12.5	13.1	19.9		12.9			10.5	11.4	-1.9	-1.9	
2003 f f - Forecast	6.6	10.2	9.3		7.0			2.5	4.3	-5.1	-7.2	-6.1

	Tota	al Health Exp	anditurae Na				10 /
			enultures, ive	wroundiand a	ina Labrador	, 1985–200	GDP Implicit
	D. I.P.	All Drugs			alth Expenditure		Price Index - Canada
	Public	Private	Total	Public	Private	Total	
			(\$ per ca	nita)			(1997 = 100)
_	25.22	105.05			040.40	1.050.50	
	35.23 42.28	185.85 138.46	221.08 180.75	1,016.34 1,115.18	340.16 294.15	1,356.50 1,409.34	73.6 75.6
	48.86	152.59	201.45	1,205.91	326.89	1,532.79	79.2
	52.48	158.33	210.81	1,276.14	342.81	1,618.95	82.8
	57.04	164.05	221.09	1,366.63	353.75	1,720.39	86.6
	64.87	171.22	236.09	1,515.29	381.55	1,896.84	89.2
	73.83	171.22	252.56	1,562.86	427.13	1,989.99	91.6
	80.30	192.14	272.44	1,600.38	463.99	2,064.37	92.8
	88.12	200.04	288.16	1,594.84	489.98	2,084.82	94.1
	97.12	204.95	302.06	1,650.45	521.78	2,172.23	95.2
	103.58	223.22	326.80	1,714.87	519.94	2,234.81	97.4
	105.37	241.44	346.81	1,740.60	495.64	2,236.23	99.0
	106.67	229.78	336.45	1,852.54	513.46	2,365.99	100.0
	115.01	252.83	367.84	2,050.30	604.55	2,654.85	99.6
	125.36	280.95	406.32	2,349.27	606.21	2,955.47	101.4
	146.98	313.53	460.50	2,494.72	690.20	3,184.92	105.4
	169.91	332.15	502.06	2,731.11	736.85	3,467.97	106.7
	193.51	359.76	553.27	2,919.71	784.35	3,704.06	107.8
	213.40	373.39	586.79	3,017.78	821.06	3,838.84	111.4
			(annı	ıal percentage chanç	ge)		
	20.0	-25.5	-18.2	9.7	-13.5	3.9	2.8
	15.6	10.2	11.5	8.1	11.1	8.8	4.7
	7.4	3.8	4.6	5.8	4.9	5.6	4.5
	8.7	3.6	4.9	7.1	3.2	6.3	4.6
	13.7	4.4	6.8	10.9	7.9	10.3	3.0
	13.8 8.8	4.4 7.5	7.0 7.9	3.1 2.4	11.9	4.9 3.7	2.8 1.3
	9.7	4.1	5.8	-0.3	8.6 5.6	1.0	1.4
	10.2	2.5	4.8	3.5	6.5	4.2	1.1
	6.7	8.9	8.2	3.9	-0.4	2.9	2.3
	1.7	8.2	6.1	1.5	-4.7	0.1	1.7
	1.2	-4.8	-3.0	6.4	3.6	5.8	1.0
	7.8	10.0	9.3	10.7	17.7	12.2	-0.4
	9.0	11.1	10.5	14.6	0.3	11.3	1.8
	17.2	11.6	13.3	6.2	13.9	7.8	4.0
	15.6	5.9	9.0	9.5	6.8	8.9	1.3
	13.9	8.3	10.2	6.9	6.4	6.8	1.0
	10.3	3.8	6.1	3.4	4.7	3.6	3.3
			-	inflation in the Cana			
	17.2	-28.3	-21.0	6.9	-16.3	1.1	
	10.8 2.9	5.5 -0.8	6.7	3.4	6.4	4.0	
	4.1	-1.0	0.1 0.3	1.3 2.5	0.4 -1.4	1.1 1.7	
		1.0					
	10.7	1.3	3.8	7.9	4.8	7.2	
	11.1	1.6	4.2	0.4	9.2	2.2	
	7.5 8.3	6.2 2.7	6.6 4.3	1.1 -1.8	7.4 4.2	2.5 -0.4	
	9.1	1.4	4.3 3.7	2.4	5.4	3.1	
	4.3	6.6	5.9	1.6	-2.7	0.5	
	0.1	6.5	4.5	-0.2	-6.3	-1.6	
	0.2	-5.8	-4.0	5.4	2.6	4.8	
	8.3 7.2	10.5 9.3	9.8 8.7	11.1 12.8	18.2 -1.5	12.6	
	1.2	9.3	8.7	12.0	-1.5	9.5	
	13.3	7.6	9.4	2.2	9.9	3.8	
	14.3	4.7	7.8	8.2	5.5	7.6	
	12.9	7.3	9.2	5.9	5.4	5.8	

Table B.2.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985–2003

Personal   Personal				Public		Prescrib	ed Drugs	Private				Prescribed D	
Page		Provincial	Federal	Social Secu	Drug		Insurers*	Out-of-		Prescribed	Over the	Personal Health	Total Non-Presc.
1986										Drugs		Supplies	Drugs
1986   2,1	ear						(\$ mill	ions)					
1987   3.5	985	1.7	0.8	0.0		2.5			19.5	22.0			10.7
1988			0.9			3.1							12.1
1899													14.0
1990 6.5 0.6 0.1 - 7.3 - 18.0 25.3 - 1991 194 7.4 0.7 0.1 - 8.2 - 17.1 25.3 - 7.8 1992 7.6 0.7 0.4 - 8.6 - 18.6 - 18.8 2.7 8.8 6.7 1993 7.5 0.8 0.3 - 8.6 - 21.8 30.5 8.0 6.7 1994 7.7 0.9 0.3 - 8.9 - 23.8 32.8 8.8 6.7 1995 8.5 1.0 0.4 - 9.8 - 22.7 33.0 32.8 8.8 6.7 1996 8.5 1.0 0.4 - 9.8 - 22.7 33.0 35.8 8.8 6.7 1997 9.1 1.0 0.4 - 9.8 - 22.7 33.0 45.1 8.3 1998 10.4 1.2 0.5 - 12.2 - 33.0 45.1 8.3 1999 120 1.4 0.6 - 13.9 - 33.6 47.6 8.7 8.5 1999 120 1.4 0.6 - 13.9 - 33.6 47.6 8.7 8.5 1999 120 1.4 0.6 - 13.9 - 33.0 45.1 8.3 8.5 1999 120 1.5 7 0.8 - 19.1 1.0 - 44.0 6.8 6.7 8.7 8.5 1999 120 1.4 0.6 - 33.9 - 22.5 - 33.0 45.1 8.3 8.5 1999 120 1.5 7 0.8 - 19.1 1.0 - 44.0 6.8 6.7 8.7 8.5 1999 120 1.5 7 2.7 0.8 - 19.1 1.0 - 44.0 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2 6.2													11.8
1991	∌89	5.5	0.5	0.1		6.0			15.0	21.0			9.9
1982	990	6.5	0.6	0.1		7.3			18.0	25.3			10.6
1993			0.7	0.1		8.2			17.1	25.3			13.5
1995													
1995 8.5 1.0 0.4 9.8 28.4 38.3 8.2 8.3 1996 8.5 1.0 0.4 9.8 29.7 39.5 6.5 6.9 1997 9.1 1.0 0.4 9.8 22.7 39.5 6.5 6.9 1998 10.4 1.2 0.5 12.2 33.0 45.1 8.3 8.5 1999 12.0 1.4 0.6 13.9 33.0 45.1 8.3 8.5 1999 12.0 1.4 0.6 13.9 33.0 45.1 8.3 8.5 2000 14.0 2.3 0.7 17.0 38.0 53.0 8.5 8.0 2001 15.7 2.7 0.8 19.1 43.0 62.2 9.3 8.4 20021 17.1 3.0 0.7 20.8 47.3 68.1 10.1 9.0 20031 18.3 3.3 0.9 22.5 53.0 75.5 10.0 9.3 2008 201 17.1 3.0 0.7 20.8 47.3 68.1 10.1 9.0 20031 18.3 3.3 0.9 22.5 53.0 75.5 10.0 9.3 2009 1998 2.7.8 16.1 44.0 24.4 34.1 27.5 10.0 9.3 2019 17.9 17.4 0.9 13.7 48.5 21.0 7.6 19.1 2019 17.9 17.4 0.9 13.7 48.5 21.5 19.1 19.1 2020 1998 2.2 18.3 30.7 20.5 20.7 18.8 20.1 19.1 19.1 2031 1988 30.7 20.5 20.7 18.1 2.7 19.1 2040 1988 30.7 20.5 20.7 18.8 20.1 19.1 21991 13.5 7.0 0.4 4 12.7 19.1 21992 2.5 4.8 218.0 5.2 20.7 118.8 20.1 19.1 21993 1.7 2 48 13.3 0.3 15.2 10.0 8.5 19.2 21998 1.4 6 16.2 2.0 1.1 5 3.5 10.0 119.2 16.7 7.3 5.1 2000 16.8 69.8 10.0 15.1 11.2 16.7 11.2 17.2 11.2 17.2 11.2 18.2 18.2 20.1 19.1 2000 17.9 18.8 30.7 20.5 20.7 19.9 19.9 19.5 8.3 7.1 2000 18.8 18.3 30.7 20.5 20.7 19.9 19.9 19.5 8.3 7.1 2000 18.8 18.3 30.7 20.5 20.7 19.9 19.9 19.5 8.3 7.1 2000 18.8 18.4 18.4 18.2 18.2 18.2 18.2 18.2 18.2 18.2 18.2													
1996   8.5	994	7.7	0.9	0.3		8.9			23.8	32.8	8.8	8.7	17.6
1997	995	8.5	1.0	0.4		9.8			28.4	38.3	8.2	8.3	16.5
1988	996	8.5	1.0	0.4		9.8			29.7	39.5	6.5	6.3	12.8
1999	997	9.1	1.0	0.4		10.6			28.8	39.4	6.8	6.9	13.7
14.0	998	10.4	1.2	0.5		12.2			33.0	45.1	8.3	8.5	16.7
19.00	999	12.0	1.4	0.6		13.9			33.6	47.6	8.7	8.5	17.2
19.00	000	14 0	23	0.7		17.0			36.0	53.0	8.5	8 0	16.4
2002   17.1   3.0   0.7   20.8     47.3   68.1   10.1   9.0													
18.3   3.3   0.9     22.5       53.0   75.5   10.0   9.3													
1986													
1986							(annual percen	tage change)					
1986	985												
1987									-34.1				13.2
1989   17.9													16.0
1990	988	32.4	-40.9	20.2		16.1			21.5	19.8			-16.1
1991 13.5 7.0 -0.4	989	17.9	-17.4	0.9		13.7			21.5	19.1			-16.1
1991 13.5 7.0 -0.4 12.7 4.7 0.3 1992 2.5 4.5 218.0 5.2 10.0 8.5 1993 1-1.7 24.8 1-13.70.3 10.0 8.5 1994 2.8 12.0 1-1.5 3.5 19.2 7.6 2.0 3.7 1995 10.2 8.6 9.8 10.0 19.2 16.7 7.3 5.1 1996 0.0 3.8 4.40.2 4.3 3.2 20.7 24.1 1997 7.4 8.3 14.7 7.80.3 4.3 3.2 20.7 24.1 1997 7.4 8.3 14.7 7.80.3 14.5 14.6 21.2 23.2 1998 14.6 16.2 21.0 15.1 14.5 14.6 21.2 23.2 1999 14.7 14.6 16.2 22.0 14.5 14.5 14.6 21.2 23.2 2000 16.8 66.4 26.3 22.1 7.2 11.6 3.3 4.0 2001 12.4 16.8 4.4 12.6 12.6 19.4 17.2 9.9 5.4 2002 1 8.9 11.4 9.4 8.5 9.9 9.5 8.3 7.1 2003 1 7.2 11.4 22.2 8.3 12.1 11.0 19.9 9.5 8.3 7.1 2003 1 7.2 11.4 22.2 8.3 12.1 11.0 12.1 11.0 3.3 7.1 1986 7.6 3.2 0.2 11.0 15.9 11.0 45.9 56.9 1987 1987 12.1 3.5 0.3 18.9 18.1 19.9 42.0 60.0 1988 15.7 2.0 0.3 18.1 19.9 42.0 60.0 1989 17.6 16.6 0.3 19.9 17.0 18.0 42.0 60.0 1999 17.6 16.6 0.3 19.9 19.7 42.9 62.6 19.6 17.8 1991 19.1 18.8 0.3 21.2 19.7 44.1 65.2 1999 19.9 15.0 15.1 1994 15.3 18.8 0.7 19.7 19.7 44.9 62.6 19.6 18.8 17.6 1994 15.3 18.8 0.7 17.7 19.9 44.1 65.2 1999 15.5 15.5 18.8 0.7 19.9 19.9 44.1 65.2 1999 15.0 15.1 1994 15.3 18.8 0.7 17.7 19.9 44.1 65.2 1999 15.0 15.1 1994 15.3 18.8 0.7 17.7 17.7 47.4 65.1 17.5 17.3 1995 15.5 18.8 0.7 17.7 18.8 66.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 65.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 65.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 19.9 65.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 19.9 65.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 19.9 65.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 19.9 19.9 65	990	10.0	20.7	20 5		20.7			10.0	20.1			7.5
1992   2.5													27.3
1993													21.5
1994 2.8 12.0 -1.5 3.5 9.2 7.6 -2.0 3.7  1995 10.2 8.6 9.8 10.0 19.2 16.7 7.3 -5.1  1996 0.0 -3.8 4.4 0.2 4.3 3.2 -20.7 -24.1  1997 7.4 8.3 14.7 7.8 4.3 3.2 -20.7 -24.1  1998 14.6 16.2 21.0 15.1 14.5 14.6 21.2 23.2  1999 14.7 14.0 11.9 14.5 2.0 5.4 5.8 0.1  2000 16.8 66.4 26.3 22.1 7.2 11.6 -3.3 -6.0  2001 12.4 16.8 4.4 12.6 19.4 17.2 9.9 5.4  2002 1 8.9 11.4 -9.4 8.5 9.9 9.5 8.3 7.1  2003 1 7.2 11.4 22.2 8.3 12.1 11.0 -0.3 3.7  1986 7.6 3.2 0.2 11.0 45.9 56.9  1987 12.1 3.5 0.3 15.9 15.9 35.3 51.3  1988 15.7 2.0 0.3 15.9 15.1 42.0 60.0  1989 17.6 1.6 0.3 19.6 48.5 66.1  1990 18.2 1.8 0.3 20.3 48.5 66.1  1991 19.1 1.8 0.3 20.3 44.5 68.1  1992 17.3 1.5 0.9 19.7 18.0 44.5 63.6 18.8 17.8  1993 15.6 1.7 0.7 18.0 45.6 63.6 18.8 17.8  1994 15.3 1.8 0.7 17.7 47.4 65.1 17.5 17.3  1995 15.5 1.8 0.7 17.9 47.4 65.1 17.5 17.3  1996 15.5 1.8 0.7 17.9 17.9 47.4 65.1 17.5 17.3  1996 15.5 1.8 0.7 17.9 17.9 47.4 65.1 17.5 17.3  1997 17.1 2.0 0.8 17.9 17.9 54.3 74.2 12.8 13.0												7.8	
1996         0.0         -3.8         4.4	994	2.8	12.0	-1.5		3.5			9.2	7.6	-2.0	3.7	0.7
1996   0.0   -3.8   4.4     -0.2       4.3   3.2   -20.7   -24.1   1997   7.4   8.3   14.7     7.8       3.0   -0.3   4.9   9.2   1998   14.6   16.2   21.0     18.5       14.5   14.6   21.2   23.2   1999   14.7   14.0   11.9     14.5       2.0   5.4   5.8   0.1   2000   16.8   66.4   26.3     22.1       7.2   11.6   -3.3   -6.0   2001   12.4   16.8   4.4     12.6       19.4   17.2   9.9   5.4   2002 f   8.9   11.4   9.4     8.5       19.4   17.2   9.9   5.4   2003 f   7.2   11.4   22.2     8.3       12.1   11.0   -0.3   3.7   2003 f   7.2   11.4   22.2     8.3       12.1   11.0   -0.3   3.7   2004   18.6   7.6   3.2   0.2     11.0     45.9   56.9       1986   7.6   3.2   0.2     11.0     45.9   56.9       1987   12.1   3.5   0.3     18.1       45.9   56.9       1989   17.6   1.6   0.3     18.1       48.5   68.1       1990   18.2   1.8   0.3     20.3       44.1   65.2       1991   1911   1.8   0.3     21.2       44.1   65.2       1992   17.3   1.5   0.9     19.7       44.1   65.2       1993   15.6   1.7   0.7     18.0       47.4   65.1   17.5   17.3   1995   15.5   1.8   0.7     18.0       47.4   65.1   17.5   17.3   1996   16.2   1.8   0.7     18.0       47.4   65.1   17.5   17.3   1997   15.5   1.8   0.7     18.0       50.8   75.5   12.4   12.0   1997   15.1   15.5   1.8   0.7     18.8       50.6   87.5   51.2   12.8   13.0   1997   17.1   2.0   0.8     19.9       50.8   75.5   12.4   12.0   1997   17.1   2.0   0.8     19.9       54.3   74.2   12.8   13.0   1997   17.1   2.0   0.8     19.9       54.3   74.2   12.8   13.0   1997   17.1   2.0   0.8     19.9       54.3   74.2   12.8   13.0	995	10.2	8.6	9.8		10.0			19.2	16.7	-73	-5.1	-6.2
1997         7.4         8.3         14.7													-22.4
1998       14.6       16.2       21.0													
2000 16.8 66.4 26.3 22.1 7.2 11.6 3.3 -6.0 2001 12.4 16.8 4.4 12.6 19.4 17.2 9.9 5.4 2002 f 8.9 11.4 -9.4 8.5 9.9 9.5 8.3 7.1 2003 f 7.2 11.4 22.2 8.3 12.1 11.0 -0.3 3.7 2003 f 7.2 11.4 22.2 8.3 12.1 11.0 -0.3 3.7 2003 f 7.2 11.4 22.2 8.3 12.1 11.0 -0.3 3.7 2003 f 7.2 11.4 22.2 8.3 12.1 11.0 12.1 12.1													
2001         12.4         16.8         4.4	999	14.7	14.0	11.9		14.5			2.0	5.4	5.8	0.1	3.0
2001         12.4         16.8         4.4	000	16.9	66.4	26.3		22.1			7.2	11.6	-33	-6.0	-4.6
2002 f         8.9         11.4         -9.4          8.5           19.9         9.5         8.3         7.1           (percentage share of total drug expenditure)													
2003 f   7.2													7.7
1985         5.1         2.3         0.1          7.6           59.7         67.3           1986         7.6         3.2         0.2          11.0           45.9         56.9           1987         12.1         3.5         0.3          15.9           35.3         51.3            1988         15.7         2.0         0.3          18.1           42.0         60.0            1989         17.6         1.6         0.3          19.6           48.5         68.1            1999            48.5         68.1            1999            48.5         68.1            1999                  1999 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
1986       7.6       3.2       0.2        11.0         45.9       56.9           1987       12.1       3.5       0.3        15.9        35.3       51.3           1988       15.7       2.0       0.3        18.1         42.0       60.0            1989       17.6       1.6       0.3        19.6         48.5       68.1            1990       18.2       1.8       0.3        20.3        50.1       70.4            1991       19.1       1.8       0.3        21.2        44.1       65.2            1992       17.3       1.5       0.9        19.7        42.9       62.6       19.6       17.8         1993       15.6       1.7       0.7        18.0         45.6       63.6       18.8       17.6         1994       15.3						(percen	tage share of to	tal drug expe	nditure)				
1987       12.1       3.5       0.3        15.9         35.3       51.3         198         1988       15.7       2.0       0.3        18.1         42.0       60.0            1989       17.6       1.6       0.3        19.6         48.5       68.1            1990       18.2       1.8       0.3        20.3         50.1       70.4            1991       19.1       1.8       0.3        21.2         44.1       65.2            1992       17.3       1.5       0.9        19.7         42.9       62.6       19.6       17.8         1993       15.6       1.7       0.7        18.0         47.4       65.1       17.5       17.3         1994       15.3       1.8       0.7        17.9         47.4       65.1	985	5.1	2.3	0.1		7.6			59.7	67.3			32.7
1988       15.7       2.0       0.3        18.1         42.0       60.0         19.6         1989       17.6       1.6       0.3        19.6         48.5       68.1            1990       18.2       1.8       0.3        20.3         50.1       70.4            1991       19.1       1.8       0.3        21.2         44.1       65.2            1992       17.3       1.5       0.9        19.7         42.9       62.6       19.6       17.8         1993       15.6       1.7       0.7        18.0        45.6       63.6       18.8       17.6         1994       15.3       1.8       0.7        17.7        47.4       65.1       17.5       17.3         1995       15.5       1.8       0.7        17.9        52.0       69.9       15.0       15.1         199	986	7.6	3.2	0.2		11.0			45.9	56.9			43.1
1989       17.6       1.6       0.3        19.6         48.5       68.1            1990       18.2       1.8       0.3        20.3        50.1       70.4           1991       19.1       1.8       0.3        21.2         44.1       65.2           1992       17.3       1.5       0.9        19.7         42.9       62.6       19.6       17.8         1993       15.6       1.7       0.7        18.0         45.6       63.6       18.8       17.6         1994       15.3       1.8       0.7        17.7         47.4       65.1       17.5       17.3         1995       15.5       1.8       0.7        17.9         52.0       69.9       15.0       15.1         1996       16.2       1.8       0.7        18.8         56.8       75.5       12.4       12.0         1997 <td< td=""><td>987</td><td>12.1</td><td>3.5</td><td>0.3</td><td></td><td>15.9</td><td></td><td></td><td>35.3</td><td>51.3</td><td></td><td></td><td>48.7</td></td<>	987	12.1	3.5	0.3		15.9			35.3	51.3			48.7
1990 18.2 1.8 0.3 20.3 50.1 70.4 1991 19.1 1.8 0.3 21.2 44.1 65.2 1992 17.3 1.5 0.9 19.7 42.9 62.6 19.6 17.8 1993 15.6 1.7 0.7 18.0 45.6 63.6 18.8 17.6 1994 15.3 1.8 0.7 17.7 47.4 65.1 17.5 17.3 1995 15.5 1.8 0.7 17.9 47.4 65.1 17.5 17.3 1996 16.2 1.8 0.7 18.8 52.0 69.9 15.0 15.1 1996 16.2 1.8 0.7 18.8 56.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 54.3 74.2 12.8 13.0			2.0	0.3		18.1			42.0	60.0			40.0
1991     19.1     1.8     0.3      21.2       44.1     65.2         1992     17.3     1.5     0.9      19.7       42.9     62.6     19.6     17.8       1993     15.6     1.7     0.7      18.0       45.6     63.6     18.8     17.6       1994     15.3     1.8     0.7      17.7       47.4     65.1     17.5     17.3       1995     15.5     1.8     0.7      17.9      52.0     69.9     15.0     15.1       1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9      54.3     74.2     12.8     13.0	989	17.6	1.6	0.3		19.6			48.5	68.1			31.9
1991     19.1     1.8     0.3      21.2       44.1     65.2         1992     17.3     1.5     0.9      19.7       42.9     62.6     19.6     17.8       1993     15.6     1.7     0.7      18.0       45.6     63.6     18.8     17.6       1994     15.3     1.8     0.7      17.7       47.4     65.1     17.5     17.3       1995     15.5     1.8     0.7      17.9      52.0     69.9     15.0     15.1       1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9      54.3     74.2     12.8     13.0	990	18.2	1.8	0.3		20.3			50.1	70.4			29.6
1992     17.3     1.5     0.9      19.7       42.9     62.6     19.6     17.8       1993     15.6     1.7     0.7      18.0       45.6     63.6     18.8     17.6       1994     15.3     1.8     0.7      17.7       47.4     65.1     17.5     17.3       1995     15.5     1.8     0.7      17.9      52.0     69.9     15.0     15.1       1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9       54.3     74.2     12.8     13.0													34.8
1993     15.6     1.7     0.7      18.0      45.6     63.6     18.8     17.6       1994     15.3     1.8     0.7      17.7       47.4     65.1     17.5     17.3       1995     15.5     1.8     0.7      17.9      52.0     69.9     15.0     15.1       1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9       54.3     74.2     12.8     13.0													
1995 15.5 1.8 0.7 17.9 52.0 69.9 15.0 15.1 1996 16.2 1.8 0.7 18.8 56.8 75.5 12.4 12.0 1997 17.1 2.0 0.8 19.9 54.3 74.2 12.8 13.0	993										18.8		
1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9       54.3     74.2     12.8     13.0	994	15.3	1.8	0.7		17.7			47.4	65.1	17.5	17.3	34.9
1996     16.2     1.8     0.7      18.8       56.8     75.5     12.4     12.0       1997     17.1     2.0     0.8      19.9       54.3     74.2     12.8     13.0	995	15.5	1.8	0.7		17.9			52.0	69.9	15.0	15.1	30.1
4000 400 400 400 400	997	17.1	2.0	0.8		19.9			54.3	74.2	12.8	13.0	25.8
1998 16.9 1.9 0.9 19.7 53.3 73.0 13.3 13.7	998	16.9	1.9	0.9		19.7			53.3	73.0	13.3	13.7	27.0
1999 18.5 2.1 0.9 21.5 51.9 73.4 13.5 13.1	999	18.5	2.1	0.9		21.5			51.9	73.4	13.5	13.1	26.6
2000 20.1 3.3 1.1 24.5 51.9 76.4 12.2 11.5	000	20.1	3.3	1.1		24.5			51.9	76.4	12.2	11.5	23.6
2001 19.7 3.3 1.0 24.0 53.9 77.9 11.6 10.5													
2002 f 19.6 3.4 0.8 23.9 54.3 78.1 11.6 10.3													
2003 f 19.3 3.5 0.9 23.7 55.9 79.6 10.6 9.8													
f - Forecast													
* Note: Confidentiality precludes reporting provincial level insurance data.	Note: Confider	ntiality precludes	s reporting pro	ovincial level in	surance data.								CIHI 2004

		_				as a Share of 1985–2003 (d		e and	
		All Drugs	Exponditures		alth Expenditure	2000 (0	Share of Drug	gs in Public, Priva lealth Expenditure	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
'ear			(\$ millio	ons)			(pe	rcentage share)	
985	2.5	30.2	32.7	128.3	52.9	181.2	1.9	57.1	18.
986	3.1	25.0	28.0	138.0	49.6	187.6	2.2	50.3	15.
987	4.6	24.2	28.8	149.7	53.3	202.9	3.1	45.4	14.
988	5.3	24.1	29.4	163.0	56.5	219.5	3.3	42.7	13.
989	6.0	24.9	30.9	174.4	64.9	239.3	3.5	38.3	12.
990	7.3	28.6	35.9	186.3	70.0	256.2	3.9	40.9	14.
991	8.2	30.6	38.8	203.8	76.8	280.6	4.0	39.9	13.
992	8.6	35.2	43.9	209.2	85.8	295.0	4.1	41.1	14.
993	8.6	39.3	47.9	218.2	93.5	311.7	4.0	42.0	15.
994	8.9	41.4	50.3	217.0	96.3	313.3	4.1	43.0	16.
1995	9.8	44.9	54.7	222.8	103.3	326.1	4.4	43.5	16.
996	9.8	42.4	52.3	233.0	105.0	338.0	4.2	40.4	15.
1997	10.6	42.5	53.0	229.9	109.9	339.9	4.6	38.6	15.
1998	12.2	49.7	61.8	245.8	112.6	358.4	4.9	44.1	17.
1999	13.9	50.8	64.8	260.5	116.9	377.5	5.3	43.5	17.
2000	17.0	52.5	69.5	278.0	123.3	401.4	6.1	42.5	17.
2001	19.1	60.7	79.9	308.2	146.1	454.3	6.2	41.6	17.
2002 f	20.8	66.3	87.1	348.4	155.2	503.6	6.0	42.7	17.
2003 f	22.5	72.3	94.9	372.9	165.7	538.6	6.0	43.7	17.
			(annual percenta	age change)					
	-								
1985	24.4	17.0	14.2			 2 E			
1986 1987	24.4 48.5	-17.3 -3.1	-14.2 2.6	7.6 8.5	-6.3 7.4	3.5 8.2			
1988	16.1	-0.3	2.3	8.9	6.1	8.2			
1989	13.7	3.1	5.0	7.0	14.9	9.1			
1990	20.7	14.9	16.0	6.8	7.7	7.0			
1991	12.7	7.2	8.3	9.4	9.8	9.5			
1992 1993	5.2 -0.3	15.1 11.4	13.0 9.1	2.7 4.3	11.6 9.0	5.1 5.7			
1994	3.5	5.4	5.1	-0.6	3.0	0.5			
1995	10.0	8.4	8.7	2.7	7.2	4.1			
1996	-0.2	-5.5	-4.5	4.6	1.7	3.6			
1997 1998	7.8 15.1	0.0 17.0	1.5 16.6	-1.3 6.9	4.7 2.4	0.5 5.5			
1999	14.5	2.3	4.7	6.0	3.8	5.3			
2000	22.1	3.2	7.3	6.7	5.5	6.3			
2001	12.6	15.7	15.0	10.8	18.5	13.2			
2002 f	8.5	9.3	9.1	13.0	6.2	10.8			
2003 f	8.3	9.1	8.9	7.0	6.8	7.0			
	(percentage s	hare of total drug	expenditure)						
1985	7.6	92.4	100.0						
1986	11.0	89.0	100.0						
1987	15.9	84.1	100.0						
1988	18.1	81.9	100.0						
1989	19.6	80.4	100.0						
1990	20.3	79.7	100.0						
1991	21.2	78.8	100.0						
1992	19.7	80.3	100.0						
1993	18.0	82.0	100.0						
1994	17.7	82.3	100.0						
1995	17.9	82.1	100.0						
1996	18.8	81.2	100.0						
1997	19.9	80.1	100.0						
1998	19.7	80.3	100.0						
1999	21.5	78.5	100.0						
2000	24.5	75.5	100.0						
	24.0	76.0	100.0						
2001									
2001 2002 f	23.9	76.1	100.0						

CIHI 2004

Table B.2.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Prince Edward Island, 1985–2003

			Public		Prescribe	ea Drugs	Private				Prescribed December 10 Prescribed 10 Prescri	
	Provincial	Federal	Social Secu	rity Funde	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
	Frovilleiai	reuerai _	W.C.B.	Drug	Public	ilisuleis	Pocket	Private	Prescribed	the	Health	Non-Presc.
				Insurance Funds					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ per c	apita)					
1985	13.08	6.01	0.33		19.42			152.95	172.37			83.63
1986	16.61	6.94	0.47		24.02			100.25	124.27			94.14
1987	27.17	7.80	0.66		35.62			79.09	114.72			109.04
1988 1989	35.77 41.92	4.59 3.77	0.79 0.79		41.15 46.48			95.54 115.34	136.69 161.82			90.98 75.86
1990	50.03	4.91	0.95		55.88			137.70	193.59			81.26
1991	56.89	5.26	0.94		63.09			131.41	194.50			103.63
1992	58.12	5.01	2.99		66.12			144.08	210.20	65.73	59.68	
1993	56.53	6.18	2.56		65.27			165.28	230.55	68.24	63.70	131.94
1994	57.56	6.86	2.49		66.91			178.75	245.65	66.21	65.44	131.65
1995	62.95	7.39	2.72		73.06			211.56	284.62	60.91	61.67	122.58
1996	62.35	7.04	2.81		72.20			218.51	290.71	47.84	46.35	
1997	66.82	7.61	3.21		77.64			211.50	289.13	50.05	50.46	100.51
1998	76.76	8.86	3.90		89.52			242.67	332.19	60.77	62.32	123.09
1999	87.75	10.07	4.35		102.17			246.71	348.88	64.10	62.19	126.29
2000	102.36	16.74	5.48		124.58			264.09	388.67	61.92	58.37	120.30
2001	114.85	19.53	5.72		140.10			314.79	454.89	67.96	61.42	129.39
2002 f	124.80	21.71	5.17		151.69			345.06	496.75	73.45	65.61	139.06
2003 f	133.03	24.06	6.28		163.37			384.64	548.01	72.83	67.63	140.46
						(annual percent	age change)					
1985												
1986	27.0	15.4	43.2		23.7			-34.5	-27.9			12.6
1987	63.5	12.4	39.5		48.3			-21.1	-7.7			15.8
1988	31.7	-41.2	19.5		15.5			20.8	19.2			-16.6
1989	17.2	-17.9	0.3		13.0			20.7	18.4			-16.6
1990	19.3	30.2	20.1		20.2			19.4	19.6			7.1
1991	13.7	7.2	-0.2		12.9			-4.6	0.5			27.5
1992 1993	2.2 -2.7	-4.8 23.5	216.8 -14.6		4.8 -1.3			9.6 14.7	8.1 9.7	3.8	6.7	21.0 5.2
1994	1.8	10.9	-14.0		2.5			8.1	6.6	-3.0	2.7	
1995	9.4	7.8	9.0		9.2			18.4	15.9	-8.0	-5.8	-6.9
1996	-0.9	-4.7	3.4		-1.2			3.3	2.1	-21.5	-24.8	
1997	7.2	8.0	14.4		7.5			-3.2	-0.5	4.6	8.9	
1998	14.9	16.5	21.3		15.3			14.7	14.9	21.4	23.5	
1999	14.3	13.6	11.5		14.1			1.7	5.0	5.5	-0.2	
2000	16.7	66.2	26.2		21.9			7.0	11.4	-3.4	-6.1	-4.7
2001	12.2	16.7	4.3		12.5			19.2	17.0	9.8	5.2	
2002 f	8.7	11.2	-9.6		8.3			9.6	9.2	8.1	6.8	
2003 f	6.6	10.8	21.5		7.7			11.5	10.3	-0.8	3.1	
				(annual p	ercentage cha	nge in excess o	f inflation in 1	the Canadian	economy)			
1985												
1986	24.2	12.6	40.4		20.9			-37.3	-30.7			9.8
1987	58.8	7.7	34.8		43.6			-25.8	-12.4			11.1
1988 1989	27.2 12.6	-45.7 -22.4	15.0 -4.3		11.0 8.4			16.3 16.2	14.6 13.8			-21.1 -21.2
1990	16.3	27.2	17.1		17.2			16.4	16.6			4.1
1991 1992	10.9	4.4	-3.0		10.1			-7.3	-2.3			24.8
1992	0.9 -4.2	-6.1 22.1	215.6 -16.1		3.5 -2.7			8.4 13.3	6.8 8.2	2.4	 5.3	19.8
1994	0.7	9.8	-3.5		1.4			7.0	5.5	-4.1	1.6	
1995 1996	7.0 -2.6	5.5 -6.4	6.7 1.7		6.9 -2.8			16.0 1.6	13.5 0.5	-10.3 -23.1	-8.1 -26.5	
1996	-2.6 6.2	-6.4 7.1	1.7		-2.8 6.5			-4.2	-1.5	3.6	-26.5 7.9	
1998	15.3	16.9	21.7		15.7			15.2	15.3	21.9	23.9	
1999	12.5	11.8	9.7		12.3			-0.1	3.2	3.7	-2.0	
2000	12.7	62.2	22.2		18.0			3.1	7.4	-7.4	-10.1	-8.7
2000	10.9	15.4	3.0		11.2			17.9	15.8	8.5	4.0	
2001 2002 f	7.7	10.2	-10.6		7.3			8.6	8.2	7.1	5.8	
2003 f	3.3	7.5	18.2		4.4			8.2	7.0	-4.1	-0.2	
f - Forecast												
* Note: Confide	ntiality precludes	reporting pro	vincial/territoria	al level insurar	nce data.							CIHI 2004

	Total Health	Expenditures	s, Prince Edw	Source of Fi ard Island, 1	985-2003	(continued)
	All Drugs		Ша	alth Eunanditura		GDP Implicit Price Index – Canad
Public	Private	Total	Public	alth Expenditure Private	Total	Frice index — Canad
		(\$ per ca	pita)			(1997 = 100)
19.42	236.58	256.00	1,004.74	414.66	1,419.40	73.6
24.02	194.39	218.41	1,074.57	386.13	1,460.70	75.6
35.62	188.13	223.76	1,164.10	414.24	1,578.34	79.2
41.15 46.48	186.53 191.20	227.67 237.68	1,260.71 1,340.84	436.97 499.18	1,697.67 1,840.01	82.8 86.6
55.88	218.96	274.84	1,426.83	535.91	1,962.74	89.2
63.09	235.04	298.14	1,563.81	589.69	2,153.50	91.6 92.8
66.12 65.27	269.50 297.22	335.62 362.49	1,599.57 1,651.43	655.88 707.51	2,255.45 2,358.94	92.8
66.91	310.40	377.30	1,626.43	722.12	2,348.55	95.2
73.06	334.14	407.20	1,657.77	768.76	2,426.52	97.4
72.20 77.64	312.70	384.90 389.64	1,716.36	773.82 807.80	2,490.18	99.0 100.0
89.52	312.00 365.75	389.64 455.28	1,689.18 1,809.86	829.29	2,496.98 2,639.15	99.6
102.17	373.00	475.17	1,911.42	857.97	2,769.38	101.4
124.58	384.39	508.97	2,037.19	903.54	2,940.73	105.4
140.10 151.69	444.18 484.12	584.28 635.81	2,255.13 2,543.14	1,068.94 1,132.57	3,324.07 3,675.71	106.7 107.8
163.37	525.10	688.47	2,706.15	1,202.80	3,908.95	111.4
			ual percentage cha			
23.7	-17.8	-14.7	7.0	-6.9	2.9	2.8
48.3	-3.2	2.4	8.3	7.3	8.1	4.7
15.5	-0.9	1.7	8.3	5.5	7.6	4.5
13.0	2.5	4.4	6.4	14.2	8.4	4.6
20.2	14.5	15.6	6.4	7.4	6.7	3.0
12.9	7.3	8.5	9.6	10.0	9.7	2.8
4.8	14.7	12.6	2.3	11.2	4.7	1.3
-1.3	10.3	8.0	3.2	7.9	4.6	1.4
2.5	4.4	4.1	-1.5	2.1	-0.4	1.1
9.2	7.6	7.9	1.9	6.5	3.3	2.3
-1.2	-6.4	-5.5	3.5	0.7	2.6	1.7
7.5	-0.2	1.2	-1.6	4.4	0.3	1.0
15.3	17.2	16.8	7.1	2.7	5.7	-0.4
14.1	2.0	4.4	5.6	3.5	4.9	1.8
21.9	3.1	7.1	6.6	5.3	6.2	4.0
12.5	15.6	14.8	10.7	18.3	13.0	1.3
8.3	9.0	8.8	12.8	6.0	10.6	1.0
7.7	8.5	8.3	6.4	6.2	6.3	3.3
(a	nnual percentage c	nange in excess of	inflation in the Can	adian economy)		
20.9	-20.6	-17.5	4.1	-9.7	0.1	
43.6	-8.0	-2.3	3.6	2.5	3.3	
11.0	-5.4	-2.8	3.8	1.0	3.0	
8.4	-2.1	-0.2	1.8	9.7	3.8	
17.2	11.5	12.6	3.4	4.3	3.6	
10.1	4.6	5.7	6.8	7.3	7.0	
3.5	13.4	11.3	1.0	10.0	3.5	
-2.7	8.8	6.6	1.8	6.4	3.1	
1.4	3.3	3.0	-2.6	1.0	-1.5	
6.9	5.3	5.6	-0.4	4.1	1.0	
-2.8	-8.1	-7.1	1.9	-1.0	1.0	
6.5	-1.2	0.2	-2.6	3.4	-0.7	
15.7	17.7	17.3	7.6	3.1	6.1	
12.3	0.2	2.6	3.8	1.7	3.1	
18.0 11.2	-0.9 14.3	3.1 13.5	2.6 9.4	1.3 17.0	2.2 11.8	
7.3	8.0	7.8	9.4 11.8	4.9	9.6	
		7.0		7.0	5.5	

Table B.3.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985–2003

			Public		Prescribe	ed Drugs	Private				Prescribed Do	
	Provincial	Federal	Social Secu	rity Funde	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
	FIOVIIICIAI	rederai _	W.C.B.	Drug Insurance Funds	Public	insurers	Pocket	Private	Prescribed Drugs	the Counter Drugs	Health Supplies	Non-Presc. Drugs
⁄ear	-			runus		(\$ mill	ions)			Drugs		
985	45.5	2.3	0.2		48.0			38.7	86.7			61.
986	53.1	2.4	0.2		55.7			59.6	115.3			69.2
1987	62.3	2.6	0.2		65.1			67.7	132.8			80.2
1988	72.2	3.4	0.3		76.0			74.8	150.8			78.9
1989	82.1	4.2	0.3		86.6			82.5	169.1			77.7
1990	83.0	5.0	0.3		88.3			96.0	184.2			79.3
1991	83.0	5.6	0.5		89.1			106.2	195.3			80.6
1992	89.0	5.9	0.5		95.4			118.4	213.8	48.7	44.3	93.0
1993 1994	88.5 83.2	6.8 7.3	0.6 0.6		95.9 91.1			132.7 137.8	228.6 228.9	51.3 49.9	47.9 49.3	99.1 99.1
1994	63.2	7.3	0.0		91.1			137.0	220.9	49.9	45.5	33.1
1995	83.9	8.9	0.7		93.5			148.7	242.2	45.9	46.5	92.4
1996	83.3	8.4	0.7		92.5			159.4	251.8	51.6	50.0	101.7
1997	86.8	9.8	0.7		97.3			170.5	267.9	47.0	47.4	94.3
1998	99.5	14.4	0.8		114.7			198.7	313.4	52.4	53.7	106.1
1999	110.7	14.8	1.1		126.5			201.5	328.0	53.1	51.5	104.5
2000	117.3	18.8	1.4		137.4			227.3	364.7	53.1	50.1	103.2
2001	128.7	22.3	1.9		152.9			247.5	400.4	58.0	52.5	110.5
2002 f	139.1	25.6	2.2		166.9			266.1	433.0	62.5	55.9	118.4
2003 f	153.4	29.5	2.6		185.6	 (annual percen		291.8	477.4	62.7	57.2	119.9
1005												
1985 1986	16.7	3.8	16.4		16.1			54.0	33.0			13.2
1987	17.2	3.o 8.3	4.2		16.8			13.6	15.1			16.0
1988	16.0	32.7	48.7		16.8			10.4	13.5			-1.6
1989	13.7	21.9	-7.8		14.0			10.4	12.2			-1.6
1990	1.0	20.1	6.4		1.9			16.3	8.9			2.1
1991	0.1	12.4	41.5		0.9			10.6	6.0			1.7
1992	7.2	5.3	2.6		7.1			11.5	9.5			15.4
1993	-0.5	15.4	20.2		0.6			12.1	6.9	5.2	8.1	6.6
1994	-6.0	6.6	6.1		-5.0			3.9	0.1	-2.7	3.0	0.0
1995	0.8	21.6	15.7		2.6			7.9	5.8	-7.9	-5.7	-6.8
1996	-0.7	-5.0	5.2		-1.1			7.2	4.0	12.5	7.7	10.1
1997	4.2	16.2	-1.0		5.3			7.0	6.4	-9.1	-5.4	-7.2
1998	14.5	47.4	16.2		17.9			16.5	17.0	11.5	13.4	12.4
1999	11.3	2.5	27.0		10.3			1.4	4.7	1.3	-4.1	-1.5
2000	5.9	27.1	28.6		8.6			12.8	11.2	0.2	-2.7	-1.2
2001	9.8	18.6	39.0		11.3			8.9	9.8	9.2	4.7	7.0
2002 f	8.1	14.9	18.0		9.2			7.5	8.1	7.8	6.5	7.2
2003 f	10.3	15.4	17.4		11.2		 tal daug ava	9.7	10.3	0.3	2.3	1.2
					-	age share of to						
1985	30.8	1.5	0.1		32.5			26.2	58.7			41.3
1986 1987	28.8 29.2	1.3 1.2	0.1 0.1		30.2 30.5			32.3 31.8	62.5 62.3			37.5 37.7
1988	31.5	1.5	0.1		33.1			32.5	65.6			34.4
1989	33.3	1.7	0.1		35.1			33.4	68.5			31.5
1990	31.5	1.9	0.1		33.5			36.4	69.9			30.1
1991	30.1	2.0	0.1		32.3			38.5	70.8			29.2
1992	29.0	1.9	0.2		31.1			38.6	69.7	15.9	14.4	30.3
1993	27.0	2.1	0.2		29.3			40.5	69.8	15.6	14.6	30.2
1994	25.4	2.2	0.2		27.8			42.0	69.8	15.2	15.0	30.2
1995	25.1	2.6	0.2		27.9			44.5	72.4	13.7	13.9	27.6
1996	23.6	2.4	0.2		26.2			45.1	71.2	14.6	14.2	28.8
1997	24.0	2.7	0.2		26.9			47.1	74.0	13.0	13.1	26.0
1998	23.7	3.4	0.2		27.4			47.4	74.7	12.5	12.8	25.3
1999	25.6	3.4	0.2		29.3			46.6	75.8	12.3	11.9	24.2
2000	25.1	4.0	0.3		29.4			48.6	77.9	11.4	10.7	22.1
2001	25.2	4.4	0.4		29.9			48.5	78.4	11.4	10.3	21.6
2002 f	25.2	4.6	0.4		30.3			48.3	78.5	11.3	10.1	21.5
2003 f f - Forecast	25.7	4.9	0.4		31.1			48.9	79.9	10.5	9.6	20.1

1987 1988 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999	948.0 55.7 65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5 137.4 152.9 166.9	99.8 128.8 147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 264.9 304.7 306.0 330.6	Total  (\$ millio  147.8  184.5  213.0  229.7  246.8  263.5  275.9  306.8  327.7  328.1  334.6  353.5  362.2  419.5	Public	285.3 353.7 395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2 617.6	1,232.5 1,376.9 1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	Share of Drugs Total Hea	entage share)  35.0 36.4 37.4 36.6 34.1 35.7 36.0 38.1 40.0	12.1 13.1 14.1 14.1 15.1
1985 1986 1987 1988 1999 1991 1992 1993 1994 1995 1996 1997 1998 1999	48.0 55.7 65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	99.8 128.8 147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 264.9 304.7 306.0 330.6	(\$ millio 147.8 184.5 213.0 229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	947.2 1,023.2 1,165.5 1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	285.3 353.7 395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2 617.6	1,232.5 1,376.9 1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	9 (perc) 5.1 5.4 5.6 6.5 6.8 6.4 6.1 6.5 6.6	97 97 97 97 97 97 97 97 97 97 97 97 97 9	12.4 13.4 14.4 14.1 14.1 15.
985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 2000 2001	55.7 65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	128.8 147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	147.8 184.5 213.0 229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	947.2 1,023.2 1,165.5 1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1	353.7 395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2	1,376.9 1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	5.1 5.4 5.6 6.5 6.8 6.4 6.1 6.5 6.6	35.0 36.4 37.4 36.6 34.1 35.7 36.0 38.1 40.0	13. 13. 14. 14. 14. 15.
1985 1986 1987 1988 1999 1991 1992 1993 1994 1995 1996 1997 1998 1999	55.7 65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	128.8 147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	147.8 184.5 213.0 229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	947.2 1,023.2 1,165.5 1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1	353.7 395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2	1,376.9 1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	5.1 5.4 5.6 6.5 6.8 6.4 6.1 6.5 6.6	35.0 36.4 37.4 36.6 34.1 35.7 36.0 38.1 40.0	13. 13. 14. 14. 14. 15.
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999	55.7 65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	128.8 147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	184.5 213.0 229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,023.2 1,165.5 1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1	353.7 395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2	1,376.9 1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	5.4 5.6 6.5 6.8 6.4 6.1 6.5 6.6	36.4 37.4 36.6 34.1 35.7 36.0 38.1 40.0	13.4 13.6 14.5 14.7 14.7 15.7
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	65.1 76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	147.9 153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	213.0 229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,165.5 1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1	395.0 420.1 470.3 490.4 518.8 554.5 579.5 608.2 617.6	1,560.6 1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	5.6 6.5 6.8 6.4 6.1 6.5 6.6	37.4 36.6 34.1 35.7 36.0 38.1 40.0	13.6 14.5 14.1 14.1 14.0 15.1
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	76.0 86.6 88.3 89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	153.7 160.2 175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	229.7 246.8 263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,165.0 1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	420.1 470.3 490.4 518.8 554.5 579.5 608.2 617.6	1,585.0 1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	6.5 6.8 6.4 6.1 6.5 6.6	36.6 34.1 35.7 36.0 38.1 40.0	14.5 14.1 14.0 15.1
1995 1996 1997 1998 1999 2000 2001 2002 f	88.3 89.1 95.4 96.9 91.1 93.5 92.5 97.3 114.7 126.5	175.3 186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	263.5 275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,281.5 1,376.6 1,451.2 1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	490.4 518.8 554.5 579.5 608.2 617.6	1,751.8 1,866.9 1,970.0 2,031.6 2,025.0 2,021.4	6.4 6.1 6.5 6.6	35.7 36.0 38.1 40.0	14.1 14.0 15.1
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5 137.4 152.9	186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,451.2 1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	518.8 554.5 579.5 608.2 617.6	1,970.0 2,031.6 2,025.0 2,021.4	6.1 6.5 6.6	36.0 38.1 40.0	14.0 15.1
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	89.1 95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5 137.4 152.9	186.8 211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	275.9 306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,451.2 1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	518.8 554.5 579.5 608.2 617.6	1,970.0 2,031.6 2,025.0 2,021.4	6.1 6.5 6.6	36.0 38.1 40.0	14.0 15.1
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	95.4 95.9 91.1 93.5 92.5 97.3 114.7 126.5	211.4 231.8 237.0 241.1 261.1 264.9 304.7 306.0	306.8 327.7 328.1 334.6 353.5 362.2 419.5	1,477.0 1,445.5 1,413.1 1,440.0 1,438.2	554.5 579.5 608.2 617.6	2,031.6 2,025.0 2,021.4	6.5 6.6	38.1 40.0	15.1
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f	95.9 91.1 93.5 92.5 97.3 114.7 126.5 137.4 152.9	231.8 237.0 241.1 261.1 264.9 304.7 306.0	327.7 328.1 334.6 353.5 362.2 419.5	1,445.5 1,413.1 1,440.0 1,438.2	579.5 608.2 617.6	2,025.0 2,021.4	6.6	40.0	
1996 1997 1998 1999 2000 2001 2002 f	93.5 92.5 97.3 114.7 126.5 137.4 152.9	241.1 261.1 264.9 304.7 306.0	334.6 353.5 362.2 419.5	1,440.0 1,438.2	617.6		6.4	20.0	
1997 1998 1999 2000 2001 2002 f	92.5 97.3 114.7 126.5 137.4 152.9	261.1 264.9 304.7 306.0 330.6	353.5 362.2 419.5	1,438.2		0.057.0		39.0	16.2
1996 1997 1998 1999 2000 2001 2002 f 2003 f	92.5 97.3 114.7 126.5 137.4 152.9	261.1 264.9 304.7 306.0 330.6	353.5 362.2 419.5	1,438.2			6.5	39.0	16.3
1997 1998 1999 2000 2001 2002 f	97.3 114.7 126.5 137.4 152.9	264.9 304.7 306.0 330.6	362.2 419.5		643.3	2,057.6 2,081.6	6.4	39.0 40.6	17.0
1998 1999 2000 2001 2002 f	114.7 126.5 137.4 152.9	304.7 306.0 330.6	419.5	1,009.1	690.8	2,359.8	5.8	38.3	15.3
1999 2000 2001 2002 f	126.5 137.4 152.9	306.0 330.6		1,786.4	755.0	2,541.4	6.4	40.4	16.5
2001 2002 f	152.9		432.5	1,905.7	756.0	2,661.7	6.6	40.5	16.3
2001 2002 f	152.9		400.0	1 000 7	040.5	0.010.1	7.0	20.0	10.0
2002 f		358.0	468.0 510.9	1,966.7 2,082.2	849.5 909.1	2,816.1 2,991.2	7.0 7.3	38.9 39.4	16.6 17.1
	100.0	384.5	551.4	2,274.9	1,001.6	3,276.5	7.3	38.4	16.8
20001	185.6	411.7	597.3	2,444.0	1,038.7	3,482.7	7.6	39.6	17.2
			(annual percenta						
_									
1985	10.1								
1986 1987	16.1 16.8	29.1 14.9	24.9 15.4	8.0 13.9	24.0 11.7	11.7 13.3			
1988	16.8	3.9	7.8	-0.1	6.3	1.6			
1989	14.0	4.2	7.5	10.0	12.0	10.5			
1990	1.9	9.4	6.8	7.4	4.3	6.6			
1991	0.9	6.6	4.7	5.4	5.8	5.5			
1992 1993	7.1 0.6	13.2 9.6	11.2 6.8	1.8 -2.1	6.9 4.5	3.1 -0.3			
1994	-5.0	2.2	0.1	-2.1	5.0	-0.3			
1995	2.6	1.7	2.0	1.9	1.5	1.8			
1996	-1.1	8.3	5.7	-0.1	4.2	1.2			
1997 1998	5.3	1.5 15.1	2.5 15.8	16.1	7.4 9.3	13.4 7.7			
1999	17.9 10.3	0.4	3.1	7.0 6.7	0.1	4.7			
1000	10.0	0.4	0.1	0.7	0.1	4.7			
2000	8.6	8.0	8.2	3.2	12.4	5.8			
2001	11.3	8.3	9.2	5.9	7.0	6.2			
2002 f 2003 f	9.2	7.4	7.9	9.3	10.2	9.5			
2003 1	11.2	7.1	8.3	7.4	3.7	6.3			
_	(percentage s	share of total drug	expenditure)	-					
1985	32.5	67.5	100.0						
1986	30.2	69.8	100.0						
1987	30.5	69.5	100.0						
1988	33.1	66.9	100.0						
1989	35.1	64.9	100.0						
1990	33.5	66.5	100.0						
1991	32.3	67.7	100.0						
1992	31.1	68.9	100.0						
1993	29.3	70.7	100.0						
1994	27.8	72.2	100.0						
1995	27.9	72.1	100.0						
1996	26.2	73.8	100.0						
1997	26.9	73.1	100.0						
1998	27.4	72.6	100.0						
1999	29.3	70.7	100.0						
2000	29.4	70.6	100.0						
2001	29.9	70.1	100.0						
2002 f	30.3	69.7	100.0						
2003 f	31.1	68.9	100.0						

Table B.3.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nova Scotia, 1985–2003

Year	51.41 59.72 69.69 80.51 90.89 91.20 90.73	2.59 2.67 2.88	Public Social Secu W.C.B.	Drug Insurance Funds	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed	Over the	te (Out-of-Poo Personal Health	Total Non-Presc.
1985 1986 1987 1988 1989 1990	51.41 59.72 69.69 80.51 90.89 91.20	2.59 2.67 2.88	W.C.B.	Drug Insurance		ilisurers."			Prescribed	the		
1985 1986 1987 1988 1989 1990	59.72 69.69 80.51 90.89 91.20	2.67 2.88	0.21	Funds					Drugs	Counter	Supplies	Drugs
1985 1986 1987 1988 1989 1990	59.72 69.69 80.51 90.89 91.20	2.67 2.88	0.21							Drugs		
1986 1987 1988 1989 1990 1991	59.72 69.69 80.51 90.89 91.20	2.67 2.88	0.21			(\$ per c	apita)					
1987 1988 1989 1990 1991	69.69 80.51 90.89 91.20	2.88			54.21			43.74	97.94			
1988 1989 1990 1991	80.51 90.89 91.20		0.24		62.63			67.05	129.68			77.77
1989 1990 1991	90.89 91.20		0.25		72.82			75.80	148.61			89.77
1990 1991	91.20	3.81	0.37		84.68			83.31	167.99			87.95
1991		4.61	0.34		95.83			91.30	187.13			85.92
	90.73	5.50	0.36		97.05			105.50	202.55			87.16
1992	50.75	6.14	0.50		97.37			116.04	213.41			88.07
	96.80	6.44	0.51		103.75			128.74	232.49	53.01	48.13	101.14
1993	95.81	7.39	0.61		103.82			143.56	247.38	55.48	51.79	107.28
1994	89.76	7.86	0.65		98.27			148.69	246.96	53.79	53.16	106.95
1995	90.40	9.54	0.75		100.69			160.23	260.92	49.45	50.07	99.52
1996	89.46	9.03	0.78		99.28			171.12	270.39	55.45	53.72	
1997	93.13	10.48	0.78		104.39			182.88	287.28	50.37	50.79	
1998	106.74	15.46	0.90		123.11			213.19	336.30	56.19	57.63	
1999	118.53	15.82	1.14		135.49			215.75	351.24	56.81	55.12	
2000	105.55	20.11	4 4-		147 10			0.40.40	200 50	E0.00	E0 0:	110 51
2000	125.55 138.03	20.11 23.89	1.47 2.05		147.13 163.96			243.42 265.49	390.56 429.45	56.90	53.64	
2001 2002 f	138.03	23.69	2.05		178.63			284.79	463.42	62.25 66.94	56.26 59.80	
2002 f	163.91	31.53	2.82		198.27			311.78	510.05	67.00	61.06	
20001	100.01	01.00	2.02			(annual percen			010.00	07.00	01.00	120.00
_												
1985												
1986	16.2	3.3	15.8		15.5			53.3	32.4			12.7
1987	16.7	7.8	3.7		16.3			13.0	14.6			15.4
1988	15.5	32.1	48.1		16.3			9.9	13.0			
1989	12.9	21.0	-8.5		13.2			9.6	11.4			-2.3
1990	0.3	19.3	5.8		1.3			15.6	8.2			1.4
1991	-0.5	11.7	40.7		0.3			10.0	5.4			1.0
1992	6.7	4.8	2.1		6.5			10.9	8.9			14.8
1993	-1.0	14.8	19.7		0.1			11.5	6.4	4.7	7.6	
1994	-6.3	6.3	5.7		-5.3			3.6	-0.2	-3.1	2.6	-0.3
1995	0.7	21.4	15.6		2.5			7.8	5.7	-8.1	-5.8	-6.9
1996	-1.0	-5.3	4.8		-1.4			6.8	3.6	12.1	7.3	
1997	4.1	16.0	-1.1		5.2			6.9	6.2	-9.2	-5.5	-7.3
1998	14.6	47.5	16.3		17.9			16.6	17.1	11.6	13.5	12.5
1999	11.0	2.3	26.7		10.1			1.2	4.4	1.1	-4.3	-1.7
2000	5.9	27.1	28.5		8.6			12.8	11.2	0.2	-2.7	-1.2
2001	9.9	18.8	39.3		11.4			9.1	10.0	9.4	4.9	
2001 2002 f	7.8	14.6	17.7		8.9			7.3	7.9	7.5	6.3	
2002 f	10.1	15.2	17.7		11.0			9.5	10.1	0.1	2.1	1.1
2003 1	10.1	15.2	17.2			ige in excess o				0.1	2.1	11
_				(dilliddi pei	contage onan	ige iii exeess e	i iiiiiddoii iii	the Ganadia	r coording,			
1985												
1986	13.4	0.5	13.0		12.7			50.5	29.6			9.9
1987	11.9	3.1	-1.0		11.5			8.3	9.9			
1988 1989	11.0 8.3	27.6 16.4	43.6 -13.1		11.8 8.6			5.4 5.0	8.5 6.8			-6.5 -6.9
	0.5	10.4	-13.1	-44	0.0			5.0	0.0			-0.5
1990	-2.7	16.3	2.7		-1.8			12.5	5.2			-1.6
1991	-3.3	9.0	37.9		-2.4			7.2	2.6			
1992	5.4	3.6	0.9		5.3			9.7	7.7			
1993	-2.5	13.4	18.2		-1.4			10.1	5.0	3.2	6.2	
1994	-7.4	5.2	4.6		-6.4			2.5	-1.3	-4.1	1.5	-1.4
1995	-1.6	19.1	13.3		0.1			5.4	3.3	-10.4	-8.2	-9.3
1996	-2.7	-7.0	3.1		-3.1			5.1	2.0	10.5	5.6	
1997	3.1	15.1	-2.1		4.2			5.9	5.3	-10.2	-6.5	
1998	15.0	47.9	16.7		18.4			17.0	17.5	12.0	13.9	
1999	9.2	0.5	24.9		8.2			-0.6	2.6	-0.7	-6.2	-3.5
2000	2.0	22.2	24.0		4.6			0.0	7.0	2.0	67	E 0
2000	2.0	23.2	24.6		4.6			8.9	7.2	-3.8	-6.7	
2001 2002 f	8.7 6.8	17.5 13.6	38.0 16.7		10.2 7.9			7.8 6.3	8.7 6.9	8.1 6.5	3.6 5.3	
2002 f 2003 f	6.8	11.9	13.9		7.9			6.2	6.8	-3.2	-1.2	
f - Forecast	0.5	5						0.2	0.0	0.2		
* Note: Confidenti	ality precludes	reporting provi	ncial/territorial	l level insurance	e data.							CIHI 2004

Public			uics, itova oc	otia, 1985–	2003 (6011)	iiiucu,
Public	A 11 D					GDP Implicit
. 45.10	All Drugs Private	Total	Public He	Private	Total	Price Index — Canada
		(\$ per ca	nita)			(1997 = 100)
E4 21	110.74			322.36	1 202 54	
54.21 62.63	112.74 144.82	166.95 207.46	1,070.18 1,150.53	322.36 397.71	1,392.54 1,548.24	73.6 75.6
72.82	165.57	238.39	1,304.53	442.14	1,746.68	79.2
84.68	171.26	255.94	1,298.16	468.09	1,766.25	82.8
95.83	177.23	273.06	1,417.87	520.32	1,938.19	86.6
97.05	192.66	289.71	1,513.31	539.08	2,052.39	89.2
97.37	204.11	301.48	1,585.86	566.94	2,152.81	91.6
103.75	229.88	333.62	1,606.21	603.05	2,209.26	92.8
103.82	250.84	354.66	1,564.33	627.17	2,191.50	94.1
98.27	255.64	353.91	1,524.47	656.16	2,180.63	95.2
100.69	259.75	360.44	1,551.41	665.39	2,216.79	97.4
99.28	280.29	379.57	1,544.13	690.71	2,234.84	99.0
104.39	284.04	388.43	1,789.95	740.77	2,530.72	100.0
123.11	327.01	450.12	1,916.97	810.18	2,727.14	99.6
135.49	327.69	463.18	2,040.70	809.50	2,850.20	101.4
147.13	353.97	501.10	2,105.92	909.60	3,015.52	105.4
163.96	383.99	547.96	2,233.14	975.00	3,208.15	106.7
178.63	411.52	590.15	2,434.62	1,071.92	3,506.54	107.8
198.27	439.84	638.11	2,610.99	1,109.74	3,720.74	111.4
		(ann	ual percentage chan	ge)		
15.5	28.5	24.3	7.5	23.4	11.2	2.8
16.3	14.3	14.9	13.4	11.2	12.8	4.7
16.3	3.4	7.4	-0.5	5.9	1.1	4.5
13.2	3.5	6.7	9.2	11.2	9.7	4.6
1.3	8.7	6.1	6.7	3.6	5.9	3.0
0.3	5.9	4.1	4.8	5.2	4.9	2.8
6.5	12.6	10.7	1.3	6.4	2.6	1.3
0.1	9.1	6.3	-2.6	4.0	-0.8	1.4
-5.3	1.9	-0.2	-2.5	4.6	-0.5	1.1
2.5	1.6	1.8	1.8	1.4	1.7	2.3
-1.4	7.9	5.3	-0.5	3.8	0.8	1.7
5.2	1.3	2.3	15.9	7.2	13.2	1.0
17.9	15.1	15.9	7.1	9.4	7.8	-0.4
10.1	0.2	2.9	6.5	-0.1	4.5	1.8
8.6	8.0	8.2	3.2	12.4	5.8	4.0
11.4	8.5	9.4	6.0	7.2	6.4	1.3
8.9	7.2	7.7	9.0	9.9	9.3	1.0
11.0	6.9	8.1	7.2	3.5	6.1	3.3
(a	nnual percentage	cnange in excess of	inflation in the Cana	idian economy)		
12.7	25.7	21.5	4.7	20.6	8.4	
11.5	9.6	10.2	8.6	6.4	8.1	
11.8	-1.1	2.8	-5.0	1.3	-3.4	
8.6	-1.1	2.1	4.7	6.6	5.2	
-1.8	5.7	3.1	3.7	0.6	2.9	
-2.4	3.2	1.3	2.0	2.4	2.1	
5.3	11.4	9.4	0.0	5.1	1.4	
-1.4	7.7	4.9	-4.0	2.6	-2.2	
-6.4	0.8	-1.3	-3.6	3.5	-1.6	
0.1	-0.7	-0.5	-0.6	-0.9	-0.7	
-3.1	6.2	3.6	-2.1	2.1	-0.9	
4.2	0.3	1.3	14.9	6.3	12.2	
18.4	15.6	16.3	7.5	9.8 -1.9	8.2 2.7	
8.2	-1.6	1.1	4.6			
4.6	4.1	4.2	-0.8	8.4	1.8	
10.2	7.2	8.1	4.8	5.9	5.1	
7.9 7.7						
7.9	6.2 3.6	6.7 4.8	8.0 3.9	8.9 0.2	8.3 2.8	

CIHI 2004

Table B.4.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985–2003

					Prescribe	ed Drugs					Prescribed D	
	Provincial	Federal	Public Social Secu	urity Eundo	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over	te (Out-of-Po	ocket) Total
	Provincial	rederai _	W.C.B.	Drug Insurance Funds	Public	insurers."	Pocket	Private	Prescribed Drugs	the Counter Drugs	Health Supplies	Non-Presc. Drugs
Year				Tulius		(\$ million	ıs)			Drugs		
1985	33.9	1.7	0.1		35.7			38.8	74.4			48.4
1986	39.6	1.8	0.2		41.5			45.6	87.1			54.8
1987	46.2	1.9	0.2		48.4			56.1	104.5			63.6
1988	48.5	2.7	0.2		51.4			61.4	112.7			
1989	52.7	3.1	0.3		56.0			67.1	123.1			59.6
1990	58.3	3.7	0.4		62.4			80.3	142.7			0
1991	62.4	4.1	0.4		67.0			88.8	155.8			
1992	60.0	4.2	0.5		64.8			102.2		35.6	32.3	
1993	56.8	5.2	0.6		62.5			111.3		37.0	34.5	
1994	56.0	5.7	0.6		62.3			118.4	180.7	35.9	35.5	71.4
1995	58.3	6.4	0.6		65.4			127.8	193.1	33.1	33.5	66.5
1996	54.8	6.4	0.7		61.9			126.7	188.6	31.6	30.6	
1997	56.1	7.1	0.7		64.0			143.9	207.9	42.2	42.6	
1998	62.1	8.6	0.9		71.6			149.7	221.3	40.6	41.6	
1999	69.0	10.8	1.1		80.8			167.0	247.8	45.5	44.1	89.6
2000	78.4	14.2	1.4		94.0			187.7	281.6	45.7	43.1	
2001	90.1	17.2	1.7		109.0			218.9	327.9	44.7	40.4	85.0
2002 f	102.7	20.7	2.1		125.5			231.8	357.3	48.1	43.0	
2003 f	115.2	24.5	2.4		142.1			274.9	417.0	46.7	44.3	91.0
					(8	nnual percentaç	ge change)					
1985												
1986	16.9	7.6	14.5		16.4			17.6	17.1			
1987	16.8	9.3	15.9		16.4			23.0	19.9			
1988	5.0	36.1	18.5		6.3			9.3	7.9			
1989	8.6	17.3	15.6		9.1			9.3	9.2			-3.1
1990	10.7	18.6	56.5		11.4			19.7	15.9			2.2
1991	7.0	12.5	11.2		7.4			10.6	9.2			8.3
1992	-3.9	2.0	24.7		-3.4			15.1	7.1			2.8
1993	-5.4	22.5	3.7		-3.5			8.9	4.1	3.9	6.8	
1994	-1.4	10.6	5.4		-0.4			6.4	4.0	-2.8	2.9	-0.1
1995	4.2	11.6	8.4		4.9			7.9	6.9	-8.0	-5.7	-6.9
1996	-6.0	0.1	13.1		-5.2			-0.8	-2.3	-4.4	-8.5	-6.4
1997	2.5	11.0	0.1		3.3			13.6	10.2	33.5	38.9	
1998	10.7	21.1	19.3		12.0			4.0	6.4	-3.8	-2.1	
1999	11.0	25.2	23.4		12.9			11.6	12.0	12.0	6.0	8.9
2000	13.6	31.9	28.3		16.2			12.4	13.6	0.6	-2.3	-0.8
2001	14.9	20.8	25.8		16.0			16.6	16.4	-2.3	-6.4	-4.3
2002 f	14.1	20.7	19.0		15.2			5.9	9.0	7.6	6.4	7.1
2003 f	12.2	18.0	16.8		13.2			18.6	16.7	-2.8	3.1	0.0
					(percentag	ge share of total	drug expend	liture)				
1985	27.6	1.3	0.1		29.0			31.6	60.6			
1986	27.9	1.3	0.1		29.2			32.1	61.4			00.0
1987	27.5	1.2	0.1		28.8			33.4				
1988 1989	27.8 28.8	1.5	0.1		29.5 30.7			35.2 36.7	64.7 67.4			
1969	20.0	1.7	0.1		30.7			30.7	67.4			32.0
1990	28.6	1.8	0.2		30.6			39.4				
1991	28.1	1.9	0.2		30.2			40.0				
1992	25.5	1.8	0.2		27.6			43.5		15.2	13.8	
1993	23.1	2.1	0.2		25.5			45.4	70.9	15.1	14.1	
1994	22.2	2.3	0.2		24.7			47.0	71.7	14.2	14.1	28.3
1995	22.5	2.5	0.2		25.2			49.2		12.7	12.9	
1996	21.8	2.6	0.3		24.7			50.5		12.6	12.2	
1997	19.2	2.4	0.2		21.9			49.2		14.4	14.5	
1998	20.5	2.8	0.3		23.6			49.3		13.4	13.7	
1999	20.4	3.2	0.3		24.0			49.5	73.5	13.5	13.1	26.5
2000	21.2	3.8	0.4		25.4			50.7	76.0	12.3	11.6	
2001	21.8	4.2	0.4		26.4			53.0		10.8	9.8	
2002 f	22.9	4.6	0.5		28.0			51.7	79.7	10.7	9.6	
2003 f	22.7	4.8	0.5		28.0			54.1	82.1	9.2	8.7	17.9
f - Forecast	et - l'e		to a to 1 to 1 to 1 to 1									0
* Note: Confid	entiality precludes	reporting provi	ıncıal level insu	ırance data.								CIHI 2004

Table B.4.1—Part 2 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985-2003 (continued) Share of Drugs in Public, Private and All Drugs Health Expenditure **Total Health Expenditures** Public Total Public Total Public (\$ millions) (percentage share) 1985 35.7 87.2 122.9 752.2 274.1 1,026.2 4.7 31.8 12.0 1986 41.5 100.4 142.0 805.3 285.9 1,091.1 5.2 35.1 13.0 1987 48.4 119.7 168.1 888.9 305.1 1,194.0 5.4 39.2 14.1 122.9 174.3 961.0 1,291.5 37.2 13.5 1988 51.4 330.4 5.3 1989 126.7 182.8 1,047.7 352.4 1,400.1 56.0 5.3 36.0 13.1 1990 62.4 203.7 1,136.1 397.4 1,533.5 35.5 141.2 5.5 13.3 1991 67.0 154.9 221.9 1,186.9 442.4 1,629.3 5.6 35.0 13.6 1992 170.1 234.9 1,233.1 1,699.8 36.4 64.8 466.7 13.8 5.3 182.8 245.3 1.236.1 503.0 1993 62.5 1.739.1 36.3 5.1 14.1 1994 62.3 189.8 252.1 1,272.2 519.4 1,791.6 4.9 36.5 14.1 1995 65.4 194.3 259.6 1,323.0 495.0 1,818.0 4.9 39.2 14.3 250.9 1996 189.0 1,325.3 487.1 1,812.4 4.7 38.8 13.8 61.9 1997 64.0 228.7 292.7 1.305.6 549.1 1.854.7 4.9 41.6 15.8 1998 71.6 231.9 303.5 1,370.2 547.4 1,917.6 5.2 42.4 15.8 1999 80.8 256.6 337.4 1,473.6 598.8 2.072.4 5.5 42.9 16.3 276.5 370.5 1,580.5 638.4 2.218.9 43.3 2000 94.0 5.9 16.7 2001 109.0 304.0 412.9 1,741.3 708.6 2,449.9 6.3 42.9 16.9 2002 f 125.5 322.8 448.3 1,861.9 756.8 2,618.6 6.7 42.7 17.1 365.9 1,961.5 2,788.6 2003 f 142.1 508.0 827.0 18.2 (annual percentage change) 1985 1986 16.4 15.2 15.6 7 1 4.3 6.3 1987 16.4 19.2 18.4 10.4 6.7 9.4 1988 6.3 2.7 3.7 8.1 8.3 8.2 1989 9.1 3.1 4.8 9.0 6.6 8.4 1990 11.4 11.5 11.4 8.4 12.8 9.5 1991 7.4 9.6 9.0 4.5 11.3 6.2 1992 -3.4 9.8 5.8 3.9 4.3 5.5 1993 -3.5 7.4 4.4 0.2 7.8 2.3 1994 -0.4 3.9 2.8 2.9 3.3 3.0 1995 4.9 2.4 3.0 4.0 -4.7 1.5 1996 -5.2 -2.7 -3.4 0.2 -1.6 -0.3 21.0 16.6 12.7 2.3 1997 3.3 -1.5 1998 12.0 1.4 3.7 4.9 -0.3 3.4 11.2 7.5 1999 12.9 10.6 9.4 8.1 2000 16.2 7.8 9.8 7.3 6.6 7.1 2001 10 2 11.0 16.0 99 115 10 4 2002 f 15.2 6.2 8.6 6.9 6.8 6.9 2003 f 13.2 13.4 13.3 5.4 9.3 6.5 (percentage share of total drug expenditure) 1985 29.0 100.0 71.0 1986 29.2 70.8 100.0 1987 28.8 71.2 100.0 100.0 1988 29.5 70.5 1989 30.7 69.3 100.0 30.6 69.4 100.0 1990 69.8 100.0 1991 30.2 1992 27.6 72.4 100.0 1993 25.5 74.5 100.0 1994 24.7 75.3 100.0 100.0 1995 25.2 74.8 1996 24.7 75.3 100.0 1997 21.9 78.1 100.0 1998 23.6 76.4 100.0 1999 24.0 76.0 100.0 2000 25.4 74.6 100.0 2001 26.4 73.6 100.0 2002 f 28.0 72.0 100.0 72.0 100.0 2003 f 28.0

CIHI 2004

Table B.4.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, New Brunswick, 1985–2003

			D. I I		Prescribe	d Drugs				Prescribed D		
	Provincial	Federal	Public Social Secu	rity Eunda	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over Privat	te (Out-of-Po	
	Provincial	Federal _	Social Secu W.C.B.	Drug Insurance	Public	insurers*	Pocket	Private	Total Prescribed Drugs	the Counter	Health Supplies	Total Non-Presc. Drugs
Year				Funds		(\$ per cap	ita)			Drugs		
1985	46.80	2.29	0.19		49.28			53.60	102.88			66.89
1986	54.59	2.29	0.19		57.26							
1987	63.50	2.68	0.25		66.43			77.12				87.33
1988	66.43	3.63	0.30		70.36			84.01	154.37			84.30
1989	71.66	4.23	0.34		76.23			91.22				
1990	78.82	4.99	0.53		84.34			108.44	192.78			82.40
1991	83.75	5.57	0.59		89.90			119.11	209.01			88.62
1992	80.19	5.66	0.73		86.57			136.60	223.17	47.57	43.20	90.77
1993	75.83	6.92	0.75		83.50			148.60		49.37	46.09	
1994	74.59	7.64	0.79		83.03			157.80	240.84	47.88	47.33	95.21
1995	77.65	8.52	0.86		87.02			170.11	257.14	44.02	44.57	88.59
1996	72.83	8.51	0.97		82.31				250.76	42.03	40.72	
1997	74.59	9.45	0.97		85.01			191.27	276.28	56.07	56.54	
1998	82.80	11.47	1.16		95.43					54.09	55.47	
1999	91.89	14.36	1.43		107.68			222.50	330.18	60.57	58.77	119.34
2000	104.41	18.94	1.84		125.19			250.06		60.93	57.44	
2001	120.09	22.90	2.31		145.31			291.92		59.57	53.83	
2002 f	136.92	27.64	2.75		167.31					64.10	57.26	
2003 f	153.50	32.59	3.21		189.31	 nnual percentag	 (e.change	366.26	555.57	62.28	58.98	121.26
1985												
1986	16.6	7.4	14.3		16.2			17.4				13.0
1987	16.3	8.9	15.5		16.0			22.6				15.5
1988	4.6	35.6	18.1		5.9			8.9				-3.5
1989	7.9	16.6	14.8		8.3			8.6				-3.8
1990	10.0	17.8	55.5		10.6			18.9	15.1			1.6
1991	6.3	11.6	10.4		6.6			9.8	8.4			7.6
1992	-4.3	1.6	24.3		-3.7			14.7	6.8			2.4
1993	-5.4	22.4	3.6		-3.5			8.8		3.8	6.7	
1994	-1.6	10.4	5.2		-0.6			6.2		-3.0	2.7	
1995	4.1	11.5	8.3		4.8			7.8		-8.1	-5.8	
1996 1997	-6.2 2.4	-0.1 11.0	12.9 0.1		-5.4 3.3			-1.0 13.5		-4.5 33.4	-8.6 38.8	
1998	11.0	21.4	19.6		12.3			4.3		-3.5	-1.9	
1999	11.0	25.2	23.4		12.8			11.6		12.0	5.9	
2000	13.6	31.9	28.3		16.3			12.4	13.6	0.6	-2.3	-0.8
2000	15.0	20.9	25.9		16.1			16.7	16.5	-2.2	-6.3	
2002 f	14.0	20.7	18.9		15.1			5.8		7.6	6.4	
2003 f	12.1	17.9	16.7		13.1			18.6	16.7	-2.8	3.0	
				(annual per		e in excess of ir	nflation in th					
1985												
1986	13.8	4.6	11.5		13.4			14.6	14.0			10.2
1987	11.6	4.2	10.7		11.3			17.8	14.7			10.8
1988	0.1	31.1	13.6		1.4			4.4	3.0			-8.0
1989	3.3	12.0	10.3		3.8			4.0	3.9			-8.3
1990	7.0	14.8	52.5		7.6			15.8	12.1			-1.5
1991	3.5	8.9	7.6		3.8				5.7			
1992	-5.5	0.3	23.0		-5.0							
1993	-6.9	21.0	2.2		-5.0			7.3		2.3	5.3	
1994	-2.7	9.3	4.1		-1.7			5.1	2.7	-4.1	1.6	-1.4
1995	1.8	9.1	6.0		2.5			5.5		-10.4	-8.2	
1996	-7.9	-1.8 10.0	11.2		-7.1					-6.2	-10.3	
1997 1998	1.4 11.4	10.0 21.8	-0.9 20.1		2.3 12.7			12.6 4.7		32.4 -3.1	37.9 -1.5	
1998	9.2	21.8	20.1		11.0			9.8		-3.1 10.2	-1.5 4.1	
2000 2001	9.7 13.7	28.0 19.6	24.3 24.7		12.3 14.8			8.4 15.5		-3.4 -3.5	-6.2 -7.5	
2001 2002 f	13.0	19.6	17.9		14.1					6.6	5.4	
2003 f	8.8	14.6	13.4		9.8			15.3		-6.1	-0.3	
f - Forecast												
* Note: Confide	entiality precludes	reporting provi	incial/territorial	level insurance	data.							CIHI 2004

Tabla	$\mathbf{R}$	 Part	2

# Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, New Brunswick, 1985-2003 (continued)

							GDP Implicit	
		All Drugs			th Expenditure		Price Index — Canada	
	Public	Private	Total	Public	Private	Total		
ear			(\$ per ca	pita)			(1997 = 100)	
985	49.28	120.48	169.76	1,039.37	378.68	1,418.05	73.6	
986	57.26	138.51	195.77	1,110.46	394.24	1,504.71	75.6	
987	66.43	164.45	230.88	1,221.26	419.14	1,640.40	79.2	
988	70.36	168.31	238.67	1,315.80	452.44	1,768.25	82.8	
989	76.23	172.34	248.57	1,425.04	479.28	1,904.32	86.6	
990	84.34	190.84	275.18	1,535.00	536.96	2,071.96	89.2	
991	89.90	207.73	297.63	1,592.01	593.38	2,185.39	91.6	
992	86.57	227.37	313.94	1,648.31	623.91	2,272.21	92.8	
993	83.50	244.07	327.57	1,650.79	671.67	2,322.46	94.1	
994	83.03	253.01	336.05	1,695.79	692.35	2,388.13	95.2	
995	87.02	258.70	345.73	1,761.67	659.17	2,420.84	97.4	
996	82.31	251.20	333.51	1,761.66	647.44	2,409.10	99.0	
997	85.01	303.88	388.90	1,734.95	729.66	2,464.61	100.0	
998	95.43	308.99	404.42	1,825.61	729.30	2,554.91	99.6	
999	107.68	341.84	449.52	1,963.23	797.71	2,760.94	101.4	
2000	125.19	368.43	493.62	2,105.89	850.60	2,956.49	105.4	
1001	145.31	405.33	550.64	2,322.08	944.95	3,267.03	106.7	
002 f	167.31	430.29	597.60	2,481.87	1,008.75	3,490.62	107.8	
.003 f	189.31	487.52	676.83	2,613.33	1,101.86	3,715.19	111.4	
			(annu	ual percentage change	1			
985								
986	16.2	15.0	15.3	6.8	4.1	6.1	2.8	
987	16.0	18.7	17.9	10.0	6.3	9.0	4.7	
988	5.9	2.4	3.4	7.7	7.9	7.8	4.5	
989	8.3	2.4	4.1	8.3	5.9	7.7	4.6	
990	10.6	10.7	10.7	7.7	12.0	8.8	3.0	
991	6.6	8.9	8.2	3.7	10.5	5.5	2.8	
992	-3.7	9.5	5.5	3.5	5.1	4.0	1.3	
993	-3.5	7.3	4.3	0.2	7.7	2.2	1.4	
994	-0.6	3.7	2.6	2.7	3.1	2.8	1.1	
005							0.0	
995	4.8	2.2	2.9	3.9	-4.8	1.4	2.3	
996	-5.4	-2.9	-3.5	0.0	-1.8	-0.5	1.7	
997 998	3.3 12.3	21.0 1.7	16.6 4.0	-1.5 5.2	12.7 0.0	2.3 3.7	1.0 -0.4	
999	12.8	10.6	11.2	7.5	9.4	8.1	1.8	
333	12.0	10.0	11.2	7.5	5.4	0.1	1.0	
2000	16.3	7.8	9.8	7.3	6.6	7.1	4.0	
001	16.1	10.0	11.6	10.3	11.1	10.5	1.3	
2002 f	15.1	6.2	8.5	6.9	6.8	6.8	1.0	
.003 f	13.1	13.3	13.3	5.3	9.2	6.4	3.3	
	(a	nnual percentage o	change in excess of	inflation in the Canad	ian economy)			
985								
986	13.4	12.2	12.5	4.0	1.3	3.3		
987	11.3	14.0	13.2	5.2	1.6	3.3 4.3		
988	1.4	-2.2	-1.1	3.2	3.4	3.3		
989	3.8	-2.2	-0.4	3.7	1.4	3.1		
990	7.6	7.7	7.7	4.7	9.0	5.8		
991	3.8	6.1	5.4	1.0	7.7	2.7		
992	-5.0	8.2	4.2	2.3	3.9	2.7		
993	-5.0 1.7	5.9	2.9	-1.3	6.2	0.8		
994	-1.7	2.6	1.5	1.6	2.0	1.7		
995	2.5	-0.1	0.5	1.5	-7.1	-1.0		
996	-7.1	-4.6	-5.2	-1.7	-3.5	-2.2		
997	2.3	20.0	15.6	-2.5	11.7	1.3		
998	12.7	2.1	4.4	5.7	0.4	4.1		
999	11.0	8.8	9.3	5.7	7.6	6.3		
2000	12.3	3.8	5.8	3.3	2.7	3.1		
2000	12.3	3.8 8.7	10.3	9.0	9.8	9.2		
2001 2002 f	14.8	8.7 5.1	7.5	5.9	9.8 5.7	9.2 5.8		
2002 f	9.8	10.0	10.0	2.0	5.9	3.1		
				-		-		

Table B.5.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985–2003

			Public		Prescribe	d Drugs	Private				Prescribed Dite (Out-of-Por	
	Provincial	Federal _	Social Secu W.C.B.	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over the	Personal Health	Total Non-Presc. Drugs
				Funds					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ millio	ns)					
1985	250.4	7.4	2.1		260.0			342.6	602.6			230.5
1986	291.2	8.1	2.7		301.9			463.0	764.9			261.0
1987 1988	333.8 384.1	8.8 10.7	3.2 3.2		345.8 398.0			466.6 523.3	812.4 921.4			302.7 366.9
1989	437.1	12.8	3.5		453.4			582.4	1,035.8			444.8
1990	502.9	15.3	4.2		522.4			638.9	1,161.2			468.3
1991	604.0	16.7	4.9		625.6			709.4	1,335.0			534.5
1992	650.5	18.1	5.1		673.7			770.9	1,444.6	306.5	264.2	570.7
1993	686.1	21.1	5.0		712.3			882.3	1,594.6	312.4	280.8	593.1
1994	742.1	23.0	5.6		770.7			898.5	1,669.2	310.5	306.6	617.1
1995	807.0	24.1	6.3		837.4			1,005.9	1,843.3	318.6	314.5	633.2
1996	734.5	24.0	6.9		765.4			1,079.9	1,845.2	306.0	314.6	620.7
1997	697.7	26.0	7.4	172.0	903.1			1,227.2	2,130.2	278.2	294.6	572.8
1998	775.0	29.4	8.1	218.2	1,030.7			1,228.7	2,259.5	296.1	316.7	612.7
1999	917.0	34.3	9.3	264.0	1,224.7			1,434.0	2,658.7	318.0	332.4	650.5
2000	1,113.9	35.0	11.1	332.3	1,492.4			1,612.9	3,105.2	306.8	324.3	631.0
2001	1,296.9	38.4	13.5	379.9	1,728.6			1,753.2	3,481.8	312.8	322.3	635.1
2002 f	1,422.3	41.8	15.4	450.4	1,930.0			1,905.3	3,835.3	322.9	328.8	651.8
2003 f	1,595.2	45.5	17.5	538.1	2,196.4	 annual percenta	 ge change)	2,019.8	4,216.1	315.1	324.6	639.7
1005	·					•	<u> </u>					
1985	16.2	8.4	27.2		16.1			 0E 1	26.0			12.2
1986 1987	16.3	9.1	27.3 19.2		16.1 14.5			35.1 0.8	26.9 6.2			13.2 16.0
1988	14.6 15.1	21.6	1.0		15.1			12.2	13.4			21.2
1989	13.8	20.0	7.2		13.9			11.3	12.4			21.2
1990	15.0	19.2	20.8		15.2			9.7	12.1			5.3
1991	20.1	9.4	16.6		19.8			11.0	15.0			14.1
1992	7.7	8.2	3.3		7.7			8.7	8.2			6.8
1993	5.5	16.7	-0.1		5.7			14.4	10.4	1.9	6.3	3.9
1994	8.2	8.7	11.7		8.2			1.8	4.7	-0.6	9.2	4.0
1995	8.7	5.0	12.1		8.7			11.9	10.4	2.6	2.6	2.6
1996	-9.0	-0.7	9.7		-8.6			7.4	0.1	-4.0	0.0	-2.0
1997	-5.0	8.5	6.2		18.0			13.6	15.4	-9.1	-6.4	-7.7
1998	11.1	13.3	10.0	26.8	14.1			0.1	6.1	6.4	7.5	7.0
1999	18.3	16.7	15.1	21.0	18.8			16.7	17.7	7.4	5.0	6.2
2000	21.5	1.9	19.7	25.9	21.9			12.5	16.8	-3.5	-2.5	-3.0
2001	16.4	9.6	20.8	14.3	15.8			8.7	12.1	2.0	-0.6	0.7
2002 f 2003 f	9.7 12.2	9.1 8.6	14.3 14.1	18.6 19.5	11.6 13.8			8.7 6.0	10.2 9.9	3.2 -2.4	2.0 -1.3	2.6 -1.9
2003 1	12.2	0.0	14.1	19.5		ge share of tota			9.9	-2.4	-1.3	-1.9
					-							
1985	30.1	0.9	0.3		31.2			41.1	72.3			27.7
1986 1987	28.4 29.9	0.8	0.3 0.3		29.4 31.0			45.1 41.8	74.6 72.9			25.4 27.1
1988	29.8	0.8 0.8	0.3		30.9			40.6	72.9			28.5
1989	29.5	0.9	0.3		30.6			39.3	70.0			30.0
1990	30.9	0.9	0.3		32.1			39.2	71.3			28.7
1991	32.3	0.9	0.3		33.5				71.4			28.6
1992	32.3	0.9	0.3		33.4			38.3	71.7	15.2	13.1	28.3
1993	31.4	1.0	0.2		32.6			40.3	72.9	14.3	12.8	27.1
1994	32.5	1.0	0.2		33.7			39.3	73.0	13.6	13.4	27.0
1995	32.6	1.0	0.3		33.8			40.6	74.4	12.9	12.7	25.6
1996	29.8	1.0	0.3		31.0				74.8	12.4	12.8	25.2
1997	25.8	1.0	0.3	6.4	33.4			45.4	78.8	10.3	10.9	21.2
1998	27.0	1.0	0.3	7.6	35.9			42.8	78.7	10.3	11.0	21.3
1999	27.7	1.0	0.3	8.0	37.0			43.3	80.3	9.6	10.0	19.7
2000	29.8	0.9	0.3	8.9	39.9			43.2	83.1	8.2	8.7	16.9
2001	31.5	0.9	0.3	9.2	42.0			42.6	84.6	7.6	7.8	15.4
2002 f	31.7	0.9	0.3	10.0	43.0			42.5	85.5	7.2	7.3	14.5
2003 f	32.9	0.9	0.4	11.1	45.2			41.6	86.8	6.5	6.7	13.2
f - Forecast												
* Note: Confide	entiality precludes	reporting provi	incial level insu	ırance data.								CIHI 2004

	Expend					nd as a Share ( 5–2003 (conti		Table B.5. ate and	- Fait Z
		All Drugs	rtai i ioaitii L	-	alth Expenditure	2000 (001111	Share of Dru	gs in Public, Priva Health Expenditure	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ n	nillions)			(pe	ercentage share)	
1985	260.0	573.1	833.0	7,927.6	2,104.4	10,031.9	3.3	27.2	8.3
1986	301.9	724.0	1,025.9	8,051.3	2,486.1	10,537.4	3.7	29.1	9.7
1987	345.8	769.3	1,115.1	8,636.4	2,632.2	11,268.6	4.0	29.2	9.9
1988	398.0	890.3	1,288.3	9,428.4	2,850.8	12,279.2	4.2	31.2	10.5
1989	453.4	1,027.2	1,480.7	10,108.6	3,181.7	13,290.3	4.5	32.3	11.1
1990	522.4	1,107.1	1,629.5	10,814.1	3,497.4	14,311.5	4.8	31.7	11.4
1991	625.6	1,243.8	1,869.5	11,815.3	3,819.3	15,634.6	5.3	32.6	12.0
1992 1993	673.7 712.3	1,341.6 1,475.4	2,015.3 2,187.7	12,234.5 12,459.6	4,141.5 4,444.5	16,376.1 16,904.1	5.5 5.7	32.4 33.2	12.3 12.9
1994	770.7	1,515.6	2,286.3	12,459.6	4,636.6	17,310.9	6.1	32.7	13.2
1995 1996	837.4 765.4	1,639.1 1,700.5	2,476.5 2,465.9	12,708.9 12,254.7	4,646.9 4,711.9	17,355.8 16,966.6	6.6 6.2	35.3 36.1	14.3 14.5
1997	903.1	1,800.0	2,703.0	12,804.1	4,960.8	17,764.8	7.1	36.3	15.2
1998	1,030.7	1,841.5	2,872.2	13,923.6	4,983.6	18,907.1	7.4	37.0	15.2
1999	1,224.7	2,084.5	3,309.2	14,354.7	5,533.6	19,888.2	8.5	37.7	16.6
2000	1,492.4	2,243.9	3,736.2	15,350.0	5,881.1	21,231.1	9.7	38.2	17.6
2001	1,728.6	2,388.4	4,117.0	16,509.6	6,506.9	23,016.5	10.5	36.7	17.9
2002 f	1,930.0	2,557.1	4,487.1	17,409.1	6,992.3	24,401.4	11.1	36.6	18.4
2003 f	2,196.4	2,659.5	4,855.8	18,547.9	7,481.7	26,029.6	11.8	35.5	18.7
			(annual perc	entage change)					
1985									
1986	16.1	26.3	23.2	1.6	18.1	5.0			
1987	14.5	6.3	8.7	7.3	5.9	6.9			
1988 1989	15.1 13.9	15.7 15.4	15.5 14.9	9.2 7.2	8.3 11.6	9.0 8.2			
1990	15.2	7.8	10.0	7.0	9.9	7.7			
1991 1992	19.8 7.7	12.3 7.9	14.7 7.8	9.3 3.5	9.2 8.4	9.2 4.7			
1993	5.7	10.0	8.6	1.8	7.3	3.2			
1994	8.2	2.7	4.5	1.7	4.3	2.4			
1995	8.7	8.1	8.3	0.3	0.2	0.3			
1996	-8.6	3.7	-0.4	-3.6	1.4	-2.2			
1997	18.0	5.8	9.6	4.5	5.3	4.7			
1998	14.1	2.3	6.3	8.7	0.5	6.4			
1999	18.8	13.2	15.2	3.1	11.0	5.2			
2000	21.9	7.6	12.9	6.9	6.3	6.8			
2001	15.8	6.4	10.2	7.6	10.6	8.4			
2002 f	11.6	7.1	9.0	5.4	7.5	6.0			
2003 f	13.8	4.0	8.2	6.5	7.0	6.7			
	(percentage sh	nare of total drug	g expenditure)						
1985	31.2	68.8	100.0						
1986	29.4	70.6	100.0						
1987	31.0	69.0	100.0						
1988 1989	30.9 30.6	69.1 69.4	100.0 100.0						
1990	32.1	67.9	100.0						
1991 1992	33.5 33.4	66.5 66.6	100.0 100.0						
1993	32.6	67.4	100.0						
1994	33.7	66.3	100.0						
1995	33.8	66.2	100.0						
1995	33.8	69.0	100.0						
1997	33.4	66.6	100.0						
1998	35.9	64.1	100.0						
1999	37.0	63.0	100.0						
2000	39.9	60.1	100.0						
2001	42.0	58.0	100.0						
2002 f	43.0	57.0	100.0						

f - Forecast

Table B.5.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Quebec, 1985–2003

			Public		Prescribed	d Drugs	Private				Prescribed Di te (Out-of-Po	-
	Provincial	Federal _	Social Secu W.C.B.	Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter Drugs	Personal Health Supplies	Total Non-Presc Drugs
Year						(\$ per ca	pita)					
985	37.57	1.12	0.32		39.00			51.40	90.40			34.5
986	43.40	1.20	0.40		45.00			69.01	114.02			38.9
987	49.21	1.30	0.47		50.98				119.78			44.6
988	56.16	1.56	0.47		58.20			76.52	134.72			53.6
989	63.09	1.85	0.50		65.44			84.06	149.50			64.2
990	71.80	2.18	0.60		74.58			91.21	165.80			66.8
991	85.50	2.37	0.69		88.56			100.41	188.97			75.6
992	91.52	2.55	0.71		94.78			108.46	203.23	43.12	37.17	80.2
993	95.89	2.95	0.71		99.55				222.86	43.65	39.24	82.8
994	103.18	3.20	0.78		107.16			124.94	232.10	43.17	42.63	85.8
1995	111.78	3.34	0.88		116.00			139.34	255.33	44.13	43.57	87.7
1996	101.35	3.31	0.96		105.61				254.62	42.23	43.42	85.6
1997	95.91	3.57	1.01	23.65	124.14			168.69	292.83	38.24	40.50	78.7
1998	106.22	4.03	1.11	29.91	141.27			168.41	309.69	40.58	43.40	83.9
1999	125.22	4.69	1.27	36.05	167.23			195.81	363.04	43.43	45.40	88.8
2000	151 41	4.70	1.51	45 47	202.05			040.00	400.00	44.70	44.07	05.7
2000 2001	151.41 175.33	4.76 5.19	1.51 1.82	45.17 51.36	202.85 233.69			219.23 237.02	422.08 470.71	41.70 42.29	44.07 43.57	85.7° 85.8
2001 2002 f	191.08	5.19	2.07	60.51	259.28				515.25	43.39	44.18	87.5
2002 f	213.06	6.07	2.34	71.88	293.35			269.76	563.12	42.08	43.36	85.4
2003 1	213.00	0.07	2.54	71.00		nnual percenta		203.70	303.12	42.00	+3.30	00.4
					10	illiuai percenta	ge change,					
1985												
1986	15.5	7.7	26.4		15.4				26.1			12.
1987	13.4	7.9	17.9		13.3			-0.3	5.1			14.
1988	14.1	20.6	0.1		14.1				12.5			20.
1989	12.3	18.4	5.8		12.4			9.8	11.0			19.
1990	13.8	17.9	19.5		14.0			8.5	10.9			4.
1991	19.1	8.4	15.6		18.7			10.1	14.0			13.
1992	7.0	7.6	2.6		7.0			8.0	7.5			6.
1993	4.8	15.9	-0.8		5.0			13.7	9.7	1.2	5.6	3.
1994	7.6	8.2	11.2		7.6			1.3	4.1	-1.1	8.6	3.
1995	8.3	4.6	11.7		8.2			11.5	10.0	2.2	2.2	2
1996	-9.3	-1.1	9.2		-9.0			6.9	-0.3	-4.3	-0.3	-2.
1997	-5.4	8.0	5.8		17.5				15.0	-9.4	-6.7	-8.
1998	10.8	12.9	9.7	26.5	13.8			-0.2	5.8	6.1	7.2	6.
1999	17.9	16.3	14.6	20.5	18.4			16.3	17.2	7.0	4.6	5.
	00.0		40.4	25.0	04.0			40.0	400			
2000	20.9	1.5	19.1	25.3	21.3			12.0	16.3	-4.0	-2.9	-3.
2001	15.8	9.0	20.1	13.7	15.2			8.1	11.5	1.4	-1.1	0.
2002 f	9.0	8.4	13.6	17.8	10.9			8.0	9.5	2.6	1.4	2.0
2003 f	11.5	8.0	13.4	18.8	13.1				9.3	-3.0	-1.9	-2.
				(annual perd	centage chang	e in excess of	inflation in 1	the Canadian	economy)			
1985												
1986	12.7	4.9	23.6		12.6			31.5	23.3			9.
1987	8.7	3.2	13.1		8.5			-5.1	0.3			10.
1988	9.6	16.0	-4.4		9.6			6.7	8.0			15.
1989	7.8	13.9	1.2		7.9			5.3	6.4			15.
1990	10.8	14.9	16.4		10.9			5.5	7.9			1.
1991	16.3	5.7	12.9		16.0				11.2			10.
1992	5.8	6.3	1.4		5.8				6.3			4.
1993	3.3	14.5	-2.2		3.6				8.2	-0.2	4.1	1.5
1994	6.5	7.1	10.1		6.5				3.0	-2.2	7.5	2.
1995	6.0	2.2	9.3		5.9				7.7	-0.1	-0.1	-0.
1996	-11.0	-2.7	7.6		-10.6			5.3	-1.9	-6.0	-2.0	-4.
1997 1998	-6.4 11.2	7.0 13.4	4.8	26.0	16.6				14.0	-10.4	-7.7 7.6	-9. 7.
1998 1999	16.1	14.5	10.1	26.9 18.7	14.2 16.6				6.2 15.4	6.5 5.2	7.6	7. 4.
1000	10.1	14.5	12.8	10.7	10.0			14.5	15.4	5.2	2.8	4.
2000	16.9	-2.5	15.1	21.3	17.3			8.0	12.3	-8.0	-6.9	-7
2001	14.5	7.7	18.9	12.4	13.9			6.8	10.3	0.2	-2.4	-1.
2002 f	8.0	7.4	12.5	16.8	9.9				8.5	1.6	0.4	1.0
		4 7	10.1	15.5	9.8			2.1	6.0	-6.3	E 2	-5.
2003 f	8.2	4.7	10.1	10.0	9.0			2.1	0.0	-0.3	-5.2	-5.

							Table B.5.2—I
	Evno	adituua an I	Drugo Bor C	onita by Tyna	by Course o	f Einanaa .	
	Expe		_				and Public, Private and
		10	itai Heaith E	xpenditures, C	Juebec, 198	5-2003 (CO	GDP Implicit
		All Drugs		He	alth Expenditure		Price Index — Canada
	Public	Private	Total	Public	Private	Total	
			(\$ pe	r capita)			(1997 = 100)
	39.00	85.97	124.97	1,189.31	315.70	1,505.01	73.6
	45.00	107.92	152.93	1,200.16	370.59	1,570.76	75.6
	50.98	113.42	164.40	1,273.33	388.08	1,661.41	79.2
	58.20	130.18	188.37	1,378.61	416.85	1,795.46	82.8
	65.44	148.26	213.70	1,458.95	459.21	1,918.16	86.6
	74.58	158.07	232.66	1,544.02	499.35	2,043.36	89.2
	88.56	176.07	264.62	1,672.46	540.63	2,213.09	91.6
	94.78	188.75	283.53	1,721.23	582.66	2,303.89	92.8
	99.55	206.20	305.75	1,741.32	621.14	2,362.46	94.1
	107.16	210.74	317.90	1,762.32	644.69	2,407.01	95.2
	116.00	227.04	343.03	1,760.37	643.67	2,404.04	97.4
	105.61	234.66	340.27	1,691.03	650.19	2,341.22	99.0
	124.14	247.43	371.57	1,760.10	681.93	2,442.03	100.0
	141.27	252.39	393.67	1,908.39	683.06	2,591.45	99.6
	167.23	284.64	451.87	1,960.13	755.61	2,715.74	101.4
	202.85	305.00	507.85	2,086.44	799.39	2,885.82	105.4
	233.69	322.88	556.57	2,231.93	879.67	3,111.60	106.7
	259.28	343.54	602.82	2,338.84	939.38	3,278.22	107.8
	293.35	355.20	648.56	2,477.30	999.27	3,476.57	111.4
				(annual percentage		.,	
	15.4	25.5	22.4	0.9	17.4	4.4	2.8
	13.3	5.1	7.5	6.1	4.7	5.8	4.7
	14.1	14.8	14.6	8.3	7.4	8.1	4.5
	12.4	13.9	13.4	5.8	10.2	6.8	4.6
	14.0	6.6	8.9	5.8	8.7	6.5	3.0
	18.7	11.4	13.7	8.3	8.3	8.3	2.8
	7.0	7.2	7.1	2.9	7.8	4.1	1.3
	5.0	9.2	7.8	1.2	6.6	2.5	1.4
	7.6	2.2	4.0	1.2	3.8	1.9	1.1
	8.2	7.7	7.9	-0.1	-0.2	-0.1	2.3
	-9.0	3.4	-0.8	-3.9	1.0	-2.6	1.7
	17.5	5.4	9.2	4.1	4.9	4.3	1.0
	13.8	2.0	5.9	8.4	0.2	6.1	-0.4
	18.4	12.8	14.8	2.7	10.6	4.8	1.8
	21.3	7.2	12.4	6.4	5.8	6.3	4.0
	15.2	5.9	9.6	7.0	10.0	7.8	1.3
	10.9	6.4	8.3	4.8	6.8	5.4	1.0
	13.1	3.4	7.6	5.9	6.4	6.1	3.3
				s of inflation in the C			
•							
	12.6	22.7	19.6	-1.9	14.6	1.6	
	8.5	0.4	2.8	1.4	0.0	1.0	
	9.6	10.3	10.1	3.7	2.9	3.5	
	7.9	9.3	8.9	1.3	5.6	2.3	
	10.9	3.6	5.8	2.8	5.7	3.5	
	16.0	8.6	11.0	5.6	5.5	5.5	
	5.8	5.9	5.9	1.7	6.5	2.8	
	3.6	7.8	6.4	-0.3	5.2	1.1	
	6.5	1.1	2.9	0.1	2.7	0.8	
	5.9	5.4	5.6	-2.4	-2.5	-2.5	
	-10.6	1.7	-2.5	-5.6	-0.7	-4.3	
	16.6	4.5	8.2	3.1	3.9	3.3	
	14.2	2.4	6.4	8.9	0.6	6.6	
	16.6	11.0	13.0	0.9	8.8	3.0	
	17.3	3.2	8.4	2.5	1.8	2.3	
		0.2	0.4	2.0	1.0	2.0	
		4.6	8.3	5.7	8.8	6.6	
	13.9 9.9	4.6 5.4	8.3 7.3	5.7 3.8	8.8 5.8	6.6 4.3	

Table B.6.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985–2003

			Public		Prescribe	d Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Secur W.C.B.	Drug	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over the	Personal Health	Total Non-Presc.
				Insurance Funds					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ million	ıs)					
1985	399.4	13.8	7.2		420.5			579.4	999.9			487.9
1986	481.2	14.5	8.8		504.5			706.8	1,211.2			552.4
1987	574.4	15.4	10.1		599.9			748.2	1,348.1			640.6
1988	663.8	24.5	12.0		700.4			845.3	1,545.6			711.0
1989	749.5	30.7	13.5		793.8			951.9	1,745.7			789.2
1990	881.2	36.2	16.2		933.6			1,089.7	2,023.3			816.5
1991	1,012.7	37.9	20.2		1,070.8			1,201.1	2,271.9			883.5
1992	1,183.6	41.0	23.3		1,247.8			1,376.9	2,624.8	521.5	455.3	976.7
1993	1,248.0	46.7	24.2		1,318.9			1,482.1	2,801.0	558.9	478.5	1,037.5
1994	1,235.8	50.7	18.5		1,305.1			1,508.7	2,813.7	577.9	516.1	1,094.0
1995	1,379.6	52.9	19.5		1,452.0			1,660.0	3,112.0	578.4	528.8	1,107.2
1996	1,362.7	53.9	21.6		1,438.2			1,735.3	3,112.0	599.6	540.5	1,140.1
1997	1,417.2	57.6	22.3		1,438.2			2,103.4	3,600.5	662.8	603.4	1,266.2
1998 1999	1,568.2 1,727.0	65.9 73.7	23.9 25.4		1,658.0 1,826.1			2,466.3 2,387.7	4,124.3 4,213.9	700.0 748.6	646.0 679.7	1,346.0 1,428.2
.555	1,727.0	73.7	25.4		1,020.1			2,507.7	7,210.0	740.0	0/3./	1,720.2
2000	1,983.4	72.6	31.1		2,087.0			2,719.9	4,807.0	781.7	699.8	1,481.5
2001	2,264.1	83.0	35.4		2,382.4			3,016.0	5,398.4	815.0	732.3	1,547.3
2002 f	2,520.1	90.7	39.0		2,649.8			3,260.1	5,909.9	865.9	751.2	1,617.1
2003 f	2,847.8	100.9	43.1		2,991.8			3,642.8	6,634.6	857.4	768.7	1,626.1
	-				(aı	nnual percentaç	ge change)					
1985												
1986	20.5	4.8	20.8		20.0			22.0	21.1			13.2
1987	19.4	5.9	15.2		18.9			5.9	11.3			16.0
1988	15.6	59.4	19.2		16.7			13.0	14.6			11.0
1989	12.9	25.3	12.6		13.3			12.6	12.9			11.0
1000	17.0	10.0	10.0		17.0			145	45.0			2.5
1990 1991	17.6	18.0	19.8		17.6			14.5 10.2	15.9			3.5
	14.9	4.8	24.4		14.7				12.3			8.2
1992	16.9	8.0	15.4		16.5			14.6	15.5			10.6
1993 1994	5.4 -1.0	13.9 8.7	3.9 -23.3		5.7			7.6 1.8	6.7 0.5	7.2 3.4	5.1	6.2 5.4
1994	-1.0	0.7	-23.3		-1.0			1.0	0.5	3.4	7.8	5.4
1995	11.6	4.3	5.1		11.3			10.0	10.6	0.1	2.5	1.2
1996	-1.2	1.8	10.9		-1.0			4.5	2.0	3.7	2.2	3.0
1997	4.0	7.0	2.9		4.1			21.2	13.5	10.5	11.6	11.1
1998	10.7	14.3	7.4		10.8			17.3	14.5	5.6	7.1	6.3
1999	10.1	11.9	6.3		10.1			-3.2	2.2	6.9	5.2	6.1
2000	14.8	-1.6	22.3		14.3			13.9	14.1	4.4	3.0	3.7
2000	14.2	14.3	13.8		14.3			10.9	12.3	4.4	4.6	4.4
2001 2002 f	11.3	9.3	10.3		11.2			8.1	9.5	6.2	2.6	4.5
2002 f	13.0	11.2	10.3		12.9			11.7	12.3	-1.0	2.3	0.6
2003 1	13.0	11.2	10.4						12.3	-1.0	2.3	0.0
	-				(percentag	e share of total	arug expen	iditure)				
1985	26.8	0.9	0.5		28.3			38.9	67.2			32.8
1986	27.3	0.8	0.5		28.6			40.1	68.7			31.3
1987	28.9	0.8	0.5		30.2			37.6				32.2
1988	29.4	1.1	0.5		31.0							31.5
1989	29.6	1.2	0.5		31.3			37.6	68.9			31.1
1990	31.0	1.3	0.6		32.9			38.4	71.2			28.8
1991	32.1	1.2	0.6		33.9				72.0			28.0
1992	32.9	1.1	0.6		34.6					14.5	12.6	27.1
1993	32.5	1.2	0.6		34.4			38.6	73.0	14.6	12.5	27.0
1994	31.6	1.3	0.5		33.4			38.6	72.0	14.8	13.2	28.0
1995	32.7	1.3	0.5		34.4			39.3	73.8		12.5	26.2
1995	32.7 31.6	1.3	0.5		34.4					13.7 13.9	12.5	26.2 26.4
1996	29.1	1.2	0.5		33.3 30.8			40.2		13.9	12.5	26.4
1997	29.1	1.2	0.5		30.8			43.2 45.1	74.0 75.4	12.8	11.8	26.0
1998	30.6	1.2	0.4		30.3			45.1	75.4 74.7	13.3	11.8	24.6 25.3
2000	31.5	1.2	0.5		33.2			43.3	76.4	12.4	11.1	23.6
2001	32.6	1.2	0.5		34.3				77.7	11.7	10.5	22.3
2002 f	33.5	1.2	0.5		35.2			43.3	78.5	11.5	10.0	21.5
2003 f	34.5	1.2	0.5		36.2			44.1	80.3	10.4	9.3	19.7
f - Forecast												
* * * * * * * * * * * * * * * * * * * *	antiality produdes	reporting provi	incial level insur	rance data.								CIHI 2004

	Expendit	ure on Drugs	by Type, by	Source of Fir	nance, and a	s a Share of Pub	Table B.6.1—Part 2 Public, Private and ed)					
	•	Total		ditures, Onta	rio, 1985–2	003 (continued)	Share of Drug	gs in Public, Priva				
	Public	All Drugs Private	Total	Public	alth Expenditure Private	Total	Public	lealth Expenditur Private	es Total			
v			/A 111				,					
Year			(\$ millio			<del></del>		rcentage share)				
1985 1986	420.5 504.5	1,067.2 1,259.2	1,487.7 1,763.7	10,443.3 11,730.2	3,999.5 4,367.1	14,442.8 16,097.2	4.0 4.3	26.7 28.8	10.3 11.0			
1987	599.9	1,388.9	1,988.8	13,011.9	4,854.5	17,866.4	4.6	28.6	11.1			
1988	700.4	1,556.3	2,256.7	14,497.9	5,321.9	19,819.7	4.8	29.2	11.4			
1989	793.8	1,741.1	2,534.9	16,093.9	5,876.9	21,970.8	4.9	29.6	11.5			
1990	933.6	1,906.2	2,839.8	17,332.8	6,466.2	23,799.1	5.4	29.5	11.9			
1991	1,070.8	2,084.6	3,155.4	19,156.1	7,038.2	26,194.3	5.6	29.6	12.0			
1992	1,247.8	2,353.7	3,601.5	20,058.0	7,573.7	27,631.7	6.2	31.1	13.0			
1993	1,318.9	2,519.6	3,838.5	19,880.5	8,252.9	28,133.4	6.6	30.5	13.6			
1994	1,305.1	2,602.7	3,907.7	20,071.3	8,700.5	28,771.8	6.5	29.9	13.6			
1995	1,452.0	2,767.2	4,219.2	19,946.2	9,368.9	29,315.0	7.3	29.5	14.4			
1996	1,438.2	2,875.4	4,313.6	20,092.0	9,608.0	29,700.0	7.2	29.9	14.5			
1997	1,497.0	3,369.7	4,866.7	20,499.7	10,262.7	30,762.4	7.3	32.8	15.8			
1998	1,658.0	3,812.3	5,470.4	22,062.6	11,034.9	33,097.5	7.5	34.5	16.5			
1999	1,826.1	3,815.9	5,642.1	23,553.9	11,823.2	35,377.1	7.8	32.3	15.9			
2000	2,087.0	4,201.5	6,288.5	25,899.0	12,883.1	38,782.0	8.1	32.6	16.2			
2001	2,382.4	4,563.4	6,945.8	27,454.6	14,090.2	41,544.8	8.7	32.4	16.7			
2002 f	2,649.8	4,877.2	7,527.0	29,134.4	15,354.3	44,488.7	9.1	31.8	16.9			
2003 f	2,991.8	5,268.9	8,260.7	31,782.6	16,501.4	48,283.9	9.4	31.9	17.1			
			(annual percenta	age change)								
1985												
1986	20.0	18.0	18.6	12.3	9.2	11.5						
1987 1988	18.9	10.3	12.8	10.9	11.2	11.0						
1989	16.7 13.3	12.1 11.9	13.5 12.3	11.4 11.0	9.6 10.4	10.9 10.9						
1990	17.6	9.5	12.0	7.7	10.0	8.3						
1991 1992	14.7 16.5	9.4 12.9	11.1 14.1	10.5 4.7	8.8 7.6	10.1 5.5						
1993	5.7	7.0	6.6	-0.9	9.0	1.8						
1994	-1.0	3.3	1.8	1.0	5.4	2.3						
1005	11.0				7.7							
1995 1996	11.3 -1.0	6.3 3.9	8.0 2.2	-0.6 0.7	7.7 2.6	1.9 1.3						
1997	4.1	17.2	12.8	2.0	6.8	3.6						
1998	10.8	13.1	12.4	7.6	7.5	7.6						
1999	10.1	0.1	3.1	6.8	7.1	6.9						
2000	14.3	10.1	11.5	10.0	9.0	9.6						
2001	14.2	8.6	10.5	6.0	9.4	7.1						
2002 f	11.2	6.9	8.4	6.1	9.0	7.1						
2003 f	12.9	8.0	9.7	9.1	7.5	8.5						
	(percentage	share of total drug	expenditure)	=								
1985	28.3	71.7	100.0									
1986	28.6	71.7	100.0									
1987	30.2	69.8	100.0									
1988	31.0	69.0	100.0									
1989	31.3	68.7	100.0									
1990	32.9	67.1	100.0									
1991	33.9	66.1	100.0									
1992	34.6	65.4	100.0									
1993	34.4	65.6	100.0									
1994	33.4	66.6	100.0									
1995	34.4	65.6	100.0									
1996	33.3	66.7	100.0									
1997	30.8	69.2	100.0									
1998	30.3	69.7	100.0									
1999	32.4	67.6	100.0									
2000	33.2	66.8	100.0									
2001	34.3	65.7	100.0									
2002 f	35.2	64.8	100.0									
2003 f	36.2	63.8	100.0									
									CIHI 2004			

Table B.6.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Ontario, 1985–2003

	Provincial	Federal	Public				Private			Privat	e (Out-of-Po	Non-Prescribed Drugs Private (Out-of-Pocket)			
	Provincial								A 1						
		rederai _	W.C.B.	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter	Personal Health Supplies	Total Non-Presc. Drugs			
Year				Funds		(\$ per cap	ita)			Drugs					
1985	42.96	1.49	0.78		45.23			62.31	107.54			52.47			
1986	50.99	1.54	0.78		53.45				128.33			58.53			
1987	59.56	1.59	1.05		62.20				139.78			66.43			
1988	67.45	2.49	1.22		71.16				157.04			72.24			
1989	74.16	3.04	1.34		78.53				172.71			78.08			
1990	85.57	3.52	1.58		90.66			105.82	196.48			79.29			
1991	97.11	3.64	1.93		102.68			115.18	217.86			84.72			
1992	111.98	3.88	2.20		118.06				248.33	49.33	43.07	92.41			
1993	116.76	4.37	2.26		123.39			138.67	262.06	52.29	44.77	97.06			
1994	114.23	4.69	1.71		120.64			139.46	260.09	53.42	47.71	101.12			
1995	125.99	4.83	1.78		132.60			151.60	284.20	52.82	48.29	101.11			
1996	122.95	4.86	1.95		129.76			156.57	286.34	54.10	48.77	102.87			
1997	126.21	5.13	1.98		133.33			187.33	320.66	59.03	53.74	112.77			
1998	137.96	5.80	2.10		145.86				362.83	61.58	56.83	118.41			
1999	150.09	6.41	2.21		158.71			207.51	366.22	65.06	59.07	124.13			
2000	169.73	6.21	2.66		178.60				411.37	66.90	59.89	126.79			
2001	190.30	6.97	2.97		200.24				453.74	68.50	61.55	130.05			
2002 f	208.33	7.50	3.23		219.05				488.56	71.58	62.10	133.68			
2003 f	232.70	8.24	3.52		244.46	 nnual percentag	 ne change)	297.65	542.12	70.06	62.81	132.87			
1005															
1985 1986	18.7	3.3	19.0		18.2				10.2			11.6			
1986	16.8	3.3	19.0									13.5			
1988	13.2	56.2	16.8		16.4 14.4				12.3			8.8			
1989	9.9	22.0	9.6		10.4				10.0			8.1			
1990	15.4	15.8	17.6		15.4			12.4	13.8			1.5			
1991	13.5	3.5	22.8		13.3				10.9			6.9			
1992	15.3	6.5	13.8		15.0			13.1	14.0			9.1			
1993	4.3	12.6	2.7		4.5				5.5	6.0	3.9	5.0			
1994	-2.2	7.4	-24.2		-2.2			0.6	-0.8	2.2	6.6	4.2			
1995	10.3	3.1	3.9		9.9				9.3	-1.1	1.2	0.0			
1996	-2.4	0.6	9.6		-2.1			3.3	0.8	2.4	1.0	1.7			
1997	2.7	5.6	1.6		2.7				12.0	9.1	10.2	9.6			
1998	9.3	13.0	6.1		9.4				13.2	4.3	5.7	5.0			
1999	8.8	10.6	5.0		8.8			-4.4	0.9	5.6	3.9	4.8			
2000	13.1	-3.1	20.4		12.5			12.2		2.8	1.4	2.1			
2001	12.1	12.3	11.8		12.1				10.3	2.4	2.8	2.6			
2002 f	9.5	7.5	8.5		9.4				7.7	4.5	0.9	2.8			
2003 f	11.7	9.9	9.1	/annual nora	11.6	e in excess of i	 nflation in tl		11.0	-2.1	1.1	-0.6			
				(annual perc											
1985 1986	 15.9	0.5	16.2		15.4			17.4	16.5			8.8			
1986	12.1	-1.1	8.0		11.6				4.2			8.8			
1988	8.7	51.6	12.3		9.9							4.2			
1989	5.4	17.4	5.0		5.8				5.4			3.5			
1990	12.4	12.8	14.6		12.4			9.3	10.7			-1.5			
1991	10.7	0.7	20.0		10.5				8.1			4.1			
1992	14.1	5.3	12.6		13.7				12.7			7.8			
1993	2.8	11.2	1.3		3.1					4.6	2.5	3.6			
1994	-3.3	6.3	-25.3		-3.3				-1.8	1.1	5.5	3.1			
1995	8.0	0.7	1.5		7.6			6.4	6.9	-3.4	-1.1	-2.3			
1996	-4.1	-1.1	7.9		-3.8				-0.9	0.7	-0.7	0.1			
1997	1.7	4.6	0.6		1.8				11.0	8.1	9.2	8.6			
1998	9.7	13.4	6.6		9.8					4.8	6.2	5.4			
1999	7.0	8.8	3.2		7.0			-6.2	-0.9	3.8	2.1	3.0			
2000	9.1	-7.0	16.5		8.6			0.2		-1.1	-2.6	-1.8			
2001	10.8	11.0	10.5		10.8					1.1	1.5	1.3			
2002 f	8.5	6.5	7.5		8.4					3.5	-0.1	1.8			
2003 f	8.4	6.6	5.8		8.3			7.1	7.7	-5.4	-2.2	-3.9			
f - Forecast	ntiality precludes			laval iac	4.4.							CIHI 2004			

		TOtal	i leaitii Expeii	ditures, Onta	110, 1965–20	oos (contint	GDP Implici
	All Dru	gs		He	alth Expenditure		Price Index - Car
Public	Privat	te	Total	Public	Private	Total	
			(\$ per ca	pita)			(1997 = 100)
45.	23 1	14.79	160.01	1,123.23	430.17	1,553.40	73.
53.		33.42	186.87	1,242.85	462.71	1,705.55	75.
62.		44.01	206.21	1,349.18	503.36	1,852.54	79.
71.		58.13	229.28	1,473.03	540.72	2,013.75	82.
78.	55 I	72.26	250.79	1,592.27	581.43	2,173.70	86.
90.		85.11	275.77	1,683.15	627.92	2,311.07	89.
102.		99.90	302.58	1,836.97	674.92	2,511.89	91.
118. 123.		22.68 235.73	340.74 359.12	1,897.67 1,860.01	716.54 772.14	2,614.22 2,632.15	92. 94.
120.		40.58	361.22	1,855.31	804.24	2,659.56	95.
132.	60 2	252.71	385.31	1,821.57	855.61	2,677.18	97.
132.		259.44	389.20	1,812.86	866.91	2,679.77	99.
133.		800.11	433.43	1,825.72	914.00	2,739.72	100.
145.	86 3	35.39	481.25	1,940.93	970.79	2,911.71	99.
158.	71 3	31.64	490.35	2,047.04	1,027.54	3,074.57	101.
178.	60 3	859.55	538.15	2,216.36	1,102.50	3,318.85	105.
200.	24 3	83.55	583.79	2,307.57	1,184.29	3,491.85	106.
219.		03.18	622.24	2,408.48	1,269.30	3,677.78	107.
244.	46 4	30.53	674.99 (ann	2,596.98 ual percentage char	1,348.34 nge)	3,945.31	111.
							-
18	3.2	16.2	16.8	10.6	7.6	9.8	2.
	5.4	7.9	10.4	8.6	8.8	8.6	4.
	1.4 ).4	9.8 8.9	11.2 9.4	9.2 8.1	7.4 7.5	8.7 7.9	4. 4.
	5.4 3.3	7.5 8.0	10.0 9.7	5.7 9.1	8.0 7.5	6.3 8.7	3. 2.
	5.0	11.4	12.6	3.3	6.2	4.1	1.
	1.5	5.9	5.4	-2.0	7.8	0.7	1.
-2	2.2	2.1	0.6	-0.3	4.2	1.0	1.
9	9.9	5.0	6.7	-1.8	6.4	0.7	2.
	2.1	2.7	1.0	-0.5	1.3	0.1	1.
	2.7	15.7	11.4	0.7	5.4	2.2	1.4
	9.4 3.8	11.8	11.0	6.3	6.2 5.8	6.3	-0.
		-1.1	1.9	5.5		5.6	1.3
	2.5	8.4	9.7	8.3	7.3	7.9	4.
	2.1	6.7	8.5	4.1	7.4	5.2	1.
	9.4 ⊥.6	5.1 6.8	6.6 8.5	4.4 7.8	7.2 6.2	5.3 7.3	1. 3.:
				inflation in the Can		7.3	3.
15	5.4	13.4	14.0	7.8	4.8	7.0	
	.6	3.2	5.6	3.8	4.0	3.9	
	0.9	5.3	6.7	4.7	2.9	4.2	
Ę	5.8	4.4	4.8	3.5	3.0	3.4	
	2.4	4.4	6.9	2.7	5.0	3.3	
	).5	5.2	7.0	6.4	4.7	5.9	
	3.7	10.1	11.3	2.0	4.9	2.8	
	3.1 3.3	4.4 1.0	4.0 -0.5	-3.4 -1.4	6.3 3.1	-0.8 -0.1	
	7.6	2.7	4.3	-4.2	4.1	-1.7	
	3.8	1.0	-0.7	-4.2 -2.1	-0.4	-1.7	
	1.8	14.7	10.4	-0.3	4.4	1.2	
	9.8	12.2	11.5	6.7	6.7	6.7	
	7.0	-2.9	0.1	3.7	4.0	3.8	
5	3.6	4.4	5.8	4.3	3.3	4.0	
	).8	5.4	7.2	2.8	6.1	3.9	
	3.4	4.1	5.6	3.4	6.2	4.3	
8	3.3	3.5	5.2	4.5	2.9	4.0	

Table B.7.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985–2003

Year	32.5 34.6 42.3 47.5 45.5 48.5 55.4 68.1 68.1 61.1 79.6 73.8 73.7 85.9 105.6 130.9	6.5 7.2 7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7 36.9	Public Social Secu W.C.B.  0.3 0.4 0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8 0.9 1.0	rity Funds  Drug Insurance Funds	39.2 42.2 50.4 57.3 57.6 62.9 72.4 87.5 90.7 86.5	(\$ millio	   	60.0 68.2 61.9 68.1 74.9	99.2 110.4 112.3 125.4 132.5 149.1	Over the Counter Drugs	e (Out-of-Pc Personal Health Supplies	Total Non-Presc. Drugs 61.0 69. 80.7 75.6
1985 1986 1987 1988 1989 1990 1991 1992 1993 1993 1994 1995 1996 1997 1998	32.5 34.6 42.3 47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	6.5 7.2 7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.3 0.4 0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8	Drug Insurance Funds	39.2 42.2 50.4 57.3 57.6 62.9 72.4 87.5 90.7	(\$ millio	Pocket  ns)	60.0 68.2 61.9 68.1 74.9 86.2	99.2 110.4 112.3 125.4 132.5 149.1	the Counter Drugs	Health Supplies	Non-Presc. Drugs 61.0 69. 80. 75.4 70.9
1985 1986 1987 1988 1989 1990 1991 1992 1993 1993 1994 1995 1996 1997 1998	34.6 42.3 47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	7.2 7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.4 0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8	Funds	42.2 50.4 57.3 57.6 62.9 72.4 87.5 90.7		   	68.2 61.9 68.1 74.9 86.2	99.2 110.4 112.3 125.4 132.5	Drugs		61.0 69.1 80.1 75.4 70.9
1985 1986 1987 1988 1989 1990 1991 1992 1993 1993 1994 1995 1996 1997 1998	34.6 42.3 47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	7.2 7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.4 0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8		42.2 50.4 57.3 57.6 62.9 72.4 87.5 90.7		   	68.2 61.9 68.1 74.9 86.2	110.4 112.3 125.4 132.5	  		69.1 80.1 75.4 70.9
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998	34.6 42.3 47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	7.2 7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.4 0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8		42.2 50.4 57.3 57.6 62.9 72.4 87.5 90.7	   	   	68.2 61.9 68.1 74.9 86.2	110.4 112.3 125.4 132.5	  		70.9
1987 1988 1990 1990 1991 1992 1993 1994 1995 1996 1997 1998	42.3 47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	7.7 9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.4 0.5 0.6 0.7 0.7 0.8 0.7 0.8		50.4 57.3 57.6 62.9 72.4 87.5 90.7			61.9 68.1 74.9 86.2	112.3 125.4 132.5 149.1			80.1 75.4 70.9
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998	47.5 45.5 48.5 55.4 68.1 61.1 79.6 73.8 73.7 85.9 105.6	9.3 11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.5 0.6 0.7 0.7 0.8 0.7 0.8		57.3 57.6 62.9 72.4 87.5 90.7			68.1 74.9 86.2	125.4 132.5 149.1			75.4 70.9
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998	45.5 48.5 55.4 68.1 68.1 61.1 79.6 73.8 73.7 85.9 105.6	11.5 13.8 16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.6 0.7 0.7 0.8 0.7 0.8 0.8		57.6 62.9 72.4 87.5 90.7			74.9 86.2	132.5 149.1			70.9
1991 1992 1993 1994 1995 1996 1997 1998 1999	55.4 68.1 68.1 61.1 79.6 73.8 73.7 85.9 105.6	16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.7 0.8 0.7 0.8 0.8		72.4 87.5 90.7							75.3
1991 1992 1993 1994 1995 1996 1997 1998 1999	55.4 68.1 68.1 61.1 79.6 73.8 73.7 85.9 105.6	16.2 18.6 21.9 24.6 27.8 28.6 31.3 33.7	0.7 0.8 0.7 0.8 0.8		72.4 87.5 90.7							
1993 1994 1995 1996 1997 1998 1999	68.1 61.1 79.6 73.8 73.7 85.9 105.6	21.9 24.6 27.8 28.6 31.3 33.7	0.7 0.8 0.8 0.9		90.7			95.8	168.2			
1994 1995 1996 1997 1998 1999	61.1 79.6 73.8 73.7 85.9 105.6	24.6 27.8 28.6 31.3 33.7	0.8 0.8 0.9					101.6	189.1	51.5	41.6	93.2
1995 1996 1997 1998 1999	79.6 73.8 73.7 85.9 105.6	27.8 28.6 31.3 33.7	0.8 0.9		86.5			118.5	209.2	50.4	41.9	
1996 1997 1998 1999	73.8 73.7 85.9 105.6	28.6 31.3 33.7	0.9					129.1	215.6	49.4	42.5	91.9
1997 1998 1999	73.7 85.9 105.6 130.9	31.3 33.7			108.3			148.0	256.3	48.0	41.7	89.7
1998 1999	85.9 105.6 130.9	33.7	1 ^		103.2			163.4	266.7	51.0	47.3	
1999	105.6 130.9		1.0		106.0			186.7	292.7	45.0	43.7	
	130.9	30.9	1.0		120.5			189.0	309.5	51.8	50.9	
2000			1.1		143.6			180.5	324.2	54.8	50.8	
	160.8	38.4	1.3		170.7			205.3	376.0	57.7	52.6	
2001		44.5	1.6		207.0			212.3	419.3	61.5	53.2	
2002 f	181.8	49.9	1.7		233.5			227.7	461.2	63.0	54.7	
2003 f	218.1	56.4	1.9		276.4			245.4	521.8	62.0	55.6	117.6
1005						nnual percenta						
1985 1986	6.6	11.1	23.4		7.4			13.7	11.3			13.2
1987	22.2	7.4	10.2		19.6			-9.3	1.7			16.0
1988	12.4	19.8	25.2		13.6			10.1	11.7			-5.9
1989	-4.1	24.1	8.5		0.5			10.1	5.7			-5.9
1990	6.5	19.7	16.1		9.3			15.0	12.5			6.2
1991	14.3	17.8	7.1		15.0			11.2	12.8			
1992	22.9	14.4	17.9		20.9			6.1	12.5			
1993	-0.1	17.9	-10.4		3.6			16.6	10.6	-2.3	0.6	-1.0
1994	-10.2	12.1	5.3		-4.7			8.9	3.0	-1.9	1.6	-0.3
1995	30.2	13.3	9.2		25.2			14.6	18.9	-2.9	-1.9	-2.4
1996	-7.3	2.8	4.7		-4.6			10.4	4.1	6.3	13.3	
1997	-0.1	9.6	7.9		2.7			14.2	9.7	-11.8	-7.6	
1998	16.5	7.4	2.5		13.7			1.2	5.7	15.0	16.6	
1999	22.9	9.7	13.8		19.2			-4.5	4.7	5.9	-0.2	2.9
2000	24.0	4.0	20.6		18.8			13.7	16.0	5.2	3.4	
2001	22.8	16.0	18.0		21.3			3.4	11.5	6.6	1.2	
2002 f 2003 f	13.1 19.9	12.1 13.0	7.9 10.3		12.8 18.4			7.3 7.8	10.0 13.1	2.3 -1.5	2.8 1.7	
	13.3	13.0	10.3			ge share of tota			13.1	-1.5	1.7	
1985	20.3	4.1	0.2		24.5			37.4	61.9			38.1
1986	19.3	4.0	0.2		23.5			38.0	61.5			
1987	22.0	4.0	0.2		26.2			32.2	58.4			41.6
1988	23.7	4.6	0.3		28.5			33.9	62.5			37.5
1989	22.4	5.7	0.3		28.3			36.8	65.1			34.9
1990	21.6	6.1	0.3		28.0			38.4	66.4			33.6
1991	22.2	6.5	0.3		29.0			38.4	67.4			
1992	24.1 22.6	6.6	0.3		31.0			36.0	67.0 69.4	18.3	14.7	
1993 1994	19.9	7.3 8.0	0.2 0.3		30.1 28.1			39.3 42.0	70.1	16.7 16.1	13.9 13.8	
1995	23.0	8.0	0.2		31.3			42.8	74.1	13.9	12.1	25.9
1996 1997	20.2 19.3	7.8 8.2	0.2 0.3		28.3 27.8			44.8 48.9	73.1 76.7	14.0 11.8	13.0 11.5	
1998	20.8	8.2	0.3		29.2			45.8	75.1	12.6	12.4	
1999	24.6	8.6	0.3		33.4			42.0	75.4	12.8	11.8	
2000	26.9	7.9	0.3		35.1			42.2	77.3	11.9	10.8	
2001	30.1	8.3	0.3		38.8			39.8	77.5	11.5	10.0	
2002 f	31.4	8.6	0.3		40.3			39.3	79.7	10.9	9.4	
2003 f	34.1	8.8	0.3		43.2			38.4	81.6	9.7	8.7	
f - Forecast												

		Total F	lealth Expend	ditures. Manit	oha 1985-	2003 (continu	ied)			
			•			2000 (00111111	nued) Share of Drugs in Public, Private and Total Health Expenditures			
	Public	All Drugs Private	Total	Public	alth Expenditure Private	Total	Public	Private	os Total	
/ear			(\$ millio	ons)			(ре	rcentage share)		
1985	39.2	121.0	160.2	1,310.9	415.6	1,726.5	3.0	29.1	9.	
1986	42.2	137.3	179.4	1,425.8	463.9	1,889.7	3.0	29.6	9.	
1987	50.4	141.9	192.4	1,530.2	449.9	1,980.2	3.3	31.5	9.	
1988	57.3	143.4	200.7	1,634.3	435.2	2,069.4	3.5	33.0	9.	
1989	57.6	145.8	203.4	1,773.2	484.2	2,257.4	3.2	30.1	9.	
1990	62.9	161.5	224.4	1,951.1	533.2	2,484.3	3.2	30.3	9.	
1991	72.4	177.3	249.6	2,006.0	570.0	2,576.0	3.6	31.1	9.	
1992	87.5	194.8	282.3	2,099.3	602.6	2,701.9	4.2	32.3	10.	
1993	90.7	210.8	301.5	2,088.9	660.2	2,749.1	4.3	31.9	11.	
1994	86.5	221.0	307.5	2,115.7	686.3	2,801.9	4.1	32.2	11.	
1995	108.3	237.7	346.0	2,179.4	733.3	2,912.7	5.0	32.4	11.	
1996	103.2	261.8	365.0	2,185.3	783.7	2,969.0	4.7	33.4	12.	
1997	106.0	275.4	381.4	2,252.3	845.5	3,097.9	4.7	32.6	12.	
1998	120.5	291.7	412.2	2,387.4	900.2	3,287.6	5.0	32.4	12.	
1999	143.6	286.2	429.9	2,742.8	946.3	3,689.0	5.2	30.2	11.	
2000	170.7	315.6	486.3	3,004.5	1,032.7	4,037.2	5.7	30.6	12.	
2001	207.0	327.0	534.0	3,178.8	1,087.8	4,266.6	6.5	30.1	12.	
2002 f	233.5	345.3	578.8	3,403.0	1,174.2	4,577.2	6.9	29.4	12.	
2003 f	276.4	363.0	639.4	3,676.9	1,230.4	4,907.2	7.5	29.5	13.	
			(annual percenta	age change)						
1985										
1986	7.4	13.5	12.0	8.8	11.6	9.5				
1987	19.6	3.4	7.2	7.3	-3.0	4.8				
1988	13.6	1.1	4.4	6.8	-3.3	4.5				
1989	0.5	1.7	1.4	8.5	11.3	9.1				
1990	9.3	10.7	10.3	10.0	10.1	10.1				
1991	15.0	9.8	11.2	2.8	6.9	3.7				
1992	20.9	9.9	13.1	4.7	5.7	4.9				
1993	3.6	8.2	6.8	-0.5	9.6	1.7				
1994	-4.7	4.9	2.0	1.3	3.9	1.9				
1995	25.2	7.6	12.5	3.0	6.9	4.0				
1996	-4.6	10.1	5.5	0.3	6.9	1.9				
1997	2.7	5.2	4.5	3.1	7.9	4.3				
1998	13.7	5.9	8.1	6.0	6.5	6.1				
1999	19.2	-1.9	4.3	14.9	5.1	12.2				
2000	10.0	10.0	10.1	0.5	0.1	0.4				
2000	18.8	10.3	13.1	9.5	9.1	9.4				
2001 2002 f	21.3	3.6 5.6	9.8 8.4	5.8 7.1	5.3	5.7				
2002 f	12.8 18.4	5.1	10.5	8.0	7.9 4.8	7.3 7.2				
2000 1		hare of total drug		0.0	4.0	7.2				
1005										
1985	24.5	75.5	100.0							
1986 1987	23.5 26.2	76.5 73.8	100.0 100.0							
1987	28.5	73.8 71.5	100.0							
1989	28.3	71.7	100.0							
1990	28.0	72.0	100.0							
1991	29.0	71.0	100.0							
1992	31.0	69.0	100.0							
1993 1994	30.1 28.1	69.9 71.9	100.0 100.0							
1995	31.3	68.7	100.0							
1996	28.3	71.7	100.0							
1997	27.8	72.2	100.0							
1998	29.2	70.8	100.0							
1999	33.4	66.6	100.0							
2000	35.1	64.9	100.0							
2000										
		61.2								
2000 2001 2002 f	38.8 40.3	61.2 59.7	100.0 100.0							

f - Forecast

Table B.7.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Manitoba, 1985–2003

•			Public		Prescribed	l Drugs	Private				Prescribed [	
	Provincial	Federal	Social Secu	rity Funde	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	te (Out-of-Po	Total
	rioviilciai	reuefal _	W.C.B.	Drug Insurance	Public	msurers."	Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
Year				Funds		(\$ per cap	oita)			Drugs		
1985	29.98	6.00	0.28		36.26			55.40	91.67			56.35
1986	31.68	6.60	0.34		38.62			62.48	101.10			
1987	38.48	7.05	0.38		45.91			56.33	102.25			
1988	43.10	8.42	0.47		51.99			61.78	113.77			
1989	41.26	10.44	0.51		52.20			67.91	120.11			64.25
1990	43.87	12.47	0.59		56.92			77.93	134.85			68.11
1991	49.95	14.63	0.63		65.21			86.34	151.55			
1992	61.22	16.69	0.74		78.65			91.33	169.98	46.32	37.42	83.73
1993	60.90	19.59	0.66		81.15			106.06	187.21	45.06	37.46	82.52
1994	54.43	21.86	0.69		76.99			114.94	191.92	44.00	37.86	81.86
1995	70.49	24.65	0.75		95.89			131.08	226.97	42.51	36.96	79.48
1996	65.03	25.22	0.78		91.03			144.10	235.13	45.01	41.69	
1997	64.88	27.59	0.84		93.31			164.30	257.61	39.64	38.45	78.09
1998	75.51	29.60	0.86		105.97			166.11	272.09	45.52	44.77	90.29
1999	92.43	32.32	0.98		125.72			158.03	283.75	48.00	44.50	92.50
2000	114.11	33.47	1.17		148.75			178.93	327.68	50.30	45.82	96.12
2001	139.70	38.69	1.38		179.77			184.40	364.17	53.46	46.22	99.67
2002 f	157.37	43.23	1.48		202.08			197.06	399.15	54.49	47.32	101.80
2003 f	187.55	48.53	1.62		237.70			211.04	448.74	53.33	47.81	101.14
					(a	nnual percenta	ge change)					
1985												
1986	5.6	10.1	22.4		6.5			12.8	10.3			
1987	21.5	6.8	9.5		18.9			-9.8	1.1			
1988	12.0	19.4	24.8		13.2			9.7	11.3			
1989	-4.3	23.9	8.3		0.4			9.9	5.6			-6.0
1990	6.3	19.5	15.9		9.0			14.8	12.3			6.0
1991	13.9	17.3	6.8		14.6			10.8	12.4			7.8
1992	22.6	14.1	17.5		20.6			5.8	12.2			14.1
1993	-0.5	17.4	-10.8		3.2			16.1	10.1	-2.7	0.1	
1994	-10.6	11.6	4.8		-5.1			8.4	2.5	-2.4	1.1	-0.8
1995	29.5	12.7	8.7		24.6			14.0	18.3	-3.4	-2.4	-2.9
1996	-7.7	2.3	4.2		-5.1			9.9	3.6	5.9	12.8	9.1
1997	-0.2	9.4	7.8		2.5			14.0	9.6	-11.9	-7.8	
1998	16.4	7.3	2.4		13.6			1.1	5.6	14.8	16.4	
1999	22.4	9.2	13.3		18.6			-4.9	4.3	5.5	-0.6	2.5
2000	23.5	3.5	20.1		18.3			13.2	15.5	4.8	3.0	3.9
2001	22.4	15.6	17.6		20.9			3.1	11.1	6.3	0.9	3.7
2002 f	12.7	11.7	7.5		12.4			6.9	9.6	1.9	2.4	2.1
2003 f	19.2	12.3	9.6		17.6			7.1	12.4	-2.1	1.0	-0.7
•				(annual perc	entage change	e in excess of i	inflation in t	he Canadian	economy)			
1985												
1986	2.8	7.3	19.6		3.7			10.0	7.5			9.5
1987	16.7	2.0	4.8		14.1			-14.6	-3.6			
1988 1989	7.5 -8.8	14.9 19.4	20.2 3.8		8.7 -4.2			5.1 5.3	6.7 1.0			
1990	3.3	16.4	12.9		6.0			11.7	9.3			
1990	3.3 11.1	14.6	4.0		11.8				9.3			
1992	21.3	12.8	16.3		19.4			4.5	10.9			
1993	-2.0	16.0	-12.2		1.7			14.7	8.7	-4.2	-1.3	
1994	-11.7	10.5	3.7		-6.2			7.3	1.4	-3.5	0.0	
1995	27.2	10.4	6.3		22.2			11.7	15.9	-5.7	-4.7	' -5.2
1996	-9.4	0.6	2.6		-6.7			8.3	1.9	4.2	11.1	
1997	-1.2	8.4	6.8		1.5				8.6	-12.9	-8.8	
1998	16.8	7.7	2.8		14.0			1.5	6.1	15.3	16.9	
1999	20.6	7.4	11.5		16.8			-6.7	2.5	3.6	-2.4	
2000	19.5	-0.4	16.1		14.3			9.3	11.5	0.8	-1.0	-0.1
2001	21.2	14.4	16.3		19.6			1.8	9.9	5.0	-0.4	
2001 2002 f	11.6	10.7	6.5		11.4			5.9	8.6	0.9	1.4	
2003 f	15.9	9.0	6.3		14.3			3.8	9.1	-5.4	-2.3	
f - Forecast												
	tiality precludes	reporting provi	ncial/territorial	level insurance	data.							CIHI 20

	Eynendi	ture on Dru	ns Per Canita	hy Type hy	Source of Fi	inance and	Public, Private
	Expendi		-	ditures, Manit			
							GDP Implicit
_	D. I.E.	All Drugs	T-4-I		alth Expenditure	Takal	Price Index - Canad
	Public	Private	Total	Public	Private	Total	
_			(\$ per ca	pita)			(1997 = 100)
	36.26	111.76	148.02	1,211.28	383.98	1,595.25	73.6
	38.62	125.74	164.36	1,306.04	424.97	1,731.01	75.6
	45.91	129.27	175.18	1,393.62	409.78	1,803.40	79.2
	51.99	130.16	182.14	1,482.95	394.89	1,877.84	82.8
	52.20	132.15	184.35	1,606.82	438.77	2,045.59	86.6
	56.92	146.04	202.96	1,764.67	482.25	2,246.92	89.2
	65.21	159.76	224.97	1,807.82	513.71	2,321.53	91.6
	78.65	175.06	253.71	1,886.70	541.56	2,428.27	92.8
	81.15	188.58	269.73	1,869.05	590.74	2,459.79	94.1
	76.99	196.79	273.78	1,883.55	610.98	2,494.54	95.2
	95.89	210.56	306.44	1,930.11	649.42	2,579.53	97.4
	91.03	230.81	321.84	1,926.73	690.96	2,617.69	99.0
	93.31	242.39	335.70	1,982.46	744.21	2,726.67	100.0
	105.97	256.40	362.37	2,098.79	791.40	2,890.19	99.6
	125.72	250.53	376.26	2,400.69	828.24	3,228.93	101.4
	148.75	275.05	423.80	2,618.56	900.05	3,518.61	105.4
	179.77	284.07	463.85	2,761.09	944.82	3,705.90	106.7
	202.08	298.87	500.95	2,945.10	1,016.15	3,961.26	107.8
	237.70	312.17	549.87	3,162.15	1,058.12	4,220.27	111.4
_			(ann	ual percentage char	ige)		
	6.5	12.5	11.0	7.8	10.7	8.5	2.8
	18.9	2.8	6.6	6.7	-3.6	4.2	4.7
	13.2	0.7	4.0	6.4	-3.6	4.1	4.5
	0.4	1.5	1.2	8.4	11.1	8.9	4.6
	9.0	10.5	10.1	9.8	9.9	9.8	3.0
	14.6	9.4	10.8	2.4	6.5	3.3	2.8
	20.6	9.6	12.8	4.4	5.4	4.6	1.3
	3.2	7.7	6.3	-0.9	9.1	1.3	1.4
	-5.1	4.4	1.5	0.8	3.4	1.4	1.1
	24.6	7.0	11.9	2.5	6.3	3.4	2.3
	-5.1	9.6	5.0	-0.2	6.4	1.5	1.7
	2.5	5.0	4.3	2.9	7.7	4.2	1.0
	13.6	5.8	7.9	5.9	6.3	6.0	-0.4
	18.6	-2.3	3.8	14.4	4.7	11.7	1.8
	18.3	9.8	12.6	9.1	8.7	9.0	4.0
	20.9	3.3	9.5	5.4	5.0	5.3	1.3
	12.4	5.2	8.0	6.7	7.6	6.9	1.0
	17.6	4.5	9.8	7.4	4.1	6.5	3.3
				inflation in the Cana			
_							
	3.7	9.7	8.2	5.0	7.9	5.7	
	14.1	-1.9	1.8	2.0	-8.3	-0.6	
	8.7	-3.8	-0.5	1.9	-8.2	-0.4	
	-4.2	-3.0	-3.4	3.8	6.5	4.4	
	6.0	7.5	7.1	6.8	6.9	6.8	
	11.8	6.6	8.1	-0.3	3.8	0.6	
	19.4	8.3	11.5	-0.3 3.1	4.2	3.3	
	1.7	6.3	4.9	-2.4	7.6	-0.1	
	-6.2	3.3	0.4	-0.3	2.3	0.3	
	22.2	4.7	9.6	0.1	4.0	1.1	
	-6.7	7.9	3.4	-1.8	4.7	-0.2	
	1.5	4.0	3.3	1.9	6.7	3.2	
	14.0	6.2	8.4	6.3	6.8	6.4	
	16.8	-4.1	2.0	12.6	2.8	9.9	
	44.0	5.8	8.7	5.1	4.7	5.0	
	14.3						
	14.3 19.6					4 1	
	14.3 19.6 11.4	2.0 4.2	8.2 7.0	4.2 5.7	3.7 6.5	4.1 5.9	

CIHI 2004

Table B.8.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Saskatchewan, 1985–2003

<b>ear</b>	Provincial	Federal _	Public Social Secu W.C.B.		Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over	e (Out-of-Po Personal	Total
985 986 987		_										
985 986 987				Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
986 987				Funds		(\$ million	ıs)			Drugs		
986 987	67.6	6.3	0.1		74.0			26.8	100.8			35.3
	81.1	7.1	0.1		88.3			33.8	122.1			40.0
988	67.8	7.7	0.2		75.7			42.5	118.2			46.4
	63.0	9.7	0.3		73.1			53.5	126.5			58.3
989	74.8	12.2	0.2		87.2			67.3	154.5			73.2
90	88.7	14.5	0.3		103.5			79.5	183.0			74.4
91	93.5	16.8	0.3		110.6			89.2	199.8			73.0
92	85.0	19.0	0.3		104.3			99.5	203.8	40.6	35.6	76.2
93	57.8	22.4	0.4		80.6			126.7	207.3	49.9	44.9	94.8
94	56.2	25.0	0.4		81.6			141.3	222.9	48.8	45.5	94.4
95	63.8	28.0	0.5		92.2			146.8	239.0	47.4	44.7	92.1
96	66.6	28.8	0.8		96.2			148.1	244.3	44.7	44.8	89.5
97	69.3	31.2	0.8		101.3			161.2	262.5	45.8	47.3	93.1
98	78.9	33.7	0.9		113.6			167.4	280.9	44.6	46.7	91.3
99	89.1	38.8	1.1		129.0			174.0	303.0	49.6	48.7	98.2
00	100.2	42.3	1.3		143.8			185.6	329.4	53.1	51.0	104.1
01	116.3	48.1	1.6		165.9			216.1	382.1	54.9	50.1	105.1
02 f	133.7	54.3	1.9		189.9			240.5	430.4	55.8	51.2	107.0
03 f	167.5	61.1	2.2		230.7			259.9	490.6	54.0	51.4	105.4
_					(aı	nnual percentag	je change)					
185												
86	20.0	13.1	2.4		19.3			25.8	21.1			13.2
87	-16.4	8.9	42.4		-14.2			25.8	-3.2			16.0
88	-7.1	26.1	58.9		-3.5			25.8	7.0			25.6
89	18.7	25.3	-28.9		19.4			25.8	22.1			25.6
90	18.7	18.6	9.8		18.6			18.2	18.5			1.6
91	5.4	16.1	5.4		6.9			12.2	9.2			-1.9
92	-9.1	12.9	20.3		-5.7			11.5	2.0			
93	-32.0	18.1	32.9		-22.7			27.3	1.7	22.7	26.3	
94	-2.8	11.7	-2.2		1.3			11.5	7.5	-2.1	1.3	-0.5
95	13.6	11.7	16.1		13.0			3.9	7.2	-2.9	-1.9	-2.5
96	4.4	3.0	63.1		4.3			0.9	2.2	-5.8	0.4	-2.8
97	4.0	8.3	4.3		5.3			8.8	7.4	2.5	5.5	4.0
98	13.9	8.1	9.6		12.1			3.9	7.0	-2.6	-1.2	
9	12.9	15.1	22.0		13.6			3.9	7.8	11.2	4.1	7.6
00	12.4	9.0	16.4		11.4			6.7	8.7	7.0	4.9	6.0
)1	16.1	13.8	18.5		15.4			16.4	16.0	3.5	-1.8	0.9
2 f	15.0	12.8	20.9		14.4			11.3	12.7	1.6	2.1	1.8
3 f	25.2	12.6	13.9		21.5			8.1	14.0	-3.2	0.4	-1.5
-					(percentag	e share of total	drug exper	nditure)				
85	49.6	4.6	0.1		54.4			19.7	74.1			25.9
36	50.0	4.4	0.1		54.5			20.8	75.3			24.7
37	41.2	4.7	0.1		46.0			25.8	71.8			28.2
38 39	34.1 32.8	5.3 5.4	0.2 0.1		39.5 38.3			28.9 29.5	68.5 67.9			31.5 32.1
	0.4.5								74.4			
0	34.5	5.6	0.1		40.2			30.9	71.1			28.9
1	34.3	6.2	0.1 0.1		40.5 37.2			32.7 35.5	73.3 72.8	14.5	12.7	26.7 27.2
92 93	30.3 19.1	6.8 7.4	0.1		37.2 26.7			41.9	72.8 68.6	14.5 16.5	12.7 14.9	
94	17.7	7.9	0.1		25.7			44.5	70.3	15.4	14.4	
95	10.2	0.4	0.2		27.0			44.2	72.2	14.2	12 6	27.0
16	19.3 19.9	8.4 8.6	0.2 0.2		27.9 28.8			44.3 44.4	72.2 73.2	14.3 13.4	13.5 13.4	
7	19.5	8.8	0.2		28.5			45.3	73.2	12.9	13.4	
98	21.2	9.1	0.2		30.5			45.0	75.5 75.5	12.9	12.6	
99	22.2	9.7	0.2		32.2			43.4	75.5	12.4	12.0	24.5
0 1	23.1	9.8	0.3		33.2			42.8	76.0	12.2	11.8	
	23.9	9.9	0.3		34.1			44.4	78.4	11.3	10.3	
2 f	24.9	10.1	0.4		35.3			44.8	80.1	10.4	9.5	
B f	28.1	10.3	0.4		38.7			43.6	82.3	9.1	8.6	17.7
Forecast Note: Confidenti	iolity progleds	roporting asset	noial lavel is	ranca data								CIHI 2004

	Expendit	_					Public, Private	Table B.8.1 and	—Part 2
		Total Hea	alth Expendit		hewan, 198 alth Expenditure	5–2003 (con	Share of Drug	gs in Public, Priva lealth Expenditure	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ons)			(pei	rcentage share)	
1985	74.0	62.1	136.1	1,195.5	333.2	1,528.8	6.2	18.6	8.9
1986	88.3	73.7	162.0	1,325.9	377.7	1,703.6	6.7	19.5	9.5
1987	75.7	88.9	164.6	1,372.2	395.5	1,767.8	5.5	22.5	9.3
1988	73.1	111.7	184.8	1,468.3	369.2	1,837.5	5.0	30.3	10.1
1989	87.2	140.4	227.7	1,629.2	423.7	2,052.9	5.4	33.1	11.1
1990	103.5	153.9	257.4	1,792.1	460.1	2,252.2	5.8	33.4	11.4
1991	110.6	162.2	272.8	1,828.9	490.9	2,319.8	6.0	33.0	11.8
1992	104.3	175.8	280.1	1,819.5	505.8	2,325.4	5.7	34.7	12.0
1993 1994	80.6 81.6	221.5	302.1	1,727.8	574.1	2,301.9	4.7	38.6	13.1
1994	01.0	235.7	317.3	1,778.8	603.5	2,382.3	4.6	39.0	13.3
1995	92.2	238.8	331.1	1,820.8	618.7	2,439.5	5.1	38.6	13.6
1996	96.2	237.6	333.8	1,862.3	625.0	2,487.3	5.2	38.0	13.4
1997 1998	101.3 113.6	254.2 258.7	355.5 372.3	1,979.8 2,105.8	676.6 667.3	2,656.4 2,773.1	5.1 5.4	37.6 38.8	13.4 13.4
1999	129.0	272.2	401.2	2,103.8	699.6	2,971.3	5.7	38.9	13.4
2000 2001	143.8	289.7 321.2	433.5 487.1	2,376.8	756.4 840.9	3,133.2	6.0 6.4	38.3 38.2	13.8 14.2
2001 2002 f	165.9 189.9	347.5	537.4	2,581.1 2,727.2	891.7	3,422.0 3,618.9	7.0	39.0	14.2
2003 f	230.7	365.3	596.0	2,902.4	954.2	3,856.7	7.9	38.3	15.5
			(annual percent						
	-								
1985	10.2	10.7	10.0	10.0	12.4				
1986 1987	19.3 -14.2	18.7 20.5	19.0 1.6	10.9 3.5	13.4 4.7	11.4 3.8			
1988	-3.5	25.7	12.3	7.0	-6.7	3.9			
1989	19.4	25.7	23.2	11.0	14.8	11.7			
1990	18.6	9.6	13.0	10.0	8.6	9.7			
1990	6.9	5.4	6.0	2.1	6.7	3.0			
1992	-5.7	8.4	2.7	-0.5	3.0	0.2			
1993	-22.7	26.0	7.9	-5.0	13.5	-1.0			
1994	1.3	6.4	5.0	3.0	5.1	3.5			
1995	13.0	1.3	4.3	2.4	2.5	2.4			
1996	4.3	-0.5	0.8	2.3	1.0	2.0			
1997	5.3	7.0	6.5	6.3	8.3	6.8			
1998	12.1	1.8	4.7	6.4	-1.4	4.4			
1999	13.6	5.2	7.8	7.9	4.8	7.1			
2000	11.4	6.4	8.0	4.6	8.1	5.4			
2001	15.4	10.9	12.4	8.6	11.2	9.2			
2002 f	14.4	8.2	10.3	5.7	6.0	5.8			
2003 f	21.5	5.1	10.9	6.4	7.0	6.6			
	(percentage s	share of total drug	expenditure)	=					
1985	54.4	45.6	100.0						
1986	54.5	45.5	100.0						
1987	46.0	54.0	100.0						
1988	39.5	60.5	100.0						
1989	38.3	61.7	100.0						
1990	40.2	59.8	100.0						
1991	40.5	59.5	100.0						
1992	37.2	62.8	100.0						
1993 1994	26.7 25.7	73.3 74.3	100.0 100.0						
1995	27.9	72.1	100.0						
1996	28.8	71.2	100.0						
1997 1998	28.5	71.5 69.5	100.0						
1998	30.5 32.2	67.8	100.0 100.0						
2000	33.2	66.8	100.0						
2001 2002 f	34.1	65.9	100.0						
2002 f 2003 f	35.3 38.7	64.7 61.3	100.0 100.0						
1	33.7	00							
									CILI 2004

Table B.8.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Saskatchewan, 1985–2003

			Public		Prescribed	rugsטרע	Private				Prescribed D te (Out-of-Po	_
	Provincial	Federal	Social Secu	rity Funds	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
		_	W.C.B.	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc Drugs
				Funds					Diago	Drugs	Сиррисо	Diago
						(\$ per cap	ita)					
5	65.90	6.11	0.14		72.15				98.31			
3	78.76	6.89	0.14		85.79				118.59			
7	65.64	7.48	0.20		73.32			41.13	114.45			
3 9	61.28 73.37	9.47 11.97	0.32 0.23		71.08 85.58			52.00 66.00	123.08 151.57			56.6 71.8
) I	88.11 93.26	14.37 16.75	0.26 0.27		102.73 110.29				181.70 199.30			73.8 72.7
2		18.90							203.03			
	84.66		0.33		103.88					40.47	35.45	
3 1	57.37 55.63	22.26 24.80	0.44 0.43		80.07 80.85			125.84 139.94	205.90 220.79	49.53 48.37	44.64 45.12	
5	62.89	27.57	0.49		90.94			144.72	235.66	46.73	44.05	90.7
3	65.33	28.25	0.80		94.39				239.76	43.82	44.00	
7	68.04	30.62	0.83		99.49			158.31	257.80	44.96	46.46	
3	77.57	33.12	0.91		111.61				276.11	43.82	45.92	
9	87.81	38.23	1.12		127.15			171.45	298.60	48.87	47.95	96.8
)	99.38	41.95	1.31		142.64			184.19	326.83	52.65	50.65	103.3
l	116.26	48.10	1.56		165.92			216.10	382.02	54.91	50.13	105.0
2 f	134.35	54.50	1.90		190.75			241.63	432.38	56.06	51.41	107.4
3 f	168.33	61.41	2.17		231.91			261.27	493.17	54.28	51.64	105.93
					(aı	nnual percentag	je change)					
5												
3	19.5	12.7	2.1		18.9			25.4	20.6			12.
7	-16.7	8.5	41.9		-14.5			25.4	-3.5			15.
3	-6.6	26.6	59.6		-3.1			26.4	7.5			26.
9	19.7	26.4	-28.3		20.4			26.9	23.2			26.
)	20.1	20.0	11.1		20.0			19.7	19.9			2.8
I	5.9	16.6	5.9		7.4			12.7	9.7			-1.
2	-9.2	12.8	20.1		-5.8			11.4	1.9			4.3
3	-32.2	17.8	32.6		-22.9			26.9	1.4	22.4	25.9	24.0
1	-3.0	11.4	-2.4		1.0			11.2	7.2	-2.3	1.1	-0.7
5	13.1	11.1	15.6		12.5			3.4	6.7	-3.4	-2.4	-2.9
3	3.9	2.5	62.3		3.8				1.7	-6.2	-0.1	-3.3
7	4.1	8.4	4.4		5.4			8.9	7.5	2.6	5.6	4.
3	14.0	8.2	9.7		12.2			3.9	7.1	-2.5	-1.2	
9	13.2	15.4	22.3		13.9			4.2	8.1	11.5	4.4	
)	13.2	9.8	17.2		12.2			7.4	9.5	7.7	5.6	6.
ı I	17.0	14.6	19.4		16.3			17.3	16.9	4.3	-1.0	
1 2 f	15.6	13.3	21.5		15.0			11.8	13.2	2.1	2.5	
2 i 3 f	25.3	12.7	13.9		21.6			8.1	14.1	-3.2	0.4	
,	20.0	12.7	10.0			e in excess of in				0.2	0.4	
5												-
3	16.7	9.9	-0.7		16.1			22.6	17.8			10.
7	-21.4	3.7	37.2		-19.3				-8.2			
3	-11.2	22.1	55.1		-7.6				3.0			
9	15.2	21.9	-32.9		15.8				18.6			
)	17.1	17.0	8.1		17.0			16.6	16.8			-0.
l	3.1	17.0	3.1		4.6				6.9			
ı 2	-10.5	11.5	18.9		4.6 -7.1			10.0	0.6			
<u>2</u> 3	-10.5	16.3	31.1		-7.1 -24.4				0.0	20.9	24.5	
1	-33.7 -4.1	10.3	-3.5		-24.4				6.1	-3.4	0.0	
5	10.7	8.8	13.3		10.1				4.4	-5.7	-4.7	
3	2.2	0.8	60.6		2.1				0.1	-7.9	-1.8	
,	3.2	7.4	3.4		4.4				6.5	1.6	4.6	
3	14.4	8.6	10.1		12.6			4.4	7.5	-2.1	-0.7	
9	11.4	13.6	20.5		12.1			2.4	6.3	9.7	2.6	6.
)	9.2	5.8	13.2		8.2			3.5	5.5	3.8	1.6	2.
	15.7	13.4	18.1		15.0			16.1	15.6	3.0	-2.3	0.4
		100	20.5		14.0			10.8	12.2	1.1	1.5	1.3
f	14.5	12.3										
1 2 f 3 f	14.5 22.0	9.4	10.6		18.3				10.8	-6.5	-2.9	

	101411101	iitii Expeliulti	ires, Saskatt	hewan, 198	5-2003 (60	GDP Implic
D. L.E.	All Drugs	T-4-I		ealth Expenditure	Tatal	Price Index - Ca
Public	Private	Total	Public	Private	Total	
		(\$ per ca	pita)			(1997 = 100)
72.15	60.60	132.75	1,165.85	324.93	1,490.78	
72.15 85.79		157.44	1,288.21	366.97	1,655.19	73. 75.
73.32		159.35	1,328.72	383.01	1,711.73	79.2
71.08	108.66	179.74	1,428.29	359.13	1,787.42	82.8
85.58	137.80	223.37	1,598.43	415.71	2,014.15	86.6
102.73	152.81	255.54	1,779.42	456.84	2,236.27	89.2
110.29	161.76	272.06	1,824.01	489.59	2,313.60	91.6
103.88		278.95	1,812.37	503.84	2,316.20	92.8
80.07		300.07	1,716.06	570.19	2,286.25	94.1
80.85	233.43	314.28	1,762.05	597.81	2,359.87	95.2
90.94		326.44	1,795.42	610.08	2,405.50	97.4
94.39		327.58	1,827.39	613.28	2,440.67	99.0
99.49		349.22	1,944.64	664.63	2,609.26	100.0
111.61 127.15	254.25 268.27	365.86 395.42	2,069.57 2,238.79	655.84 689.44	2,725.41 2,928.23	99.6 101.4
142.64		430.13	2,358.50	750.53	3,109.03	105.4
165.92 190.75		487.06 539.85	2,580.72	840.81 895.74	3,421.53	106.7 107.8
231.91	367.19	599.09	2,739.54 2,917.48	959.18	3,635.28 3,876.66	111.4
			ual percentage cha		-,	
18.9	18.2	18.6	10.5	12.9	11.0	2.8
-14.5		1.2	3.1	4.4	3.4	4.7
-3.1	26.3	12.8	7.5	-6.2	4.4	4.5
20.4	26.8	24.3	11.9	15.8	12.7	4.6
20.0		14.4	11.3	9.9	11.0	3.0
7.4		6.5	2.5	7.2	3.5	2.8
-5.8		2.5	-0.6	2.9	0.1	1.3
-22.9 1.0		7.6 4.7	-5.3 2.7	13.2 4.8	-1.3 3.2	1.4 1.1
12.5		3.9	1.9	2.1	1.9	2.3
3.8		0.3	1.8	0.5	1.5	1.7
5.4		6.6	6.4	8.4	6.9	1.0
12.2	1.8	4.8	6.4	-1.3	4.5	-0.4
13.9	5.5	8.1	8.2	5.1	7.4	1.8
12.2	7.2	8.8	5.3	8.9	6.2	4.0
16.3	11.7	13.2	9.4	12.0	10.1	1.3
15.0		10.8	6.2	6.5	6.2	1.0
21.6 (a	5.2 Innual percentage c	11.0 hange in excess of	6.5	7.1 nadian economy)	6.6	3.3
16.1	 15.4	 15.8	 7.7	10.1	8.2	
-19.3		-3.5	-1.6	-0.4	-1.3	
-7.6		8.3	3.0	-10.8	-0.1	
15.8	22.2	19.7	7.3	11.2	8.1	
17.0	7.9	11.4	8.3	6.9	8.0	
4.6		3.7	-0.3	4.4	0.7	
-7.1	7.0	1.3	-1.9	1.6	-1.1	
-24.4		6.1	-6.8	11.7	-2.7	
-0.1	5.0	3.6	1.6	3.7	2.1	
10.1	-1.4	1.5	-0.4	-0.3	-0.4	
2.1	-2.6	-1.3	0.1	-1.1	-0.2	
4.4		5.6	5.4	7.4	5.9	
12.6		5.2	6.9	-0.9	4.9	
12.1	3.7	6.3	6.4	3.3	5.6	
8.2	3.2	4.8	1.4	4.9	2.2	
15.0 14.0		12.0 9.8	8.2 5.1	10.8 5.5	8.8 5.2	

Table B.9.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Alberta, 1985–2003

					Prescribe	d Drugs					Prescribed D	
			Public				Private				te (Out-of-Po	
	Provincial	Federal _	Social Secu W.C.B.	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year				Funds		(\$ millio	ns)			Drugs		
1985	69.5	6.4	0.9		76.7			134.5	211.2			113.1
1986	83.2	7.0	1.2		91.4			147.9	239.3			128.1
1987	95.7	7.4	1.5		104.6			153.1	257.7			148.5
1988	108.0	9.1	1.6		118.7			172.6	291.3			163.3
1989	159.7	11.1	1.8		172.7			194.5	367.2			179.6
1990	179.5	13.2	2.2		194.9			219.0	413.9			184.3
1991	189.2	15.3	2.7		207.1			241.2	448.3			192.8
1992 1993	205.6 205.8	17.1 20.4	3.0 3.7		225.6 229.9			256.8 297.0	482.4 526.9	103.3	91.2	194.4 213.0
1993	208.1	20.4	3.7		234.2			309.4	543.7	114.2 111.6	98.7 106.1	213.0
1995	212.5	26.0	3.1		241.5			323.6	565.1	112.3	108.9	221.2
1996	232.6	26.3	3.5		262.4			360.2	622.6	120.5	112.5	233.0
1997	254.8	29.3	3.5		287.6			403.5	691.1	135.4	125.9	261.3
1998	278.1	32.8	4.2		315.0			430.1	745.1	143.6	135.0	278.6
1999	328.2	41.2	5.2		374.6			494.4	869.1	156.9	136.7	293.6
2000	387.1	45.1	5.7		437.8			556.5	994.3	165.3	150.0	315.3
2001	451.0	51.4	7.7		510.1			617.5	1,127.7	184.1	159.9	344.0
2002 f	539.5	58.2	8.7		606.5			693.2	1,299.7	191.9	169.7	361.6
2003 f	567.4	65.6	10.2		643.2			744.1	1,387.3	197.6	174.8	372.5
					(a	innual percenta	ge change)					
1985												
1986 1987	19.8	9.8	33.7		19.1			10.0	13.3			13.2
1988	15.1 12.7	6.1 22.8	23.4 13.0		14.5 13.5			3.5 12.7	7.7 13.0			16.0 10.0
1989	48.0	22.5	10.2		45.5			12.7	26.1			10.0
1990	12.4	18.0	22.6		12.9			12.6	12.7			2.7
1991	5.4	16.1	19.6		6.3			10.1	8.3			4.6
1992	8.7	11.8	11.9		8.9			6.5	7.6			0.8
1993	0.1	19.6	23.9		1.9			15.7	9.2	10.6	8.3	9.5
1994	1.1	11.9	-11.4		1.9			4.2	3.2	-2.3	7.4	2.2
1995	2.1	13.7	-5.1		3.1			4.6	3.9	0.7	2.6	1.6
1996	9.5	1.3	11.9		8.6			11.3	10.2	7.3	3.3	5.3
1997	9.6	11.5	-0.3		9.6			12.0	11.0	12.3	11.9	12.1
1998 1999	9.1 18.0	11.8 25.8	21.3 22.9		9.5 18.9			6.6 15.0	7.8 16.6	6.0 9.3	7.2 1.3	6.6 5.4
2000	17.9	9.3	9.8		16.9			12.6	14.4	5.3	9.7	7.4
2001	16.5	14.1	36.1		16.5			11.0	13.4	11.4	6.6	9.1
2002 f 2003 f	19.6 5.2	13.2 12.6	13.6 17.1		18.9 6.1			12.3 7.3	15.3 6.7	4.2 3.0	6.1 3.0	5.1 3.0
2003 1	5.2	12.0	17.1			ge share of tota	 al drug expe		0.7	3.0	3.0	3.0
1985	21.4	2.0	0.3		23.7			41.5	65.1			34.9
1986	22.6	1.9	0.3		24.9			40.3	65.1			34.9
1987	23.6	1.8	0.4		25.8			37.7	63.4			36.6
1988	23.7	2.0	0.4		26.1			38.0	64.1			35.9
1989	29.2	2.0	0.3		31.6			35.6	67.2			32.8
1990	30.0	2.2	0.4		32.6			36.6	69.2			30.8
1991	29.5	2.4	0.4		32.3			37.6	69.9			30.1
1992	30.4	2.5	0.4		33.3			37.9	71.3	15.3	13.5	28.7
1993	27.8	2.8	0.5		31.1			40.1	71.2	15.4	13.3	28.8
1994	27.3	3.0	0.4		30.8			40.6	71.4	14.7	13.9	28.6
1995	27.0	3.3	0.4		30.7			41.2	71.9	14.3	13.8	28.1
1996	27.2	3.1	0.4		30.7				72.8	14.1	13.1	27.2
1997 1998	26.8 27.2	3.1 3.2	0.4 0.4		30.2 30.8			42.4 42.0	72.6 72.8	14.2 14.0	13.2 13.2	27.4 27.2
1998	27.2	3.2	0.4		30.8			42.0 42.5	72.8 74.7	13.5	11.8	27.2 25.3
2000	29.6	3.4	0.4		33.4			42.5	75.9	12.6	11.5	24.1
2000	30.6	3.4	0.4		34.7			42.0	76.6	12.5	10.9	23.4
2001 2002 f	32.5	3.5	0.5		36.5			41.7	78.2	11.6	10.9	21.8
2002 f	32.2	3.7	0.6		36.5			42.3	78.8	11.2	9.9	21.2
f - Forecast												
* Note: Coabide	entiality precludes	reporting prov	incial level insi	urance data.								CIHI 2004

Put  Year  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1999 2000 2001 2002 f 2003 f  1985 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f	76.7 91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	Total  All Drugs  Private  247.6 276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6		nditures, Albertella (1988)	831.3 910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,779.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9	4,070.4 4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9 8,673.0	Share of Drug Total He Public	s in Public, Priva ealth Expenditure Private  29.8 30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8.0 8.3 9.0 9.4 10.2 10.6 11.3 12.7
Year  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1999 2000 2001 2002 f 2003 f  (pe	76.7 91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	247.6 276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	(\$ millio 324.3 367.4 406.2 454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	9000 3,239.1 3,537.9 3,514.4 3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	831.3 910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,070.4 4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,312.9 7,067.5 7,592.9	Public  (perd 2.4 2.6 3.0 3.3 4.3 4.5 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	Private  29.8 30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8.8.9.9.10.10.11.12.12.13.
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1999 2000 2001 2002 f 2003 f  (pe	91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	324.3 367.4 406.2 454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	3,239.1 3,537.9 3,514.4 3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	2.4 2.6 3.0 3.3 4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	29.8 30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8. 9. 10. 10. 10. 11. 12.
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f 1985 1986 1987 1998 1999 2000 2001 2002 f 2003 f (pe	91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	324.3 367.4 406.2 454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	3,239.1 3,537.9 3,514.4 3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	2.4 2.6 3.0 3.3 4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	29.8 30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8. 9. 10. 10. 10. 11. 12.
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1999 2000 2001 2002 f 2003 f  (pe	91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	367.4 406.2 454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	3,537.9 3,514.4 3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	2.6 3.0 3.3 4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8.3 9.6 9.4 10.3 10.6 10.6 11.3 12.7 12.8
1987 1988 1989 1990 1991 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1999 2000 2001 2002 f 2003 f  (pe	91.4 104.6 118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	276.0 301.6 335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	367.4 406.2 454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	3,537.9 3,514.4 3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	910.6 985.5 1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,448.5 4,499.9 4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	2.6 3.0 3.3 4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	30.3 30.6 28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	8.6 9.6 9.4 10.2 10.6 10.6 11.3 12.7
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 202 f 203 f  (pe	118.7 172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	335.9 374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	454.6 546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	3,645.6 4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,184.9 1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	4,830.6 5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	3.3 4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	28.3 28.4 28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	10.2 10.4 10.6 10.5 11.3 12.7
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1997 1998 1999 2000 2011 202 f 203 f  (pe	172.7 194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	374.0 403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	546.7 598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,031.0 4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,318.8 1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	5,349.8 5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.3 4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	9.4 10.2 10.4 10.6 11.5 12.1 12.5
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1980 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	194.9 207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	403.4 434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	598.3 641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,326.9 4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,422.5 1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	5,749.4 6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.5 4.5 4.7 4.8 5.2 5.6 5.9 5.8	28.4 28.8 28.5 29.7 29.7 30.2 32.1 31.2	10.4 10.6 10.5 11.3 12.1 12.8
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9	6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.5 4.7 4.8 5.2 5.6 5.9 5.8	28.8 28.5 29.7 29.7 30.2 32.1 31.2	10.6 10.5 11.3 12.1 12.8
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	207.1 225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	434.0 451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	641.1 676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,557.5 4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,505.1 1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9	6,062.5 6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.5 4.7 4.8 5.2 5.6 5.9 5.8	28.8 28.5 29.7 29.7 30.2 32.1 31.2	10.6 10.5 11.3 12.1 12.8
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	225.6 229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	451.2 510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	676.9 739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,846.4 4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,584.2 1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	6,430.7 6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.7 4.8 5.2 5.6 5.9 5.8	28.5 29.7 29.7 30.2 32.1 31.2	10.5 11.3 12.1 12.9
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f   1985 1986 1987 1998 1999 2000 201 2091 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	229.9 234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	510.0 527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	739.8 761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,800.5 4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,719.8 1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	6,520.4 6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	4.8 5.2 5.6 5.9 5.8	29.7 29.7 30.2 32.1 31.2	11.3 12.1 12.9 13.6
1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1999 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989 1990	234.2 241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	527.1 544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	761.4 786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,527.8 4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,777.6 1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	6,305.4 6,084.6 6,312.9 7,067.5 7,592.9	5.2 5.6 5.9 5.8	29.7 30.2 32.1 31.2	12.1 12.9 13.6
1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	241.5 262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	544.8 593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	786.3 855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,283.5 4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,801.1 1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	6,084.6 6,312.9 7,067.5 7,592.9	5.6 5.9 5.8	30.2 32.1 31.2	12.9 13.6
1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1998 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989 1990	262.4 287.6 315.0 374.6 437.8 510.1 606.5 643.2	593.2 664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	855.6 952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,466.5 4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	1,846.4 2,131.0 2,251.7 2,467.9 2,802.4	6,312.9 7,067.5 7,592.9	5.9 5.8	32.1 31.2	13.6
1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1988 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe	287.6 315.0 374.6 437.8 510.1 606.5 643.2	664.8 708.6 788.1 871.8 961.5 1,054.8 1,116.6	952.4 1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	4,936.5 5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	2,131.0 2,251.7 2,467.9 2,802.4	7,067.5 7,592.9	5.8	31.2	
1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1988 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989 1990	315.0 374.6 437.8 510.1 606.5 643.2	708.6 788.1 871.8 961.5 1,054.8 1,116.6	1,023.7 1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	5,341.2 6,205.2 6,780.6 7,696.2 8,459.3	2,251.7 2,467.9 2,802.4	7,592.9			10.5
1999 2000 2001 2002 f 2003 f  1985 1986 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989	374.6 437.8 510.1 606.5 643.2	788.1 871.8 961.5 1,054.8 1,116.6	1,162.7 1,309.6 1,471.7 1,661.3 1,759.8	6,205.2 6,780.6 7,696.2 8,459.3	2,467.9 2,802.4		E 0		13.5
2000 2001 2002 f 2003 f  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989 1990	437.8 510.1 606.5 643.2	871.8 961.5 1,054.8 1,116.6	1,309.6 1,471.7 1,661.3 1,759.8	6,780.6 7,696.2 8,459.3	2,802.4	8,673.0		31.5	13.5
2001 2002 f 2003 f  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe  1985 1986 1987 1988 1989	510.1 606.5 643.2	961.5 1,054.8 1,116.6	1,471.7 1,661.3 1,759.8	7,696.2 8,459.3			6.0	31.9	13.4
2001 2002 f 2003 f  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe  1985 1986 1987 1988 1989	510.1 606.5 643.2	961.5 1,054.8 1,116.6	1,471.7 1,661.3 1,759.8	7,696.2 8,459.3		9,582.9	6.5	31.1	13.7
2002 f 2003 f  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989 1990	606.5 643.2	1,054.8 1,116.6	1,661.3 1,759.8	8,459.3	3,160.3	10,856.5	6.6	30.4	13.6
2003 f  1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe  1985 1986 1987 1988 1989 1990	643.2  19.1	1,116.6	1,759.8		3,329.6	11,788.8	7.2	31.7	14.1
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  [pe	 19.1			9,044.4	3,603.5	12,647.9	7.1	31.0	13.9
1986 1987 1988 1989 1990 1991 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f	19.1		(aiiii)uai percenta		3,003.5	12,047.9	7.1	31.0	13.3
1986 1987 1988 1989 1990 1991 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989	19.1			ige change,					
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f									
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f		11.5	13.3	9.2	9.5	9.3			
1989  1990  1991  1992  1993  1994  1995  1996  1997  1998  1999  2000  2001  2002 f  2003 f  (pe  1985  1986  1987  1988  1989  1990	14.5	9.3	10.6	-0.7	8.2	1.2			
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  (pe 1985 1986 1987 1988 1989	13.5	11.3	11.9	3.7	20.2	7.3			
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f	45.5	11.4	20.3	10.6	11.3	10.7			
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f	12.9	7.8	9.4	7.3	7.9	7.5			
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f (pe 1985 1986 1987 1988 1989	6.3	7.6	7.2	5.3	5.8	5.4			
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f \$\frac{\text{\text{pe}}}{\text{\text{pe}}}\$\$ 1985 1986 1987 1988 1989	8.9	4.0	5.6	6.3	5.3	6.1			
1994  1995  1996  1997  1998  1999  2000  2001  2002 f  2003 f  (pe  1985  1986  1987  1988  1989	1.9	13.0	9.3	-0.9	8.6	1.4			
1995 1996 1997 1998 1999 2000 2001 2002 f 2003 f  1985 1986 1987 1988 1989	1.9	3.4	2.9	-5.7	3.4	-3.3			
1996 1997 1998 1999 2000 2001 2002 f 2003 f \$\frac{\text{(pe}}{\text{1985}}\$\$\$\$1986 1987 1988 1989									
1997 1998 1999 2000 2001 2002 f 2003 f	3.1	3.4	3.3	-5.4	1.3	-3.5			
1998 1999 2000 2001 2002 f 2003 f (pe 1985 1986 1987 1988 1989	8.6	8.9	8.8	4.3	2.5	3.8			
1999 2000 2001 2002 f 2003 f  (pe  1985 1986 1987 1988 1989	9.6	12.1	11.3	10.5	15.4	12.0			
2000 2001 2002 f 2003 f	9.5	6.6	7.5	8.2	5.7	7.4			
2001 2002 f 2003 f 1985 1986 1987 1988 1989	18.9	11.2	13.6	16.2	9.6	14.2			
2001 2002 f 2003 f 1985 1986 1987 1988 1989	16.9	10.6	12.6	9.3	13.6	10.5			
2002 f 2003 f (pe 1985 1986 1987 1988 1989	16.5	10.3	12.4	13.5	12.8	13.3			
2003 f (pe 1985 1986 1987 1988 1989 1990	18.9	9.7	12.9	9.9	5.4	8.6			
1985 1986 1987 1988 1989	6.1	5.9	5.9	6.9	8.2	7.3			
1985 1986 1987 1988 1989		are of total drug							
1986 1987 1988 1989									
1987 1988 1989 1990	23.7	76.3	100.0						
1988 1989 1990	24.9	75.1	100.0						
1989 1990	25.8	74.2	100.0						
1990	26.1	73.9	100.0						
	31.6	68.4	100.0						
	32.6	67.4	100.0						
i ·	32.3	67.7	100.0						
1992	33.3	66.7	100.0						
1993	31.1	68.9	100.0						
1994	30.8	69.2	100.0						
1995		69.3	100.0						
1996	30.7	69.3	100.0						
1997	30.7 30.7	69.8	100.0						
1998	30.7 30.7 30.2	69.2	100.0						
1999	30.7 30.7 30.2 30.8	67.8	100.0						
2000	30.7 30.7 30.2	66.6	100.0						
	30.7 30.7 30.2 30.8 32.2								
2001	30.7 30.7 30.2 30.8 32.2	65.3	100.0						
2002 f	30.7 30.7 30.2 30.8 32.2 33.4 34.7	00 -	100.0						
2003 f	30.7 30.7 30.2 30.8 32.2 33.4 34.7 36.5	63.5	100.0						
f - Forecast	30.7 30.7 30.2 30.8 32.2 33.4 34.7	63.5 63.5							CIHI 2004

Table B.9.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Alberta, 1985–2003

			D. I.P.		Prescribe	Drugs	Dui 1				Prescribed D	-
-			Public				Private				e (Out-of-Po	
	Provincial	Federal	Social Secu		Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
			W.C.B.	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
				Funds					2.ugo	Drugs	Саррисс	2.490
-						(\$ per cap	pita)					
	28.91	2.65	0.37		31.93			55.96	87.89			47.0
	34.23	2.87	0.48		37.59			60.86	98.44			52.69
	39.32	3.04	0.60		42.96			62.87	105.83			60.99
	43.98	3.71	0.67		48.36			70.31	118.67			66.53
	64.01	4.47	0.73		69.20			77.94	147.14			71.96
	70.48	5.16	0.87		76.52			86.00	162.51			72.36
	72.98	5.89	1.02		79.89			93.03	172.92			74.37
	78.09	6.48	1.13		85.70			97.53	183.24	39.22	34.62	73.84
	77.14	7.65	1.38		86.18			111.35	197.53	42.82	37.01	79.83
	77.07	8.46	1.21		86.74			114.58	201.32	41.33	39.28	80.61
	77.70	9.50	1.13		88.33			118.34	206.67	41.08	39.81	80.89
	83.81	9.49	1.25		94.55			129.79	224.34	43.44	40.53	83.97
	90.05	10.37	1.22		101.64			142.56	244.20	47.85	44.49	92.34
	95.90	11.31	1.45		108.65			148.33	256.98	49.52	46.55	96.07
	111.14	13.97	1.74		126.85			167.42	294.27	53.14	46.29	99.43
	128.81	15.00	1.88		145.69			185.19	330.88	55.02	49.90	104.92
	147.55	16.82	2.52		166.89			202.01	368.91	60.24	52.30	112.54
	173.22	18.69	2.81		194.73			222.60	417.32	61.61	54.49	116.10
	179.90	20.79	3.25		203.94			235.96	439.89	62.67	55.43	118.10
-					(a	nnual percenta	ge change)					
	18.4	8.6	32.2		17.7			8.7	12.0			11.9
	14.9	5.9	23.2		14.3			3.3	7.5			15.8
	11.9	21.8	12.1		12.6			11.8	12.1			9.1
	45.5	20.5	8.4		43.1			10.9	24.0			8.2
	10.1	15.6	20.1		10.6			10.3	10.4			0.6
	3.5	14.0	17.5		4.4			8.2	6.4			2.8
	7.0	10.1	10.2		7.3			4.8	6.0			-0.7
	-1.2	18.0	22.3		0.6			14.2	7.8	9.2	6.9	8.1
	-0.1	10.5	-12.5		0.6			2.9	1.9	-3.5	6.1	1.0
	0.8	12.3	-6.3		1.8			3.3	2.7	-0.6	1.4	0.4
	7.9	-0.2	10.3		7.0			9.7	8.6	5.7	1.8	3.8
	7.4	9.3	-2.2		7.5			9.8	8.9	10.2	9.8	10.0
	6.5	9.1	18.4		6.9			4.0	5.2	3.5	4.6	4.0
	15.9	23.5	20.6		16.7			12.9	14.5	7.3	-0.6	3.5
	15.9	7.4	7.9		14.9			10.6	12.4	3.5	7.8	5.5
	14.6	12.2	33.8		14.6			9.1	11.5	9.5	4.8	7.3
	17.4	11.1	11.5		16.7			10.2	13.1	2.3	4.2	3.2
	3.9	11.2	15.7		4.7			6.0	5.4	1.7	1.7	1.7
-				(annual perc	entage chang	e in excess of i	inflation in t	he Canadian	economy)			
	15.6	5.8	29.4		14.9			5.9	9.2			9.1
	10.1	1.1	18.5		9.5			-1.4	2.8			11.0
	7.3 41.0	17.3 15.9	7.6 3.8		8.1 38.5			7.3 6.3	7.6 19.4			4.6 3.6
	7.1	12.6	17.1		7.5			7.3	7.4			-2.5
	0.8	11.3	14.8		1.6			5.4	3.6			0.0
	5.7	8.8	8.9		6.0			3.6	4.7			-2.0
	-2.6 -1.2	16.6 9.4	20.8 -13.6		-0.9 -0.4			12.7 1.8	6.4 0.8	7.7 -4.6	5.5 5.0	6.7 -0.1
	-1.5	10.0	-8.6		-0.5			0.9	0.3	-2.9	-1.0	-2.0
	6.2	-1.9	8.6		5.4			8.0	6.9	4.1	0.1	2.1
	6.5	8.3	-3.2		6.5			8.8	7.9	9.2	8.8	9.0
	6.9	9.5	18.8		7.3			4.5	5.7	3.9	5.1	4.5
	444	21.7	18.8		14.9			11.1	12.7	5.5	-2.4	1.7
	14.1											
	14.1 11.9	3.4	4.0		10.9			6.6	8.5	-0.4	3.8	1.6
	11.9 13.3	3.4 10.9	32.5		13.3			7.8	10.2	8.2	3.5	6.0
	11.9	3.4										

							Table B.9.2-P	art 2
	Expend						Public, Private and	
		Total	Health Exper	nditures, Albe	erta, 1985–2	2003 (conti		
		All Drugs		u	alth Expenditure		GDP Implicit Price Index – Canada	
	Public	Private	Total	Public	Private	Total	File illuex — Callada	
Year			(\$ per ca	pita)			(1997 = 100)	
1985	31.93	103.03	134.95	1,347.98	345.94	1,693.92	73.6	
1986	37.59	113.54	151.13	1,455.36	374.58	1,829.95	75.6	
1987	42.96	123.86	166.81	1,443.08	404.68	1,847.76	79.2	
1988	48.36	136.84	185.20	1,485.33	482.78	1,968.11	82.8	
1989	69.20	149.90	219.10	1,615.48	528.50	2,143.98	86.6	
1990	76.52	158.36	234.87	1,698.71	558.47	2,257.18	89.2	
1991	79.89	167.40	247.29	1,757.86	580.52	2,338.38	91.6	
1992	85.70	171.37	257.08	1,840.71	601.71	2,442.42	92.8	
1993	86.18	191.18	277.36	1,799.67	644.75	2,444.42	94.1	
1994	86.74	195.19	281.92	1,676.53	658.21	2,334.74	95.2	
1995	88.33	199.23	287.56	1,566.45	658.67	2,225.12	97.4	
1996	94.55	213.76	308.31	1,609.44	665.33	2,274.78	99.0	
1997	101.64	234.91	336.55	1,744.31	753.00	2,497.31	100.0	
1998	108.65	244.40	353.05	1,842.14	776.58	2,618.72	99.6	
1999	126.85	266.85	393.70	2,101.13	835.65	2,936.77	101.4	
2000	145.69	290.11	435.80	2,256.47	932.59	3,189.06	105.4	
2001	166.89	314.56	481.45	2,517.79	1,033.87	3,551.66	106.7	
2002 f	194.73	338.70	533.42	2,716.19	1,069.09	3,785.28	107.8	
2003 f	203.94	354.06	558.00	2,867.84	1,142.62	4,010.46	111.4	
			(ann	ual percentage cha	nge)			
1985								
1986	 17.7	10.2	12.0	8.0	8.3	8.0	2.8	
1987	14.3	9.1	10.4	-0.8	8.0	1.0	4.7	
1988	12.6	10.5	11.0	2.9	19.3	6.5	4.5	
1989	43.1	9.5	18.3	8.8	9.5	8.9	4.6	
1000	10.0	F 0	7.0	F 0	F 7	F 0	2.0	
1990	10.6	5.6	7.2	5.2	5.7 3.9	5.3	3.0	
1991 1992	4.4 7.3	5.7 2.4	5.3 4.0	3.5 4.7	3.7	3.6 4.4	2.8 1.3	
1993	0.6	11.6	7.9	-2.2	7.2	0.1	1.4	
1994	0.6	2.1	1.6	-6.8	2.1	-4.5	1.1	
1995	1.8	2.1	2.0	-6.6	0.1	-4.7	2.3	
1996	7.0	7.3	7.2	2.7	1.0	2.2	1.7	
1997	7.5	9.9	9.2	8.4	13.2	9.8	1.0	
1998 1999	6.9 16.7	4.0 9.2	4.9 11.5	5.6 14.1	3.1 7.6	4.9 12.1	-0.4 1.8	
1000	10.7	0.2	11.5	14.1	7.0	12.1	1.0	
2000	14.9	8.7	10.7	7.4	11.6	8.6	4.0	
2001	14.6	8.4	10.5	11.6	10.9	11.4	1.3	
2002 f	16.7	7.7	10.8	7.9	3.4	6.6	1.0	
2003 f	4.7	4.5	4.6	5.6	6.9	5.9	3.3	
	(an	nual percentage cl	nange in excess of	inflation in the Car	adian economy)			
1985								
1986	14.9	7.4	9.2	5.2	5.5	5.2		
1987	9.5	4.3	5.6	-5.6	3.3	-3.8		
1988	8.1	6.0	6.5	-1.6	14.8	2.0		
1989	38.5	5.0	13.7	4.2	4.9	4.4		
1990	7.5	2.6	4.2	2.1	2.6	2.3		
1991	1.6	3.0	2.5	0.7	1.2	0.8		
1992	6.0	1.1	2.7	3.5	2.4	3.2		
1993	-0.9	10.1	6.5	-3.7	5.7	-1.4		
1994	-0.4	1.0	0.5	-7.9	1.0	-5.6		
1995	-0.5	-0.3	-0.3	-8.9	-2.3	-7.0		
1996	-0.5 5.4	-0.3 5.6	-0.3 5.5	-8.9 1.1	-2.3 -0.7	-7.0 0.6		
1997	6.5	8.9	8.2	7.4	12.2	8.8		
1998	7.3	4.5	5.3	6.0	3.6	5.3		
1999	14.9	7.4	9.7	12.3	5.8	10.3		
2000	10.9	4.7	6.7	3.4	7.6	4.6		
2001 2002 f	13.3 15.7	7.2 6.7	9.2 9.8	10.3	9.6	10.1 5.6		
2002 f 2003 f	15.7	1.2	1.3	6.9 2.3	2.4 3.6	2.6		
				2.3	0.0	2.0		
f - Forecast							C	IHI 2004

Table B.10.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985–2003

			Public		Prescribed	d Drugs	Private				Prescribed D	
v	Provincial	Federal _	Social Secu W.C.B.	Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year	-					(\$ millio	ons)					
1985	128.5	7.8	1.4		137.7			121.1	258.8			157.7
1986	151.4	8.6	1.5		161.5			105.6	267.0			178.5
1987	153.5	9.2	1.7		164.4			134.9	299.2			207.0
1988	169.8	14.0	2.0		185.7			159.6	345.3			219.3
1989	196.5	18.0	2.1		216.7			188.9	405.6			232.3
1990	232.6	21.2	2.4		256.3			216.8	473.0			248.6
1991	275.4	24.4	2.7		302.4			241.1	543.5			266.2
1992	311.8	26.5	3.1		341.5			268.1	609.5	149.5	134.7	284.2
1993	346.0	32.1	3.5		381.6			303.1	684.7	164.4	146.0	310.4
1994	339.4	35.8	4.0		379.2			323.2	702.5	169.4	156.9	326.3
1995	349.5	40.5	4.2		394.1			353.5	747.6	172.3	163.8	336.0
1996	379.4	44.2	3.9		427.5			374.9	802.4	178.3	166.3	344.5
1997	418.7	45.3	4.0		468.0			412.2	880.2	182.4	172.7	355.0
1998	457.8	49.4	5.1		512.3			480.0	992.4	193.5	185.0	378.5
1999	515.6	54.2	5.9		575.7			505.7	1,081.4	210.8	196.7	407.6
2000	595.4	58.2	6.8		660.4			570.1	1,230.5	222.9	199.6	422.6
2001	659.1	65.6	7.4		732.1			641.0	1,373.1	229.5	208.1	437.7
2002 f	696.7	73.3	7.2		777.2			691.2	1,468.5	245.9	220.1	466.1
2003 f	638.4	82.0	7.6		728.0			764.4	1,492.4	244.8	223.1	468.0
					(a	nnual percenta	ge change)					
1005												
1985 1986	17.0	0.6	4.7		17.0			12.0				13.2
1987	17.8 1.4	9.6 7.3	4.7 15.5		17.2 1.8			-12.8 27.8	3.2 12.1			16.0
1988	10.6	7.3 51.5	16.5		13.0			18.4	15.4			5.9
1989	15.8	29.1	9.0		16.7			18.4	17.5			5.9
1990 1991	18.3 18.4	17.9 14.6	14.0 10.1		18.2 18.0			14.7 11.3	16.6 14.9			7.1 7.1
1992	13.2	9.0	16.1		12.9			11.3	12.1			6.8
1993	11.0	21.0	11.6		11.7			13.1	12.1	10.0	8.4	9.2
1994	-1.9	11.6	14.1		-0.6			6.6	2.6	3.0	7.4	5.1
1995	3.0	12.9	5.7		3.9			9.4	6.4	1.7	4.4	3.0
1996	8.6	9.1	-6.0		8.5			6.1	7.3	3.5	1.5	2.5
1997 1998	10.3 9.4	2.6 9.2	2.1 25.6		9.5 9.5			10.0 16.4	9.7 12.7	2.3 6.1	3.9 7.1	3.1 6.6
1999	12.6	9.7	17.2		12.4			5.4	9.0	9.0	6.3	7.7
1000	12.0	0.7	17.2		12.4			0.4	0.0		0.0	,.,
2000	15.5	7.3	15.1		14.7			12.7	13.8	5.7	1.5	3.7
2001	10.7	12.7	8.3		10.9			12.4	11.6	3.0	4.3	3.6
2002 f	5.7	11.8	-3.0		6.2			7.8	6.9	7.2	5.8	6.5
2003 f	-8.4	11.8	6.1		-6.3			10.6	1.6	-0.5	1.4	0.4
	-				(percentag	ge share of total	al drug expe	enditure)				
1985	30.9	1.9	0.3		33.1			29.1	62.1			37.9
1986	34.0	1.9	0.3		36.2			23.7	59.9			40.1
1987	30.3	1.8	0.3		32.5			26.6	59.1			40.9
1988	30.1	2.5	0.3		32.9			28.3	61.2			38.8
1989	30.8	2.8	0.3		34.0			29.6	63.6			36.4
1990	32.2	2.9	0.3		35.5			30.0	65.5			34.5
1991	34.0	3.0	0.3		37.3			29.8	67.1			32.9
1992	34.9	3.0	0.3		38.2			30.0	68.2	16.7	15.1	31.8
1993	34.8	3.2	0.3		38.3			30.5	68.8	16.5	14.7	31.2
1994	33.0	3.5	0.4		36.9			31.4	68.3	16.5	15.3	31.7
1995	32.2	3.7	0.4		36.4			32.6	69.0	15.9	15.1	31.0
1996	33.1	3.9	0.3		37.3			32.7	70.0	15.5	14.5	30.0
1997	33.9	3.7	0.3		37.9			33.4	71.3	14.8	14.0	28.7
1998	33.4	3.6	0.4		37.4			35.0	72.4	14.1	13.5	27.6
1999	34.6	3.6	0.4		38.7			34.0	72.6	14.2	13.2	27.4
2000	36.0	3.5	0.4		40.0			34.5	74.4	13.5	12.1	25.6
2000	36.4	3.6	0.4		40.4			35.4	75.8	12.7	11.5	24.2
2001 2002 f	36.0	3.8	0.4		40.4			35.4	75.8 75.9	12.7	11.4	24.2
2002 f	32.6	4.2	0.4		37.1			39.0	76.1	12.5	11.4	23.9
f - Forecast												

Table B.10.1—Part 2 Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985-2003 (continued) Share of Drugs in Public, Private and All Drugs Health Expenditure **Total Health Expenditures** Public Private Public Private Total Public Private Year (\$ millions) (percentage share) 1985 137.7 278.8 416.5 3,410.1 1,227.1 4,637.3 4.0 22.7 1986 161.5 284.1 445.6 3,666.0 1,317.2 4,983.3 4.4 21.6 8.9 1987 164.4 341.9 506.3 3,895.3 1,444.9 5,340.3 4.2 23.7 9.5 1988 185.7 378.9 564.6 4,241.2 1,596.8 5,838.0 4.4 23.7 9.7 421.2 637.9 1989 216.7 4.736.0 1,773.0 6.509.0 4.6 23.8 9.8 1990 721.7 5,386.7 1,986.0 256.3 465.4 7,372.6 4.8 23.4 9.8 1991 302.4 507.3 809.7 5,967.2 2,159.5 8,126.7 23.5 10.0 5.1 893.7 6.477.9 1992 341.5 552.2 2,291.2 8.769.1 24.1 10.2 5.3 381.6 1993 613 5 995 1 6 869 8 2 427 0 9 296 7 5.6 25.3 10.7 1994 379.2 649.5 1,028.7 7,237.5 2,518.8 9,756.3 5.2 25.8 10.5 1995 394 1 689 5 1 083 6 7 538 4 2 560 3 10 098 7 5.2 26.9 10.7 1996 427.5 719.4 1,146.9 7,688.7 2,675.5 10.364.2 5.6 26.9 11.1 1997 468.0 767.3 1,235.2 7 960 2 2.875.2 10.835.4 5.9 26.7 11.4 1998 512.3 858.6 1,370.9 8,316.2 3,084.1 11,400.2 6.2 27.8 12.0 1999 575.7 913.3 1,489.0 9,021.1 3,275.3 12,296.4 6.4 27.9 12.1 2000 660.4 992.7 1,653.1 9,797.3 3,507.9 13,305.2 6.7 28.3 12.4 2001 732.1 1,078.7 1,810.7 10,773.7 3,783.0 14,556.6 6.8 28.5 12.4 1,157.3 1,934.5 11,546.1 4,027.0 15,573.0 2002 f 777.2 6.7 12.4 2003 f 728.0 1,232.4 1,960.4 11,939.8 4,311.4 16,251.2 6.1 28.6 12.1 (annual percentage change) 1985 7.0 7.5 1986 17.2 1.9 7.3 7.5 1987 1.8 20.3 13.6 6.3 9.7 7.2 1988 8.9 13.0 10.8 11.5 10.5 9.3 1989 16.7 11 2 13.0 117 11 0 115 1990 18.2 10.5 13.1 13.7 12.0 13.3 1991 18.0 9.0 12.2 10.8 8.7 10.2 1992 12.9 8.9 10.4 8.6 6.1 7.9 1993 11.7 11.1 11.3 6.0 5.9 6.0 1994 -0.6 5.9 3.4 5.4 3.8 4.9 1995 4 2 3.9 6 2 5.3 1.6 3.5 1996 8.5 4.3 5.8 2.0 4.5 2.6 1997 9.5 6.7 7.7 3.5 7.5 4.5 1998 9.5 11.9 11.0 4.5 7.3 5.2 1999 12.4 8.5 6.2 7.9 6.4 8.6 2000 14.7 8.7 11.0 8.6 7.1 8.2 2001 10.9 8.7 9.5 10.0 7.8 9.4 2002 f 6.2 7.3 6.8 7.2 6.4 7.0 2003 f -6.3 6.5 1.3 3.4 7.1 4.4 (percentage share of total drug expenditure) 1985 33.1 66.9 100.0 1986 63.8 100.0 36.2 100.0 1987 32.5 67.5 1988 32.9 67.1 100.0 1989 34.0 66.0 100.0 1990 35.5 64 5 100.0 1991 37.3 62.7 100.0 1992 38.2 61.8 100.0 1993 38.3 61.7 100.0 1994 36.9 63.1 100.0 1995 36.4 63.6 100.0 1996 37.3 62.7 100.0 1997 37.9 62.1 100.0 1998 37.4 62.6 100.0 38.7 100.0 1999 61.3 2000 40.0 60.0 100.0 2001 40.4 59.6 100.0 2002 f 40.2 59.8 100.0 2003 f 37.1 62.9 100.0

CIHI 2004

f - Forecast

Table B.10.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, British Columbia, 1985–2003

	-		Public		Prescribed	Drugs	Private				Prescribed D e (Out-of-Po	
	Provincial	Federal	Social Secu	rity Funds	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
		_	W.C.B.	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
Year				Funds		(\$ per ca	nita)			Drugs		
	40.04	0.00	0.47		10.01			40.70	07.00			50.04
1985 1986	43.21 50.41	2.63 2.86	0.47 0.49		46.31 53.75			40.72 35.14	87.03 88.89			53.01 59.43
1987	50.32	3.02	0.55		53.89			44.21	98.11			67.88
1988	54.50	4.48	0.63		59.62			51.23	110.85			70.39
1989	61.46	5.64	0.67		67.77			59.07	126.84			72.63
1990	70.67	6.46	0.74		77.87			65.87	143.74			75.56
1991	81.63	7.22	0.79		89.64			71.48	161.12			78.90
1992	89.90	7.65	0.90		98.45			77.29	175.73	43.10	38.83	81.93
1993	96.98	9.01	0.97		106.96			84.97	191.93	46.07	40.93	87.01
1994	92.34	9.75	1.08		103.18			87.94	191.11	46.08	42.69	88.76
1995	92.52	10.72	1.11		104.35			93.59	197.94	45.61	43.36	88.96
1996	97.94	11.40	1.02		110.35			96.76	207.12	46.01	42.91	88.92
1997	106.03	11.47	1.02		118.52			104.40	222.92	46.18	43.73	89.92
1998	114.95	12.41	1.27		128.63			120.51	249.14	48.58	46.45	95.04
1999	128.53	13.52	1.48		143.52			126.07	269.60	52.56	49.04	101.61
2000	147.40	14.41	1.69		163.50			141.14	304.64	55.19	49.42	104.61
2001	161.60	16.09	1.81		179.50			157.17	336.66	56.28	51.03	107.31
2002 f	169.31	17.82	1.74		188.87			167.98	356.86	59.77	53.49	113.26
2003 f	153.95	19.78	1.83		175.57	 nnual percenta	 nge change)	184.35	359.91	59.04	53.81	112.86
1985												
1986	16.7	8.5	3.7		16.1			-13.7	2.1			12.1
1987	-0.2	5.7	13.7		0.3			25.8	10.4			14.2
1988	8.3	48.3	14.1		10.6			15.9	13.0			3.7
1989	12.8	25.7	6.2		13.7			15.3	14.4			3.2
1990	15.0	14.5	10.8		14.9			11.5	13.3			4.0
1991	15.5	11.8	7.4		15.1			8.5	12.1			4.4
1992	10.1	6.0	12.9		9.8			8.1	9.1			3.8
1993	7.9	17.7	8.5		8.6			9.9	9.2	6.9	5.4	6.2
1994	-4.8	8.3	10.7		-3.5			3.5	-0.4	0.0	4.3	2.0
1995	0.2	9.9	2.8		1.1			6.4	3.6	-1.0	1.6	0.2
1996	5.9	6.4	-8.4		5.8			3.4	4.6	0.9	-1.0	0.0
1997	8.3	0.6	0.2		7.4			7.9	7.6	0.4	1.9	1.1
1998	8.4	8.2	24.5		8.5			15.4	11.8	5.2	6.2	5.7
1999	11.8	8.9	16.4		11.6			4.6	8.2	8.2	5.6	6.9
2000	14.7	6.6	14.3		13.9			11.9	13.0	5.0	0.8	3.0
2001	9.6	11.6	7.3		9.8			11.4	10.5	2.0	3.3	2.6
2002 f	4.8	10.8	-3.9		5.2			6.9	6.0	6.2	4.8	5.5
2003 f	-9.1	11.0	5.3	(annual nero	-7.0 entage change	in excess of	inflation in t	9.7	0.9	-1.2	0.6	-0.4
1005	_								-			
1985 1986	13.9	5.7	0.9		13.3			-16.5	-0.7			9.3
1987	-4.9	1.0	9.0		-4.5			21.1	5.6			9.5
1988	3.8	43.8	9.6		6.1			11.4	8.5			-0.8
1989	8.2	21.2	1.6		9.1			10.7	9.9			-1.4
1990	12.0	11.5	7.8		11.9			8.5	10.3			1.0
1991	12.7	9.0	4.6		12.4			5.8	9.3			1.7
1992	8.9	4.8	11.6		8.6			6.9	7.8			2.6
1993	6.4	16.3	7.0		7.2			8.5	7.8	5.5	4.0	4.8
1994	-5.9	7.2	9.6		-4.6			2.4	-1.5	-1.1	3.2	0.9
1995	-2.1	7.6	0.5		-1.2			4.1	1.2	-3.4	-0.8	-2.1
1996	4.2	4.7	-10.1		4.1			1.7	3.0	-0.8	-2.7	-1.7
1997	7.3	-0.4	-0.8		6.4			6.9	6.6	-0.6	0.9	0.1
1998	8.8	8.7	25.0		9.0			15.9	12.2	5.6	6.7	6.1
1999	10.0	7.1	14.6		9.8			2.8	6.4	6.4	3.8	5.1
2000	10.7	2.6	10.4		9.9			8.0	9.0	1.0	-3.2	-1.0
2001	8.4	10.3	6.0		8.5			10.1	9.2	0.7	2.0	1.3
2002 f 2003 f	3.8 -12.4	9.8 7.7	-4.9 2.0		4.2 -10.3			5.9 6.4	5.0 -2.4	5.2 -4.5	3.8 -2.7	4.5 -3.7
2003 I	-12.4	7.7	2.0		-10.3			0.4	-2.4	-4.5	-2.7	-3.7
f - Forecast												

	Expendi		-				Public, Private
			th Expenditu	res, British Co	olumbia, 198	35–2003 (d	GDP Implicit
_	Public	All Drugs Private	Total	Public Hea	Private	Total	Price Index — Cana
			(\$ per ca	pita)			(1997 = 100)
-	46.21	02.72			412.50	1 550 12	
	46.31 53.75	93.73 94.57	140.04 148.32	1,146.55 1,220.34	412.58 438.48	1,559.13 1,658.82	73.6 75.6
	53.89	112.09	165.99	1,277.10	473.72	1,750.82	79.2
	59.62	121.62	181.24	1,361.37	512.56	1,873.93	82.8
	67.77	131.70	199.47	1,480.99	554.42	2,035.41	86.6
	77.87	141.42	219.29	1,636.89	603.48	2,240.37	89.2
	89.64	150.38	240.03	1,768.85	640.15	2,409.00	91.6
	98.45	159.22	257.66	1,867.66	660.58	2,528.24	92.8
	106.96	171.97	278.93	1,925.71	680.32	2,606.02	94.1
	103.18	176.70	279.88	1,969.00	685.27	2,654.27	95.2
	104.35	182.55	286.90	1,995.86	677.86	2,673.72	97.4
	110.35	185.69	296.04	1,984.56	690.57	2,675.13	99.0
	118.52	194.32	312.84	2,015.98	728.17	2,744.15	100.0
	128.63	215.55	344.18	2,087.87	774.29	2,862.17	99.6
	143.52	227.68	371.21	2,248.90	816.50	3,065.40	101.4
	163.50	245.75	409.25	2,425.54	868.47	3,294.01	105.4
	179.50	264.48	443.97	2,641.61	927.55	3,569.16	106.7
	188.87	281.24	470.12	2,805.86	978.61	3,784.47	107.8
_	175.57	297.21	472.77 (ann	2,879.43 ual percentage char	1,039.76 nge)	3,919.19	111.4
	16.1	0.9	5.9	6.4	6.3	6.4	2.8
	0.3	18.5	11.9	4.7	8.0	5.5	4.7
	10.6 13.7	8.5 8.3	9.2 10.1	6.6 8.8	8.2 8.2	7.0 8.6	4.5 4.6
	14.9	7.4	9.9	10.5	8.8	10.1	3.0
	15.1	6.3	9.5	8.1	6.1	7.5	2.8
	9.8	5.9	7.3	5.6	3.2	4.9	1.3
	8.6	8.0	8.3	3.1	3.0	3.1	1.4
	-3.5	2.8	0.3	2.2	0.7	1.9	1.1
	1.1	3.3	2.5	1.4	-1.1	0.7	2.3
	5.8	1.7	3.2	-0.6	1.9	0.1	1.7
	7.4	4.6	5.7	1.6	5.4	2.6	1.0
	8.5	10.9	10.0	3.6	6.3	4.3	-0.4
	11.6	5.6	7.9	7.7	5.5	7.1	1.8
	13.9	7.9	10.2	7.9	6.4	7.5	4.0
	9.8	7.6	8.5	8.9	6.8	8.4	1.3
	5.2	6.3	5.9	6.2	5.5	6.0	1.0
	-7.0	5.7	0.6	2.6	6.2	3.6	3.3
_				inflation in the Cana			
	12.2	1.0					
	13.3 -4.5	-1.9 13.8	3.1 7.2	3.6 -0.1	3.5 3.3	3.6 0.8	
	6.1	4.0	4.7	2.1	3.7	2.5	
	9.1	3.7	5.5	4.2	3.6	4.1	
	11.9	4.4	6.9	7.5	5.8	7.0	
	12.4	3.6	6.7	5.3	3.3	4.8	
	8.6	4.6	6.1	4.3	1.9	3.7	
	7.2	6.6	6.8	1.7	1.5	1.6	
	-4.6	1.7	-0.8	1.2	-0.4	0.8	
	-1.2 4.1	1.0 0.0	0.2 1.5	-1.0 -2.2	-3.4 0.2	-1.6 -1.6	
	6.4	3.7	4.7	0.6	4.5	1.6	
	9.0	11.4	10.5	4.0	6.8	4.7	
	9.8	3.8	6.0	5.9	3.6	5.3	
	9.9	4.0	6.3	3.9	2.4	3.5	
	Ω Κ	6.3	7 7	76	h h		
	8.5 4.2	6.3 5.3	7.2 4.9	7.6 5.2	5.5 4.5	7.1 5.0	

CIHI 2004

f - Forecast

Table B.11.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Yukon Territory, 1985–2003

			Public		Prescribe	d Drugs	Private				Prescribed D	
	Territorial	Federal _	Social Secu W.C.B.	Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year						(\$ millio	ns)					
1985	0.2	0.3	0.0		0.5			1.3	1.8			1.3
1986	0.3	0.3	0.0		0.7			1.2	1.9			1.3
1987	0.7	0.4	0.0		1.1				2.3			1.2
1988	1.0	0.6	0.0		1.7			1.0	2.7			1.1
1989	1.2	0.8	0.0		2.1			1.0	3.1			1.1
1990	1.3	1.0	0.0		2.3			1.0	3.3			1.0
1991	1.6	1.2	0.0		2.8			1.2	4.0			1.3
1992	2.0	1.3	0.0		3.4			1.2	4.5	1.2	1.1	2.3
1993	2.3	1.5	0.0		3.8				6.1	1.3	1.1	2.4
1994	2.1	1.7	0.0		3.8			1.6	5.4	1.3	1.1	2.4
1995	1.5	1.8	0.0		3.4			1.7	5.1	1.3	1.2	2.5
1996	1.5	1.9	0.0		3.4			2.2	5.6	1.6	1.5	3.0
1997	1.9	2.0	0.0		4.0			3.4	7.4	1.6	1.5	3.1
1998	2.2	2.1	0.0		4.4			2.9	7.3	1.7	1.6	3.3
1999	2.7	3.1	0.0		5.8			3.0	8.8	1.8	1.7	3.5
2000	3.0	2.0	0.1		6.4			2.0	0.6	17	2.0	0.7
2000 2001	3.3 3.9	3.0 3.0	0.1 0.1		6.4 7.0			3.2 3.6	9.6 10.5	1.7 1.8	2.0 2.0	3.7 3.7
2001 2002 f	4.5	3.5	0.1		8.1				12.2	1.7	1.9	3.6
2003 f	4.0	4.1	0.1		8.2				12.2	1.8	1.9	3.6
2000 .			0		0.2						1.0	0.0
					(a	nnual percenta	ige change)					
1985												
1986	53.7	10.9	-18.3		27.7			-6.2	3.5			-5.0
1987	126.4	6.7	32.5		65.5				21.4			-1.6
1988	41.8	72.7	32.5		51.6				18.0			-12.6
1989	15.4	37.4	-42.2		23.0			-0.3	14.1			0.2
1990	5.9	17.1	98.0		10.8			-6.5	5.1			-6.2
1991	26.2	16.5	-54.9		21.5			25.0	22.5			25.2
1992	23.5	15.7	303.9		21.0			-4.1	13.4			77.9
1993	13.2	14.3	-9.1		13.5			95.5	34.5	6.7	2.4	4.7
1994	-8.4	10.1	-3.4		-1.0			-29.3	-11.5	-1.9	-0.1	-1.1
1995	-26.3	9.1	40.5		-10.1			8.0	-4.7	2.4	13.0	7.2
1996	-2.3	3.8	3.9		1.1			27.6	10.0	19.5	20.2	19.8
1997	26.0	7.0	4.8		15.2			55.4	31.0	3.1	3.9	3.5
1998	17.8	4.0	-10.8		10.4			-15.6	-1.7	3.1	4.4	3.7
1999	21.9	44.5	28.0		32.9			4.6	21.6	7.9	4.9	6.5
2000	21.4	-0.9	15.1		9.6			6.1	8.4	-3.9	19.5	7.4
2001	17.7	0.4	59.6		9.8				10.1	1.7	-2.8	-0.7
2002 f	17.5	15.0	10.3		16.3				15.8	-1.8	-1.8	-1.8
2003 f	-11.7	16.7	13.2		0.8			-2.4	-0.3	1.9	-2.6	-0.4
					Ingraonta	ge share of tota	al drug ava					
							ai uiug expe					
1985	6.7	9.5	0.3		16.6			41.3	57.8			42.2
1986	10.3	10.6	0.3		21.2				59.9			40.1
1987	20.9	10.0	0.3		31.2				64.9			35.1
1988 1989	27.6 28.9	16.2 20.2	0.4 0.2		44.1 49.3				71.4 73.9			28.6 26.1
1990	30.0	23.1	0.4		53.5				76.1			23.9
1991	30.7	21.9	0.1		52.7				75.7			24.3
1992	29.4	19.6	0.4		49.4				66.5	17.9	15.6	33.5
1993	26.7	18.0	0.3		45.1				71.8	15.4	12.8	28.2
1994	26.8	21.7	0.3		48.8			20.7	69.5	16.5	14.0	30.5
1995	20.0	23.9	0.5		44.3			22.6	66.9	17.1	16.0	33.1
1996	17.2	21.9	0.4		39.6			25.4	65.0	18.0	17.0	35.0
1997	17.9	19.3	0.4		37.6			32.6	70.1	15.3	14.6	29.9
1998	21.1	20.1	0.3		41.5				69.0	15.8	15.2	31.0
1999	22.0	24.8	0.4		47.2			24.6	71.8	14.6	13.6	28.2
2000	24.7	22.8	0.4		47.8			24.2	72.0	12.9	15.1	28.0
2000	27.1	21.3	0.6		49.1				74.0	12.3	13.7	26.0
2001 2002 f	28.6	22.1	0.6		51.3				77.1	10.9	12.1	22.9
2003 f	25.4	25.9	0.7		51.9			25.2	//.1	11.1	11.8	22.9
	25.4	25.9	0.7		51.9			25.2	77.1	11.1	11.8	22.9

	Expendit					as a Share of 35–2003 (con	Public, Private	able B.11.1 and	—Part 2
		All Drugs			alth Expenditure		Share of Drug	s in Public, Priva	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ons)			(per	centage share)	
1985	0.5	2.6	3.2	32.9	6.8	39.7	1.6	38.9	8.0
1986	0.7	2.5	3.2	37.0	5.6	42.6	1.8	44.4	7.4
1987	1.1	2.4	3.5	39.1	5.6	44.7	2.8	43.3	7.9
1988	1.7	2.1	3.8	40.6	5.2	45.8	4.1	40.8	8.3
1989	2.1	2.1	4.2	44.2	5.3	49.5	4.7	40.3	8.5
1990	2.3	2.0	4.3	48.5	5.0	53.6	4.7	39.6	8.0
1991	2.8	2.5	5.3	56.5	6.1	62.6	4.9	41.0	8.4
1992 1993	3.4 3.8	3.4 4.7	6.8 8.5	60.6 69.0	6.9 10.6	67.5 79.6	5.6 5.5	49.7 44.1	10.1 10.6
1994	3.8	4.0	7.7	83.3	9.9	93.2	4.5	40.2	8.3
1995	3.4	4.3	7.7	84.4	10.5	94.8	4.0	40.8	8.1
1996	3.4	5.2	8.7	91.3	18.1	109.4	3.8	28.9	7.9
1997	4.0	6.6	10.5	85.4	17.2	102.6	4.6	38.3	10.3
1998	4.4	6.2	10.5	87.5	16.0	103.5	5.0	38.5	10.2
1999	5.8	6.5	12.3	91.5	16.9	108.4	6.3	38.4	11.4
2000	6.4	6.9	13.3	98.9	24.6	123.5	6.4	28.2	10.8
2001	7.0	7.3	14.2	117.2	27.0	144.3	6.0	26.8	9.9
2002 f	8.1	7.7	15.8	121.1	32.0	153.0	6.7	24.1	10.4
2003 f	8.2	7.6	15.8	122.9	32.4	155.4	6.7	23.5	10.2
			(annual percent	age change)					
1985					47.0				
1986 1987	27.7 65.5	-5.6 -2.1	-0.1 12.2	12.3 5.8	-17.3 0.4	7.2 5.1			
1988	51.6	-12.9	7.3	3.8	-7.5	2.3			
1989	23.0	-0.1	10.1	9.1	1.2	8.2			
1990	10.8	-6.3	2.1	9.7	-4.8	8.2			
1991	21.5	25.1	23.2	16.4	20.9	16.8			
1992	21.0	38.2	29.1	7.2	14.1	7.9			
1993	13.5	35.3	24.5	14.0	52.5	17.9			
1994	-1.0	-14.8	-8.6	20.7	-6.7	17.0			
1995	-10.1	7.6	-1.1	1.3	6.1	1.8			
1996	1.1	23.0	13.3	8.2	73.4	15.4			
1997	15.2	25.4	21.4	-6.4	-5.3	-6.2			
1998	10.4	-6.3	0.0	2.4	-6.9	0.9			
1999	32.9	5.6	16.9	4.6	5.9	4.8			
2000	9.6	6.8	8.1	8.0	45.6	13.9			
2001	9.8	4.5	7.0	18.6	9.8	16.8			
2002 f 2003 f	16.3 0.8	6.3 -1.5	11.2 -0.3	3.3 1.6	18.2 1.4	6.1 1.5			
2003 1		share of total drug		1.0	1.4	1.5			
				-					
1985	16.6	83.4	100.0						
1986 1987	21.2 31.2	78.8 68.8	100.0 100.0						
1988	44.1	55.9	100.0						
1989	49.3	50.7	100.0						
1990	53.5	46.5	100.0						
1991	52.7	47.3	100.0						
1992	49.4	50.6	100.0						
1993	45.1	54.9	100.0						
1994	48.8	51.2	100.0						
1995	44.3	55.7	100.0						
1996	39.6	60.4	100.0						
1997	37.6	62.4	100.0						
1998 1999	41.5 47.2	58.5 52.8	100.0 100.0						
2000	47.8	52.2	100.0						
2001	49.1	50.9	100.0						
2002 f	51.3	48.7	100.0						
2003 f	51.9	48.1	100.0						

f - Forecast

Table B.11.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Yukon Territory, 1985–2003

			Public		Prescribed	d Drugs	Private				Prescribed D	
	Territorial	Federal _	Social Secu W.C.B.	Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter Drugs	Personal Health Supplies	Total Non-Presc Drugs
Year						(\$ per ca	pita)					
1985	8.73	12.38	0.40		21.51			53.66	75.17			54.7
1986	13.36	13.65	0.33		27.34			50.07	77.41			51.78
1987	28.81	13.87	0.41		43.10			46.44	89.54			48.51
1988	39.46	23.14	0.53		63.12			38.94	102.06			40.97
1989	44.68	31.20	0.30		76.17			38.08	114.25			40.28
1990	46.19	35.65	0.58		82.41			34.77	117.18			36.89
1991	56.02	39.91	0.25		96.18			41.78	137.95			44.38
1992	66.44	44.31	0.97		111.72			38.47	150.19	40.52	35.28	75.80
1993	74.64	50.24	0.87		125.74			74.59	200.34	42.89	35.83	78.72
1994	69.86	56.56	0.86		127.28			53.92	181.20	43.00	36.58	79.59
1995	50.23	60.17	1.18		111.59			56.82	168.41	42.94	40.31	83.25
1996	47.63	60.58	1.19		109.40			70.33	179.73	49.79	47.00	96.79
1997	59.26	63.97	1.23		124.46			107.92	232.38	50.68	48.20	98.89
1998	71.27	67.89	1.12		140.28			93.02	233.30	53.34	51.37	104.71
1999	87.87	99.30	1.45		188.62			98.45	287.07	58.26	54.53	112.79
2000	107.91	99.59	1.69		209.19	=		105.64	314.83	56.62	65.94	122.56
2000	128.25	100.91	2.73		231.89			117.97	349.86	58.14	64.74	122.89
2002 f	150.67	116.12	3.01		269.80				405.26	57.09	63.57	120.66
2003 f	128.97	131.47	3.31		263.75			128.16	391.91	56.41	60.08	116.49
					(a	innual percenta	ige change)					
1985												
1986	52.9	10.3	-18.7		27.1			-6.7	3.0			-5.5
1987	115.7	1.6	26.2		57.6			-7.2	15.7			-6.3
1988	36.9	66.8	28.0		46.5			-16.2	14.0			-15.5
1989	13.2	34.8	-43.3		20.7			-2.2	12.0			-1.7
1990	3.4	14.3	93.3		8.2			-8.7	2.6			-8.4
1991	21.3	11.9	-56.6		16.7			20.1	17.7			20.3
1992	18.6	11.0	287.7		16.2			-7.9	8.9			70.8
1993	12.3	13.4	-9.8		12.6				33.4	5.8	1.6	3.9
1994	-6.4	12.6	-1.2		1.2			-27.7	-9.6	0.3	2.1	1.1
1995	-28.1	6.4	37.1		-12.3			5.4	-7.1	-0.1	10.2	4.6
1996	-5.2	0.7	0.8		-2.0			23.8	6.7	16.0	16.6	16.3
1997	24.4	5.6	3.5		13.8			53.5	29.3	1.8	2.6	2.2
1998	20.3	6.1	-9.0		12.7			-13.8	0.4	5.2	6.6	5.9
1999	23.3	46.3	29.5		34.5			5.8	23.1	9.2	6.2	7.7
2000	22.0	0.0	10.5		10.0			7.0	0.7	2.0	20.0	0.7
2000 2001	22.8 18.9	0.3 1.3	16.5 61.1		10.9 10.9			7.3 11.7	9.7 11.1	-2.8 2.7	20.9	8.7 0.3
	17.5										-1.8	
2002 f 2003 f	-14.4	15.1 13.2	10.3 9.8		16.3 -2.2			14.8 -5.4	15.8 -3.3	-1.8 -1.2	-1.8 -5.5	-1.8 -3.5
2003 1	-14.4	13.2	9.0			e in excess of				-1.2	-5.5	-3.0
				(annual perc	entage chang	e iii excess oi	iiiiatioii iii	trie Cariadian	economy)			
1985					24.2							
1986 1987	50.1 110.9	7.5	-21.5 21.5		24.3			-9.5	0.2			-8.3 -11.1
1988	32.4	-3.2 62.3	23.5		52.9 41.9			-12.0 -20.7	10.9 9.5			-11.1
1989	8.7	30.3	-47.9		16.1			-6.8	7.4			-6.2
1990	0.4	11.2	90.3		5.2			-11.7	-0.5			-11.4
1991 1992	18.5 17.3	9.2 9.8	-59.4 286.5		13.9 14.9				15.0 7.6			17.5 69.5
1992	10.9	9.8 11.9	-11.3		11.1				31.9	4.4	0.1	2.4
1994	-7.5	11.5	-2.3		0.1			-28.8	-10.7	-0.8	1.0	
1005	20.4		0.4.7		44.7					0.5	7.0	
1995 1996	-30.4	4.1	34.7		-14.7				-9.4	-2.5	7.9	2.3
1996	-6.9 23.4	-1.0 4.6	-0.9 2.5		-3.6 12.8			22.1 52.5	5.1 28.3	14.3 0.8	14.9 1.6	14.6 1.2
1997	20.7	6.6	-8.5		13.2				0.8	5.7	7.0	
1999	21.5	44.5	27.7		32.7				21.2	7.4	4.4	5.9
2000	18.8	-3.7	12.5		6.9				5.7	-6.8	16.9	4.7
2001	17.6	0.1	59.9		9.6				9.9	1.4	-3.1	-1.0
2002 f	16.5	14.1	9.3		15.3				14.8	-2.8 -4.5	-2.8	
2003 f f - Forecast	-17.7	9.9	6.5		-5.5			-8.7	-6.6	-4.5	-8.8	-6.8
. rorcoast				level insurance								CIHI 2004

		Total Hea	lth Expenditu	res, Yukon T	erritory, 198	35–2003 (d
	Public	All Drugs Private	Total	Public He	alth Expenditure Private	Total
			(\$ per ca	pita)		
	21.51	108.45	129.96	1,351.18	278.89	1,630.07
	27.34	101.85	129.19	1,510.29	229.51	1,739.80
	43.10	94.95	138.05	1,521.49	219.52	1,741.02
	63.12	79.90	143.03	1,524.93	196.03	1,720.95
	76.17	78.36	154.53	1,632.10	194.61	1,826.71
	82.41	71.66	154.07	1,747.95	180.81	1,928.76
	96.18	86.16	182.33	1,954.71	210.04	2,164.74
	111.72	114.27	225.99	2,011.98	230.03	2,242.01
	125.74	153.32	279.06	2,274.52	347.90	2,622.42
	127.28	133.51	260.79	2,805.60	331.74	3,137.34
	111.59	140.07	251.66	2,771.87	343.47	3,115.33
	109.40	167.12	276.53	2,908.40	577.74	3,486.14
	124.46	206.81	331.27	2,687.26	540.01	3,227.26
	140.28	197.73	338.01	2,809.69	513.00	3,322.69
	188.62	211.24	399.87	2,972.94	549.56	3,522.50
	209.19	228.20	437.39	2 240 67	809.49	4,059.16
	209.19	228.20 240.86	437.39 472.75	3,249.67 3,891.40	809.49 897.38	4,059.16 4,788.79
f	269.80	240.86 256.12	525.92	4,019.26	1,061.01	4,788.79 5,080.27
f	263.75	244.65	508.40	3,958.45	1,043.22	5,001.67
				ual percentage cha		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
			(ann			
	27.1	-6.1	-0.6	11.8	 -17.7	6.7
	57.6	-6.8	6.9	0.7	-4.4	0.1
	46.5	-15.8	3.6	0.2	-10.7	-1.2
	20.7	-1.9	8.0	7.0	-0.7	6.1
	8.2	-8.5	-0.3	7.1	-7.1	5.6
	16.7	20.2	18.3	11.8	16.2	12.2
	16.2	32.6	23.9	2.9	9.5	3.6
	12.6	34.2	23.5	13.0	51.2	17.0
	1.2	-12.9	-6.5	23.3	-4.6	19.6
	-12.3	4.9	-3.5	-1.2	3.5	-0.7
	-2.0	19.3	9.9	4.9	68.2	11.9
	13.8	23.7	19.8	-7.6	-6.5	-7.4
	12.7	-4.4	2.0	4.6	-5.0	3.0
	34.5	6.8	18.3	5.8	7.1	6.0
	10.9	8.0	9.4	9.3	47.3	15.2
	10.9	5.5	8.1	19.7	10.9	18.0
	16.3	6.3	11.2	3.3	18.2	6.1
	-2.2	-4.5	-3.3	-1.5	-1.7	-1.5
				inflation in the Can		
	24.3	-8.9	-3.4	9.0	-20.5	3.9
	52.9	-11.5	2.1	-4.0	-9.1	-4.7
	41.9	-20.4	-0.9	-4.3	-15.2	-5.7
	16.1	-6.5	3.5	2.5	-5.3	1.6
	5.2	-11.6	-3.3	4.1	-10.1	2.6
	13.9	17.5	15.6	9.1	13.4	9.5
	14.9	31.4	22.7	1.7	8.3	2.3
	11.1	32.7	22.0	11.6	49.8	15.5
	0.1	-14.0	-7.6	22.3	-5.7	18.5
	-14.7	2.6	-5.8	-3.5	1.2	-3.0
	-3.6	17.6	8.2	3.3	66.5	10.2
	12.8	22.8	18.8	-8.6	-7.5	-8.4
	13.2	-4.0	2.5	5.0	-4.6	3.4
	32.7	5.0	16.5	4.0	5.3	4.2
	6.9	4.1	5.4	5.3	43.3	11.3
	9.6	4.3	6.8	18.5	9.6	16.7
f f	15.3 -5.5	5.3	10.2	2.3	17.2	5.1
		-7.8	-6.6	-4.8	-5.0	-4.8

f - Forecast

Table B.12.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985–2003

-	Territorial	Federal	Public Social Secu	ulter Francis		-	Private	_			e (Out-of-Po	
		_		irity Funas	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
			W.C.B.	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
Year				Funds		(\$ million	s)			Drugs		
- 1985	1.1	2.4	0.0		3.5			2.3	5.8			4.1
1986	1.4	2.7	0.0		4.1			2.7	6.8			
1987	1.7	3.0	0.0		4.7			3.0	7.7			4.7
1988	1.9	3.2	0.0		5.1			3.4	8.6			5.1
1989	2.1	3.7	0.0		5.8			3.9	9.7			5.4
1990	2.4	4.3	0.0		6.6			3.9	10.6			5.1
1991	3.0	4.9	0.0		7.9			5.0	12.9			6.0
1992	3.6	5.7	0.0		9.3			4.9	14.2	2.4	2.1	4.5
1993	2.5	6.4	0.0		8.9			4.7	13.6	2.6	2.2	
1994	1.2	7.1	0.1		8.3			3.5	11.8	2.7	2.3	4.9
1995	1.1	7.7	0.1		8.9			3.8	12.6	2.7	2.5	5.2
1996	1.3	8.0	0.0		9.3			3.5	12.8	2.5	2.4	
1997	1.4	8.5	0.0		9.9			4.4	14.4	2.9	2.8	
1998	1.7	8.8	0.0		10.5			4.5	15.0	3.0	2.9	
1999	1.8	7.6	0.0		9.4			3.3	12.7	2.2	2.1	4.3
2000	1.9	7.6	0.0		9.5			3.4	13.0	2.2	1.4	3.6
2001	2.2	8.8	0.0		11.0			3.7	14.7	1.9	1.4	
2002 f	2.1	9.7	0.0		11.8			4.0	15.8	1.9	1.4	
2003 f	2.1	11.3	0.1		13.5			3.9	17.3	1.9	1.3	3.2
-					(a	nnual percentag	je change)					
1985												
1986	30.3	12.3	-5.7		17.7			14.6	16.5			
1987	22.0	8.5	6.9		13.1			12.7	12.9			
1988 1989	12.6 7.6	6.9 17.3	67.7 -6.6		9.2 13.5			15.4 14.2	11.6 13.8			8.6 7.2
1990	13.9	14.8	-0.9		14.4			0.2	8.7			
1991 1992	25.2 21.7	16.0	13.9		19.2			25.8	21.7			
1993	-31.8	14.9 13.3	1.0 27.0		17.4 -4.2			-1.1 -4.2	10.3 -4.2	7.3	3.0	
1994	-50.0	10.0	32.1		-6.5			-25.9	-13.2	2.5	4.3	
1995	-8.1	9.1	0.9		6.5			7.8	6.9	1.8	12.3	6.6
1996	14.4	3.3	-15.9		4.6			-6.7	1.3	-6.5	-6.0	
1997	9.9	6.5	-3.6		7.0			27.0	12.4	15.5	16.3	
1998	16.2	3.3	1.1		5.1			1.6	4.1	4.3	5.6	
1999	10.2	-13.7	-14.1		-9.9			-27.4	-15.2	-27.7	-29.7	-28.7
2000	6.8	-0.1	0.6		1.3			5.1	2.3	-0.3	-31.7	-15.5
2001	13.6	16.2	22.3		15.7			6.1	13.2	-12.4	-3.2	
2002 f	-5.2	10.1	11.7		7.0			8.6	7.4	-0.6	-0.6	-0.6
2003 f	1.4	16.7	13.0		14.0			-2.7	9.8	0.2	-3.3	-1.2
-					(percentag	e share of total	drug expend	liture)				
1985	10.9	24.5	0.2		35.6			23.4	59.0			41.0
1986	12.6	24.3	0.1		37.1			23.7	60.7			39.3
1987	13.9	23.9	0.1		38.0			24.2	62.2			
1988 1989	14.2 13.7	23.2 24.4	0.2 0.2		37.6 38.3			25.3 25.9	62.8 64.2			37.2 35.8
1990	15.1	27.1	0.2		42.4			25.1	67.5			
1991	15.7	26.1	0.2		41.9			26.2	68.2	12.0	11.0	
1992 1993	19.3 13.4	30.3 34.9	0.2 0.2		49.7 48.6			26.2 25.6	75.9 74.1	12.9 14.1	11.2 11.8	
1994	7.4	42.2	0.2		49.9			20.8	70.7	15.8	13.5	
1995 1996	6.3 7.3	43.1 45.0	0.3 0.2		49.7 52.5			21.0 19.8	70.7 72.3	15.1 14.3	14.2 13.5	
1997	7.3 7.1	45.0	0.2		49.5			22.1	72.3 71.7	14.5	13.5	
1998	7.1	41.8	0.2		49.9			21.6	71.7	14.5	14.0	
1999	10.8	44.6	0.2		55.6			19.3	74.9	13.0	12.1	
2000	11.7	45.6	0.2		57.5			20.8	78.3	13.2	8.5	
2000	11.7	48.9	0.2		61.4			20.6	76.3 81.8	10.7	7.6	
2001 2002 f	11.0	50.8	0.2		62.0			20.4	82.9	10.7	7.0	
2003 f	10.3	54.9	0.3		65.5			18.8	84.3	9.3	6.4	
f - Forecast												
* Note: Contident	tiality precludes	reporting provi	ncial level insu	ırance data.								CIHI 2004

		_				as a Share of 1985–2003 (d	Public, Private	able B.12.1 and	
		All Drugs			alth Expenditure		Share of Drug	gs in Public, Priva Iealth Expenditure	
	Public	Private	Total	Public	Private	Total	Public	Private Private	Total
Year			(\$ millio	ons)			(pe	rcentage share)	
1985	3.5	6.4	9.9	118.9	19.6	138.5	3.0	32.4	7.
1986	4.1	7.0	11.2	145.2	21.7	166.9	2.9	32.5	6.
1987	4.7	7.7	12.3	157.4	23.9	181.3	3.0	32.1	6.
1988	5.1	8.5	13.6	183.9	27.3	211.2	2.8	31.2	6.
1989	5.8	9.4	15.2	203.6	29.3	232.9	2.9	31.9	6.
1990	6.6	9.0	15.7	218.5	28.4	246.8	3.0	31.9	6.
1991	7.9	11.0	18.9	247.2	32.3	279.5	3.2	34.0	6.
1992	9.3	9.4	18.7	249.9	29.7	279.6	3.7	31.7	6.
1993	8.9	9.4	18.4	258.7	28.3	287.1	3.4	33.3	6.
1994	8.3	8.4	16.7	259.5	26.6	286.2	3.2	31.5	5.
1995	8.9	9.0	17.9	270.3	24.5	294.8	3.3	36.6	6.
1996	9.3	8.4	17.7	265.4	26.6	291.9	3.5	31.6	6.
1997	9.9	10.1	20.1	280.9	26.2	307.1	3.5	38.7	6.
1998	10.5	10.5	20.9	324.8	26.8	351.6	3.2	39.1	6.0
1999	9.4	7.5	16.9	212.5	20.9	233.5	4.4	35.9	7.3
2000	9.5	7.0	16.6	194.9	20.6	215.5	4.9	34.2	7.
2001	11.0	6.9	18.0	237.9	25.4	263.3	4.6	27.3	6.8
2002 f	11.8	7.2	19.0	264.0	26.7	290.7	4.5	27.0	6.
2003 f	13.5	7.1	20.5	282.7	26.1	308.9	4.8	27.1	6.
			(annual percenta	age change)					
1985									
1986	17.7	10.5	13.1	22.2	10.5	20.5			
1987	13.1	8.7	10.3	8.4	10.0	8.6			
1988	9.2	11.3	10.5	16.8	14.4	16.5			
1989	13.5	10.0	11.3	10.7	7.5	10.3			
1990	14.4	-3.4	3.4	7.3	-3.3	6.0			
1991	19.2	21.3	20.4	13.2	13.7	13.2			
1992	17.4	-14.2	-1.0	1.1	-7.9	0.1			
1993	-4.2	0.3	-1.9	3.5	-4.7	2.7			
1994	-6.5	-11.2	-8.9	0.3	-6.1	-0.3			
1995	6.5	7.1	6.8	4.1	-7.8	3.0			
1996	4.6	-6.4	-0.9	-1.8	8.4	-1.0			
1997	7.0	20.5	13.4	5.8	-1.5	5.2			
1998	5.1	3.5	4.3	15.6	2.4	14.5			
1999	-9.9	-28.1	-19.0	-34.6	-21.9	-33.6			
2000	1.3	-6.5	-2.2	-8.3	-1.8	-7.7			
2001	15.7	-1.5	8.4	22.0	23.7	22.2			
2002 f	7.0	4.3	6.0	11.0	5.2	10.4			
2003 f	14.0	-2.0	7.9	7.1	-2.2	6.2			
	(percentage s	hare of total drug	expenditure)						
1985	35.6	64.4	100.0						
1986	37.1	62.9	100.0						
1987	38.0	62.0	100.0						
1988	37.6	62.4	100.0						
1989	38.3	61.7	100.0						
1990	42.4	57.6	100.0						
1991	41.9	58.1	100.0						
1992	49.7	50.3	100.0						
1993	48.6	51.4	100.0						
1994	49.9	50.1	100.0						
1995	49.7	50.3	100.0						
1996	52.5	47.5	100.0						
1997	49.5	50.5	100.0						
1998	49.9	50.1	100.0						
1999	55.6	44.4	100.0						
2000	57.5	42.5	100.0						
2001	61.4	38.6	100.0						
2001									
2002 f	62.0	38.0	100.0						

CIHI 2004

f - Forecast

Table B.12.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Northwest Territories, 1985–2003

			Public		Prescribe	d Drugs	Private				Prescribed December 10 Prescribed 10 Prescri	
	Territorial	Federal	Social Secu	rity Funds	Sub-Total	Insurers*	Out-of-	Sub-Total	Total	Over	Personal	Total
		_	W.C.B.	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
V.00.				Funds		(é nou coni	ital			Drugs		
/ear						(\$ per capi						
1985 1986	19.87 25.75	44.58 49.79	0.30 0.29		64.76 75.83			42.52 48.45	107.28 124.28			
1987	31.22	53.68	0.29		85.21			54.27	139.47			
1988	34.75	56.71	0.50		91.96			61.91	153.47			
1989	36.51	64.93	0.46		101.90			69.02	170.93			
1990	40.26	72.19	0.44		112.88			66.93	179.82			86.68
1991	48.72	80.94	0.48		130.15			81.44	211.59			98.77
1992	57.97	90.92	0.48		149.37			78.73	228.10	38.68	33.67	
1993	38.86	101.25	0.60		140.71			74.12	214.83	40.80	34.09	
1994	18.97	108.66	0.77		128.40			53.56	181.96	40.79	34.70	75.49
1995	17.05	115.97	0.76		133.79			56.50	190.29	40.62	38.13	78.76
1996	19.22	118.05	0.63		137.90			51.91	189.80	37.42	35.32	72.74
1997	21.09	125.56	0.61		147.26			65.80	213.06	43.14	41.03	84.18
1998	24.63	130.34	0.62		155.58			67.20	222.79	45.21	43.54	88.74
1999	44.84	185.89	0.87		231.61			80.63	312.24	54.01	50.56	104.57
2000	48.07	186.46	0.88		235.41			85.11	320.52	54.05	34.69	88.73
2001	54.18	215.04	1.07		270.29			89.58	359.87	46.96	33.31	80.26
2002 f	50.59	233.25	1.18		285.02			95.87	380.89	46.00	32.63	78.63
2003 f	50.77	269.46	1.32		321.55			92.30	413.85	45.61	31.22	76.84
					(aı	nnual percentag	je change)					
1985												
1986	29.6	11.7	-6.3		17.1			14.0	15.8			7.6
1987	21.2	7.8	6.3		12.4			12.0	12.2			5.6
1988	11.3	5.6	65.8		7.9			14.1	10.3			7.3
1989	5.1	14.5	-8.8		10.8			11.5	11.1			4.7
1990	10.3	11.2	-4.0		10.8			-3.0	5.2			-9.1
1991	21.0	12.1	10.2		15.3			21.7	17.7			14.0
1992	19.0	12.3	-1.2		14.8			-3.3	7.8			-26.7
1993	-33.0	11.4	24.9		-5.8			-5.9	-5.8	5.5	1.2	
1994	-51.2	7.3	28.8		-8.8			-27.7	-15.3	0.0	1.8	
1995	-10.1	6.7	-1.3		4.2			5.5	4.6	-0.4	9.9	
1996	12.7	1.8	-17.1		3.1			-8.1	-0.3	-7.9	-7.4	
1997	9.8	6.4	-3.7		6.8			26.8	12.3	15.3	16.2	
1998	16.7	3.8	1.6		5.6			2.1	4.6	4.8	6.1	5.4
1999	82.1	42.6	41.9		48.9			20.0	40.2	19.5	16.1	17.8
2000	7.2	0.3	1.0		1.6			5.6	2.7	0.1	-31.4	
2001	12.7	15.3	21.3		14.8			5.3	12.3	-13.1	-4.0	-9.5
2002 f	-6.6	8.5	10.0		5.4			7.0	5.8	-2.0	-2.0	
2003 f	0.4	15.5	11.8		12.8			-3.7	8.7	-0.8	-4.3	-2.3
				(annual perc	entage change	e in excess of in	nflation in the	e Canadian e	conomy)			
1985												
1986	26.8	8.9	-9.1		14.3			11.2	13.0			4.8
1987	16.5	3.1	1.5		7.6			7.3	7.5			
1988 1989	6.8 0.5	1.1 9.9	61.2 -13.4		3.4 6.2			9.6 6.9	5.8 6.5			2.8 0.1
1990	7.2	8.1	-7.1		7.7			-6.1	2.2			
1990	18.3	9.4	7.1		12.5			18.9	14.9			
1992	17.7	11.1	-2.5		13.5			-4.6	6.5			
1993	-34.4	9.9	23.5		-7.2			-7.3	-7.3	4.1	-0.2	
1994	-52.3	6.2	27.7		-9.9			-28.8	-16.4	-1.1	0.7	
1995	-12.4	4.4	-3.6		1.9			3.1	2.2	-2.7	7.6	2.0
1996	11.0	0.1	-18.8		1.4			-9.8	-1.9	-9.6	-9.0	
1997	8.8	5.4	-4.7		5.8			25.8	11.3	14.3	15.2	
1998	17.2	4.2	2.0		6.1			2.6	5.0	5.2	6.5	
1999	80.3	40.8	40.1		47.1			18.2	38.3	17.7	14.3	
2000	3.2	-3.7	-3.0		-2.3			1.6	-1.3	-3.9	-35.4	-19.1
2001	11.5	14.1	20.0		13.5			4.0	11.0	-14.4	-5.2	
2001		7.5	9.0		4.4			6.0	4.8	-3.0	-3.0	
	-7.6	7.5	0.0		7.7			0.0	4.0	0.0	-5.0	-5.0
2001 2002 f 2003 f	-7.6 -2.9	12.2	8.5		9.5			-7.0	5.4	-4.1	-7.6	

			: NOTTOWAGE	Territories,	1985ーノいい
	i Otai i icaitii	Experientales	s, Northwest	i Gilitolies,	1303-200
Public	All Drugs Private	Total	He Public	Private	Total
i dollo	Tilvato	rotai	T dollo	Tilvato	Total
		(\$ per ca	pita)		
64.76	117.15	181.91		361.05	2,546.73
75.83	117.15	204.59	2,185.68 2,655.45	396.69	3,052.14
85.21	139.05	224.26	2,859.77	433.59	3,293.37
91.96	152.93	244.89	3,302.40	490.09	3,792.49
101.90	164.33	266.23	3,570.18	514.33	4,084.51
112.88	153.61	266.49	3,708.35	481.64	4,190.00
130.15	180.21	310.36	4,057.50	529.49	4,586.98
149.37	151.08	300.45	4,009.31	476.81	4,486.12
140.71	149.02	289.73	4,080.82	446.91	4,527.73
128.40	129.05	257.45	3,993.17	409.36	4,402.53
133.79	135.25	269.04	4,069.97	369.38	4,439.36
137.90	124.65	262.55	3,936.14	394.32	4,330.45
147.26	149.97	297.24	4,160.02	387.73	4,547.75
155.58	155.94	311.53	4,833.38	399.09	5,232.47
231.61	185.20	416.81	5,227.44	515.19	5,742.63
235.41	173.84	409.25	4,812.33	507.68	5,320.01
270.29	169.85	440.14	5,826.97	622.78	6,449.76
285.02	174.50	459.52	6,371.58	645.33	7,016.92
321.55	169.14	490.69	6,751.70 ual percentage cha	624.45 nge)	7,376.15
17.1	9.9	12.5	21.5	9.9	19.8
12.4	8.0	9.6	7.7	9.3	7.9
7.9	10.0	9.2	15.5	13.0	15.2
10.8	7.5	8.7	8.1	4.9	7.7
10.8	-6.5	0.1	3.9	-6.4	2.6
15.3	17.3	16.5	9.4	9.9	9.5
14.8	-16.2	-3.2	-1.2	-9.9	-2.2
-5.8	-1.4	-3.6	1.8	-6.3	0.9
-8.8	-13.4	-11.1	-2.1	-8.4	-2.8
4.2	4.8	4.5	1.9	-9.8	0.8
3.1	-7.8	-2.4	-3.3	6.7	-2.5
6.8	20.3	13.2	5.7	-1.7	5.0
5.6 48.9	4.0 18.8	4.8 33.8	16.2 8.2	2.9 29.1	15.1 9.7
1.6	-6.1	-1.8	-7.9	-1.5	-7.4
14.8	-2.3	7.5	21.1	22.7	21.2
5.4	2.7	4.4	9.3	3.6	8.8
12.8 (anı	-3.1 nual percentage c	6.8 hange in excess of	6.0 inflation in the Can	-3.2 nadian economy)	5.1
14.3	7.1	9.7	18.7	7.1	17.0
7.6	3.2	4.9	3.0	4.6	3.2
3.4	5.5	4.7	11.0	8.5	10.6
6.2	2.9	4.2	3.5	0.4	3.1
7.7	-9.5	-2.9	0.8	-9.4	-0.4
12.5	14.6	13.7	6.7	7.2	6.7
13.5	-17.4	-4.5	-2.4	-11.2	-3.5
-7.2	-2.8	-5.0	0.3	-7.7	-0.5
-9.9	-14.5	-12.2	-3.2	-9.5	-3.9
1.9	2.5	2.2	-0.4	-12.1	-1.5
1.4	-9.5	-4.1	-5.0	5.1	-4.1
5.8	19.3	12.2	4.7	-2.7	4.0
6.1	4.4	5.2	16.6	3.4	15.5
47.1	17.0	32.0	6.3	27.3	7.9
-2.3	-10.1	-5.8	-11.9	-5.4	-11.3
13.5 4.4	-3.6 1.7	6.3 3.4	19.8	21.4	20.0 7.8
			8.3	2.6	

f - Forecast

Table B.13.1—Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nunavut, 1985–2003

985 986 987 988 989 990 991 992	Territorial	Federal _	Public Social Secu W.C.B.	Drug Insurance	Sub-Total Public	Insurers*	Out-of-	Sub-Total	Total	Over	e (Out-of-Poo	Total
985 985 986 987 988 988 990 991				Drug Insurance		ilisurers						
				Eunda			Pocket	Private	Prescribed Drugs	the Counter	Health Supplies	Non-Presc. Drugs
6 7 8 9 0 1 2				Funds		(\$ milli	ons)			Drugs		
	1.0	0.0	0.0		1.1			1.3	2.4	1.4	1.3	2.8
	1.2	0.2	0.0		1.4			1.5	2.8	1.4	0.9	2.3
	1.2	0.4	0.0		1.7			1.5	3.2	1.3	0.9	2.2
	1.1	0.5	0.0		1.6			1.7	3.4	1.3	0.9	2.3
	1.2	0.3	0.0		1.6		 'oan shanas)	1.7	3.3	1.4	1.0	2.4
_						annual percent						
	21.7	289.9	2.4		31.3			9.2	18.9	-1.1	-32.2	-16.1
	3.7	174.5	25.7		23.1			4.2	13.4	-8.3	1.3	-4.6
	-7.9	10.2	11.7		-3.1			12.4	4.2	1.1	1.1	1.1
	8.5	-34.3	11.7		-3.5	 an chara of to	tal drug avna	-2.7	-3.1	3.5	7.8	5.3
_						age share of to						
	19.1	0.8	0.5		20.3			25.9	46.1	27.8	26.0	53.9
	23.2	3.0	0.5		26.6			28.2	54.9	27.5	17.6	45.1
	22.9	7.7	0.6		31.1			27.9	59.1	23.9	17.0	40.9
	20.4	8.3	0.6		29.3			30.5	59.8	23.5	16.7	40.2
	22.1	5.4	0.7		28.2			29.6	57.8	24.3	17.9	42.2
da*	Dan and the		udaalal Issael C									01111 2004
onridentia.	iiity precludes	reporting pro	vincial level in	surance data.								CIHI 2004

						as a Share of I 2003 (continu	ed)		
		All Drugs		He	alth Expenditure			s in Public, Priva ealth Expenditur	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
			(\$ millio	ns)			(per	centage share)	
	1.1	4.1	5.2	133.4	8.3	141.7	0.8	49.7	3
	1.4	3.8	5.2	158.8	9.2	168.0	0.9	41.3	3
	1.7	3.8	5.5	168.4	8.9	177.3	1.0	42.1	3
:	1.6	4.0	5.6	172.9	9.2	182.1	1.0	43.4	3
	1.6	4.0	5.6	176.0	9.5	185.6	0.9	42.4	3
	-		(annual percenta	ige change)		<del></del>			
	31.3	-7.9	0.0	19.1	10.6	18.6			
	23.1	-1.2	5.3	6.0	-2.9	5.6			
:	-3.1 -3.5	5.7 1.8	3.0 0.3	2.7 1.8	2.5 4.3	2.7 1.9			
		n.8		1.0	4.3	1.9			
	(percentage s								
	20.3	79.7	100.0						
	26.6	73.4	100.0						
:	31.1 29.3	68.9 70.7	100.0 100.0						
:	28.2	70.7	100.0						
	20.2	, 1.0	.00.0						

Table B.13.2—Part 1

Expenditure on Drugs Per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nunavut, 1985–2003

-		Prescribed Drugs			Non-Prescribed Drugs Private (Out-of-Pocket)							
-	Territorial	Federal _	Public Social Secu W.C.B.	rity Funds  Drug  Insurance	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over the Counter	Personal Health Supplies	Total Non-Presc. Drugs
				Funds						Drugs		
_						(\$ per c	apita)					
	36.87	1.47	0.87		39.22			49.98	89.20	53.77	50.33	
	43.76	5.60	0.87		50.23			53.24	103.47	51.86	33.28	
	44.37	15.02	1.07		60.46			54.26	114.71	46.49	32.97	
	39.99 42.44	16.19 10.40	1.17 1.28		57.35 54.12			59.65 56.77	117.00 110.89	46.00 46.58	32.62 34.39	
	.2		20			(annual percen			110.00		0 1.00	00.07
	18.7	280.3	-0.1		28.1			6.5	16.0	-3.5	-33.9	-18.2
	1.4	168.4	23.0		20.4			1.9	10.9		-0.9	-6.7
	-9.9	7.8	9.3		-5.1			9.9	2.0		-1.1	
	6.1	-35.8	9.3	 (onnual na	-5.6		f inflation in	-4.8	-5.2	1.3	5.4	3.0
_						nge in excess o						
	14.7		-4.1		24.1			2.5	12.0	-7.5	-37.8	
	0.1	167.1	-4. I 21.7		19.1			0.6	9.6	-7.5 -11.6	-37.8	
	-10.9	6.8	8.3		-6.2			8.9	1.0	-2.1	-2.1	-2.1
	2.8	-39.1	6.0		-8.9			-8.1	-8.5	-2.0	2.1	-0.3

	. Otal	Tourth Expon	ditures, Nuna	wat, 1505 2	2005 (6011)	GDP I
Public	All Drugs Private	Total	He Public	ealth Expenditure Private	Total	Price Index
		(\$ per ca	pita)			(1997 = 1
						7
						8:
						89 91
						92
						94
						95
						97.
						99.
						100.
39.22		193.30	4,971.76	310.31	5,282.08	99. 101.
50.23 60.46		188.61 194.17	5,774.24 5,988.07	334.66 317.80	6,108.89 6,305.87	105 106
57.35		195.62	6,015.84	318.69	6,334.53	107
54.12		191.87	5,991.16	325.01	6,316.17	111
		(ann	ual percentage cha	nge)		
						2.
						4.
						4. 4.
						3.0 2.1
						1.3
						1.0
						1.
						2.
						1.
						1.0
						-0.4 1.1
20.4			40.4	7.0		
28.1 20.4		-2.4 3.0	16.1 3.7	7.8 -5.0	15.7 3.2	4.0 1.3
-5.1		3.0 0.7	0.5	-5.0	0.5	1.0
-5.6		-1.9	-0.4	2.0	-0.3	3.3
(	annual percentage c	hange in excess of	inflation in the Car	adian economy)		
24.1		-6.4	12.2	3.9	11.7	
19.1 -6.2		1.7 -0.3	2.4 -0.5	-6.3 -0.7	2.0 -0.6	
-8.9		-0.3 -5.2	-0.5 -3.7	-0.7 -1.3	-0.6 -3.6	

# Series C International Comparisons

#### Table C.1

## The Share of Pharmaceutical Goods\* in Total Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2000, 2001

1985		2000		2001	
(%)		(%)		(%)	
Korea	28.7	Slovak Republic	34.0	Slovak Republic	34.0
Portugal	25.4	Italy	22.2	Hungary	30.7
Spain	20.3	Czech Republic	22.0	Italy	22.3
Japan	18.0	France	20.4	Czech Republic	21.9
Iceland	16.6	Mexico	19.5	France	21.0
Belgium	15.7	Japan	18.3	Mexico	19.9
Luxembourg	14.7	Korea	15.9	Japan	18.7
United Kingdom	14.1	Canada	15.7	Canada	16.2
Germany	13.8	Finland	15.5	Finland	15.7
New Zealand	13.3	Austria	14.9	Austria	15.1
Turkey	13.2	Greece	14.2	Germany	14.3
Switzerland	11.3	Sweden	13.9	Greece	14.0
Ireland	9.9	Germany	13.6	Australia	13.8
Finland	9.7	Australia	13.5	Sweden	13.5
Canada	9.6	Luxembourg	12.1	United States	12.4
Netherlands	9.3	United States	11.9	Switzerland	10.6
Norway	9.1	Switzerland	10.7	Ireland	10.3
United States	9.0	Ireland	10.6	Netherlands	10.1
Australia	8.1	Netherlands	10.1	Denmark	8.9
Sweden	7.0	Denmark	8.7		
Denmark	6.6				

<sup>\*</sup>The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium: Includes therapeutic devices.

Germany: Includes therapeutic means and methods (external applications, physiotherapy, speech therapy,

occupational therapy) and special devices such hearing and visual aids and orthopaedic devices.

Ireland: Includes therapeutic goods.

Turkey: Includes pharmaceutical consumption in hospitals.

United Kingdom: Includes some household expenditure on orthopaedic and surgical appliances.

Source: OECD Health Data 2003, October 2003 Update, Organisation for

Economic Cooperation and Development and CREDES, Paris

Table C.2

## The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-Durables\*, in Descending Order, OECD Reporting Countries, 1985, 2000, 2001

1985		2000		2001			
(%)		(%)		(%)	(%)		
Turkey	86.3	Slovak Republic	82.6	Ireland	93.7		
Luxembourg	86.0	Luxembourg	81.4	Slovak Republic	82.7		
New Zealand	80.4	Ireland	80.1	Czech Republic	76.7		
Germany	71.9	Czech Republic	77.8	Austria	76.1		
Sweden	70.1	Austria	75.5	Greece	75.5		
Portugal	64.7	Sweden	70.0	Germany	70.6		
United Kingdom	64.1	Germany	69.1	Sweden	69.1		
Netherlands	63.3	Greece	68.9	Japan	67.5		
Spain	62.5	Japan	66.0	France	65.9		
Iceland	61.9	France	64.9	Switzerland	62.6		
Ireland	60.7	Switzerland	60.8	Hungary	61.8		
Japan	60.6	Netherlands	60.6	Netherlands	60.6		
Belgium	51.0	Australia	54.4	Italy	54.2		
Australia	46.5	Finland	50.2	Australia	53.7		
Denmark	45.5	Denmark	49.5	Finland	51.8		
Finland	44.5	Italy	44.4	Denmark	50.5		
Norway	43.2	Canada	35.2	Canada	36.1		
Canada	29.4	United States	18.4	United States	18.7		
United States	8.6	Korea	17.4	Mexico	0.4		
		Mexico	0.3				

<sup>\*</sup>The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium: Includes therapeutic devices.

Germany: Includes therapeutic means and methods (external applications, physiotherapy, speech therapy,

occupational therapy) and special devices such hearing and visual aids and orthopaedic devices.

Ireland: Includes therapeutic goods.

**Turkey:** Includes pharmaceutical consumption in hospitals.

United Kingdom: Includes some household expenditure on orthopaedic and surgical appliances.

Source: OECD Health Data 2003, October 2003 Update, Organisation for

 $\label{eq:conomic cooperation and Development and CREDES, Paris} \label{eq:conomic cooperation}$ 

#### Table C.3

## The Share of Pharmaceutical Goods\* in Public Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2000, 2001

1985 (%)		<b>2000</b> (%)		2001 (%)			
Portugal	30.1	Slovak Republic	31.4	Slovak Republic	31.5		
Turkey	22.6	Hungary	24.9	Hungary	25.3		
Spain	15.7	Spain	21.8	Spain	22.0		
Japan	15.4	Czech Republic	18.8	Greece	18.9		
Luxembourg	14.2	Greece	17.4	Czech Republic	18.4		
Germany	12.8	France	17.4	France	18.2		
New Zealand	12.3	Austria	16.2	Austria	17.0		
Iceland	11.8	Poland	15.7	Japan	16.2		
United Kingdom	10.5	Japan	15.5	Italy	16.0		
Netherlands	8.3	Italy	13.4	Poland	15.8		
Ireland	7.9	Germany	12.6	Germany	13.5		
Finland	5.5	Switzerland	11.7	Ireland	12.7		
Sweden	5.4	Ireland	11.6	Switzerland	11.6		
Australia	5.3	Sweden	11.4	Sweden	10.9		
Norway	4.6	Luxembourg	11.2	Australia	10.9		
Canada	3.8	Australia	10.7	Finland	10.7		
Denmark	3.5	Finland	10.4	Netherlands	9.7		
United States	1.9	Netherlands	9.7	Canada	8.2		
		Canada	7.8	Denmark	5.5		
		Korea	6.2	United States	5.2		
		Denmark	5.2	Mexico	0.2		
		United States	5.0				
		Mexico	0.1				

<sup>\*</sup>The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium: Includes therapeutic devices.

Germany: Includes therapeutic means and methods (external applications, physiotherapy, speech therapy,

occupational therapy) and special devices such hearing and visual aids and orthopaedic devices.

Ireland: Includes therapeutic goods.

Turkey: Includes pharmaceutical consumption in hospitals.

United Kingdom: Includes some household expenditure on orthopaedic and surgical appliances.

Source: OECD Health Data 2003, October 2003 Update, Organisation for

Economic Cooperation and Development and CREDES, Paris

### **Appendix**

### Comparison of Provincial and Territorial Drug Subsidy Programs

## Comparison of Provincial and Territorial Drug Subsidy Programs

Table 8 gives an overview of provincial and territorial drug subsidy programs. The table was verified for accuracy with respective provincial/territorial program. Information is also available from the following websites:

Newfoundland and Labrador Prescription Drug Program http://www.gov.nf.ca/health/nlpdp

Prince Edward Island Pharmacy Services —

http://www.gov.pe.ca/infopei/Government/GovInfo/Health/Pharmacy\_Services

Nova Scotia Pharmacare —

http://www.gov.ns.ca/health/pharmacare/default.htm

New Brunswick Prescription Drug Program—http://www.gnb.ca/0212/intro-e.asp

Régime général d'assurance-médicaments du Québec (RGAM) — http://www.ramq.gouv.qc.ca/en/citoyens/assurancemedicaments/index.shtml

Ontario Drug Benefits -

http://www.health.gov.on.ca/english/providers/program/drugs/odbf mn.html

Manitoba Pharmacare Program—http://www.gov.mb.ca/health/pharmacare/index.html

Saskatchewan Drug Plan—http://www.health.gov.sk.ca/ps\_drug\_plan.html

Alberta Prescription Drug Program—

http://www.health.gov.ab.ca/ahcip/prescription/index.html

British Columbia Pharmacare—http://www.healthservices.gov.bc.ca/pharme

Yukon Pharmacare—http://www.hss.gov.yk.ca/prog/hs/insured/pharmacare.html

Northwest Territories—http://www.hlthss.gov.nt.ca/content/About HSS/about index.htm

Nunavut Planning Commission—

http://www.gov.nu.ca/hsssite/hssmain.shtml

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
British Columbia	Fair PharmaCare	All eligible Seniors not covered by other Plans	None	Based on family net income: \$0 < \$33K   1% \$33K to \$50K   2% > \$50K	PharmaCare pays 75%	1.25% <\$33K 2% \$33K to \$50K 3% >\$50K
		All eligible non- senior British Columbia citizens	None	Based on family net income: \$0 < \$15K 2% \$15K to \$30K 3% > \$30K	PharmaCare pays 70%	2% < \$15K 3% \$15K to \$30K 4% > \$30K
	PharmaCare Plan B	Residents of Long Term Care facilities	None	None	None	N/A
	PharmaCare Plan C	Social Assistance Recipients	None	None	None	N/A
	PharmaCare Plan D	Cystic Fibrosis Patients	None	None	None	N/A
	PharmaCare Plan F	Severely- Handicapped Children-At-Home Program	None	None	None	N/A
	PharmaCare Plan G	Mental Health Centre Clients	None	None	None	N/A
Alberta	Seniors	Seniors and eligible dependants	None	None	30% of prescription to a max of \$25.00 per prescription plus additional cost if higher-cost-product is selected	N/A
	Widows	Residents aged 55 to 64 who qualify for Alberta Widows' Pension and eligible dependants	None	None	30% of prescription to a max of \$25.00 per prescription plus additional cost if higher-cost-product is selected	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Alberta (cont'd)	Palliative	Palliative residents treated at home	None	None	30% of prescription to a max of \$25.00 per prescription plus additional cost if higher-cost-product is selected	The maximum amount palliative patients pay out-of-pocket is \$1,000
	Group 1	A universal plan available to all residents under the age of 65	Quarterly (3-month) rate is \$61.50 for singles and \$123 for families. Subsidized rates are available at \$43.05 for singles and \$86.10 for families.	None	30% of prescription to a max of \$25.00 per prescription plus additional cost if higher-cost-product is selected	N/A
	Province Wide Services	Residents with specific conditions may be eligible for high-cost drugs, mostly transplant and HIV drugs	None	None	None	N/A
	Supports for Independence (SFI)	Residents receiving social assistance and eligible dependants	None	None	\$2.00 per prescription for first three prescriptions each month	N/A
	Assured Income for the Severely Handicapped (AISH)	Residents receiving AISH (an income support program for adults with a permanent disability that severely impairs their ability to earn a living) and eligible dependants	None	None	\$2.00 per prescription for first three prescriptions each month	N/A
	Alberta Child Health Benefit	Children in low- income families	None	None	None	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Saskatchewan	Saskatchewan Drug Plan	All residents with Saskatchewan Health Coverage	None	Income-tested (annual threshold based on 3.4% of adjusted family income)	Income-tested (based on benefit drug costs, to help spread cost out evenly over the year)	N/A
		Seniors receiving the Saskatchewan Income Plan supplement or receiving the federal Guaranteed Income Supplement and residing in a special care home (automatically receive this deductible and co-pay but may also apply for income-tested coverage)	None	\$100 semi- annual family deductible	35% consumer co- payment after deductible has been paid	N/A
		Seniors receiving the Guaranteed Income Supplement and living in the community (automatically receive this deductible and co-pay but may also apply for income-tested coverage)	None	\$200 semi- annual family deductible (may apply for income- tested coverage)	35% consumer co- payment after deductible has been paid	N/A
	Emergency Assistance Program	Residents who require immediate treatment with covered prescription drugs and are unable to cover their share of the cost. This is a one-time benefit, and individuals are encouraged to apply for incometested coverage for future assistance.	None	None	The level of assistance provided is in accordance with the consumer's ability to pay.	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Saskatchewan (cont'd)	Family Health Benefits	Eligibility is established by the Department of Social Services, based on the number of children in the family and the family's annual income. (automatically receive this deductible and co-pay but may also apply for income-tested coverage)	None	\$100.00 semi-annual family deductible	No charge for benefit prescriptions for children; 35% consumer co- payment after deductible has been paid for adult benefit prescriptions	N/A
	Supplementary Health	Persons nominated by Saskatchewan Social Services for special coverage, including persons on Social Assistance, wards, inmates, etc.	None	None	Up to \$2.00 per prescription (some drugs covered at no charge; individuals under 18 and certain other categories receive benefit prescriptions at no charge)	N/A
	Saskatchewan Aids to Independent Living (SAIL)	Persons registered under the following SAIL programs receive Formulary and approved non-Formulary drugs at no charge: Paraplegia Program, Cystic Fibrosis Program, and Chronic End Stage Renal Disease Program	None	None	None	N/A
	Drug Plan Palliative Care Program	Residents who are in the late stages of a terminal illness	None	None	None	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Manitoba	Pharmacare	All provincial residents who are eligible for benefits under Manitoba Health's Provincial Drug Program, with the exception of residents covered under other Statutes.	None	Based on total Adjusted family income; 2.21% of <= \$15,000 or 3.31% >> \$15,000; credit of \$3,000 for spouse and dependent under 18 years; minimum of \$100 deductible is applicable	None	N/A
	Family Services	Individual Manitobans that are receiving drug benefits pursuant to the Social Assistance Health Services Drug Program.	None	None	None	N/A
	Personal Care Home	Manitoba residents of Personal Care Homes.	None	None	None	N/A
	Palliative Care	Residents who are terminally ill and wish to remain at home	None	None	None	N/A
Ontario	Ontario Drug Benefit Program	Seniors (aged 65 and older)	None	\$100.00	After deductible, up to \$6.11 per prescription	N/A
		Residents of long- term care facilities	None	None	Up to \$2.00 per prescription	N/A
		Residents of Homes for Special Care	None	None	Up to \$2.00 per prescription	N/A
		Residents receiving professional services under the Home Care program	None	None	Up to \$2.00 per prescription	N/A
		Residents receiving social assistance	None	None	Up to \$2.00 per prescription	N/A
	Trillium Drug Program	Residents with high drug costs in relation to income	None	Income-based	Up to \$2.00 per prescription	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Ontario (cont'd)	Special Drugs Program	Residents with valid Ontario Health Insurance. Coverage is product specific for a limited number of diseases or conditions.	None	None	None	N/A
Quebec	Régime général d'assurance- médicaments du Québec (RGAM)	Employment assistance (welfare) recipients (EAR) and other holders of a carnet de réclamation (claim slip)	None	\$8.33 per month	25% of prescription costs	\$16.66 per month (No deductibles and copay for EAR with severe employment constraints)
		Seniors (65 and over) receiving at least 94 % of the maximum GIS	None	\$8.33 per month	25% of prescription costs	\$16.66 per month
		Seniors (65 and over) receiving less than 94 % of the maximum GIS (partial GIS)	\$0 to \$460.00 per adult per year, depending on income	\$9.60 per month	28% of prescription costs	\$46.17 per month
		Seniors (65 and over) without GIS	\$0 to \$460.00 per adult per year, depending on income	\$9.60 per month	28% of drug costs	\$69.92 per month
		General clientele (Residents under 65 y.o. without access to a group plan)	\$0 to \$460.00 per adult per year, depending on income	\$9.60 per month	28% of prescription costs	\$69.92 per month

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
New Brunswick	Prescription Drug Program—Plan A	Seniors with GIS	None	None	\$9.05 for each prescription	\$250.00
		Seniors without GIS who qualify for benefits based on an annual income as follows: a single senior with an annual income of \$17,198 or less; a senior couple with one spouse over 65, with a combined annual income of \$26,955 or less; a senior couple with one spouse under 65, with a combined annual income of \$32,390 or less	None	None	\$15.00 per prescription	N/A
	Prescription Drug Program—Plan B	Cystic fibrosis patients or patients with juvenile or infant sclerosis of the pancreas	\$50.00 yearly registration fee	None	20% prescription cost up to a maximum of \$20.00	N/A
	Prescription Drug Program — Plan E	Individuals residing in a licensed residential facility who hold a valid health card for prescription drugs issued by the Department of Family and Community Services	None	None	\$4.00 for each prescription	\$250.00
	Prescription Drug Program—Plan F	Individuals holding a valid health card for prescription drugs issued by the Department of Family and Community Services	None	None	\$4.00 per prescription for adults (18 and over) and \$2.00 for children (under 18 years)	\$250.00 per family unit in a fiscal year
	Prescription Drug Program—Plan G	Special needs children and children under the care of the Minister of Family and Community Services	None	None	None	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
New Brunswick (cont'd)	Prescription Drug Program—Plan H	Residents who must pay for specific Multiple Sclerosis medications	\$50.00 yearly registration fee	None	Income-tested Ranges from 0-100%	N/A
	Prescription Drug Program—Plan R	Organ transplant recipients who are registered and qualify with the NBPDP	\$50.00 yearly registration fee	None	20% prescription cost up to a maximum of \$20.00	\$500.00 per family
	Prescription Drug Program—Plan T	Individuals with growth hormone deficiency or hypopituitarism who are registered and qualify with the NBPDP	\$50.00 yearly registration fee	None	20% prescription cost up to a maximum of \$20.00	\$500.00 per family
	Prescription Drug Program—Plan U	Individuals who are HIV positive and are registered with the NBPDP	\$50.00 yearly registration fee	None	20% prescription cost up to a maximum of \$20.00	\$500.00 per family
	Prescription Drug Program—Plan V	Individuals who reside in a registered nursing home	None	None	None	N/A
Nova Scotia	Seniors Pharmacare Program	Seniors (65 and older) receiving GIS and covered by MSI (Medical Services Insurance) and not having coverage through Veterans Affairs Canada, First Nations and Inuit Health, or a private drug plan	None	None	33% prescription cost (\$3.00 minimum and \$30.00 maximum)	\$350.00
		Seniors (65 and older) not receiving GIS and covered by MSI (Medical Services Insurance) and not having coverage through Veterans Affairs Canada, First Nations and Inuit Health, or a private drug plan	Up to \$390.00 per year	None	33% prescription cost (\$3.00 minimum and \$30.00 maximum)	\$350.00

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Nova Scotia (cont'd)	Department of Community Services Programs	Eligible clients and their dependents in receipt of Income Assistance, any client and/or dependent having access to another drug plan, be it from a public or private entity, will be required to use that plan and will not be eligible for the Pharmacare program	None	None	All income assistance clients and dependents are required to co-pay a flat fee of \$5.00 per prescription, unless the client or dependent is eligible for co-pay exemption	N/A
	Drug Assistance for Cancer Patients	Residents having a gross family income no greater than \$15,720 per year, and not eligible for coverage under other drug programs	None	None	None	N/A
	Multiple Sclerosis Drug Funding Assistance	Residents who meet established MS criteria and who do not have other drug coverage	None	None	\$9.35 per prescription	N/A
Prince Edward Island	Seniors Drug Cost Assistance Plan	Seniors 65 years of age or older and eligible for PEI Medicare	None	None	First \$10.00 of the medication cost plus the pharmacy professional fee for each prescription	N/A
	Financial Assistance Program	Persons whose eligibility is determined by the Social Assistance Act and Regulations	None	None	None	N/A
	Family Health Benefit Program	Families eligible for PEI Medicare, with one or more children under 18 years of age, a total annual net family income of \$20,000 or less, and approved by the program	None	None	The pharmacy professional fee for each prescription	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Prince Edward Island (cont'd)	Children-In-Care Program	Persons under 18 years of age in temporary or permanent custody of the Director of Child Welfare	None	None	None	N/A
	Diabetes Control Program	Persons with diabetes eligible for PEI Medicare and who are registered with the program	None	None	Insulin: \$8.00 per 10 mL vial of insulin or box of 1.5 mL insulin cartridges; \$16.00 per box of 3.0 mL insulin cartridges	N/A
	Multiple Sclerosis Medications Program	Persons eligible for PEI Medicare, diagnosed with relapsing-remitting or secondary progressive multiple sclerosis, and approved by the program	None	None	Income tested copay plus the pharmacy professional fee for each prescription	N/A
	Sexually Transmitted Diseases (STD) Program	Persons diagnosed with sexually transmitted disease or identified contacts of a person with a sexually transmitted disease	None	None	None	N/A
	Nursing Home and Institutional Pharmacy Programs	Residents in government Manors and private nursing homes eligible for coverage under the Social Assistance Act and Regulations	None	None	None	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Prince Edward Island (cont'd)	Disease Specific Programs (e.g. AIDS/HIV, Cystic Fibrosis, Growth Hormone, Hepatitis, and Transplant Drug Programs delivered through the Provincial Pharmacy)	Persons diagnosed with specific medical conditions	None	None	None	N/A
Newfoundland and Labrador	The Senior Citizens Drug Subsidy Program	Seniors' (65 and older) who are in receipt of the Guaranteed Income Supplement and who are registered for the Old Age Security benefits	None	None	Mark-up and Professional Fee for identified benefits	N/A
	The Income Support Program	Residents of the province who qualify for full benefit coverage under the Department of Humans Resources and Employment	None	None	None	N/A
		Residents who, due to the high cost of their medications, may qualify for drug card only benefits	None	None	None	N/A
	The Special Needs Program	Residents patients with Cystic Fibrosis or Growth Hormone	None	None	None, for identified benefits	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Yukon Territory	Pharmacare	Seniors 65 years of age or older (and seniors' spouses aged 60 years and older) registered with Yukon Health Care Insurance Plan (YCHCIP) and not having coverage through First Nations and Inuit Health	None	None	None	N/A
	Chronic Disease Program	Residents who have a chronic disease or a serious functional disability as provided under the Chronic Disease and Disability Benefits Regulations (Residents must use private insurance plans first)	None	Maximum \$250 per individual and \$500 per family	None	N/A
	Children's Drug & Optical Program	Children under the age of 19 years from low- income families	None	Maximum \$250.00 per child and \$500.00 per family	None	N/A
Northwest Territories	Extended Health Benefits Program for Specified Diseases	Resident, Non- Native or Metis and have a specified disease condition	None	None	None	N/A
	Senior's Benefit Program	Metis and Non- Native residents who are 60 years of age and older	None	None	None	N/A
	Metis Health Benefits	Eligible Metis 59 years old and younger.	None	None	None	N/A
	Indigent Health Benefits Program	Indigent individuals or families resident of the Northwest Territories, who meet the eligibility requirements according to the Indigent Health Benefits Policy	None	None	None	N/A

Table 8—Comparison of Provincial and Territorial Drug Subsidy Programs (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Nunavut	Extended Health Benefits Program	All Metis and Non-Aboriginal residents, including Seniors', who have a specific chronic condition or have reached the age of 60	None	None	None	N/A
	Indigent Health Benefits Program	All residents who do not have access to other programs	None	None	None	N/A



taking health inf rmation further à l'avant-garde de l'inf rmation sur la santé